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Abstract

Introduction
Cognitive impairments associated with cancer and cancer treatment are side effects that
have and continue to elude the oncology world. Cognitive impairments related to chemotherapy
are also known as “chemo-brain” or “chemo-fog” and encompasses deficits in cognitive domains
that include memory, verbal fluency, attention, and concentration, and one’s ability to recall
information. Patients who experience cognitive impairments during and after cancer treatments,
chemotherapy in particular, are often afflicted with impaired executive functioning, problems
with memory and recall, loss of control and decreased sense of self, increased stress and
depression, role conflicts when returning to work, and impaired quality of life. While the
treatment may impact patients’ cognitive function, other factors, including personal
characteristics and other stressors, may also influence their memory.
Objectives
The purpose of this descriptive correlational study is to determine relationships between
women with breast cancer who are currently receiving or who have received at least one type of
treatment and the negative impact that these treatments and other factors have or have had on
their memory as reported by these participants.
Methods
A descriptive correlational approach was used for this study. A one-time questionnaire
was sent via email to participants, including two instruments to assess memory; one measure of
stress and questions obtaining demographics; information related to treatments received; stress
and the negative impact of these factors on memory. Tools used to assess memory included the
Everyday Memory Questionnaire (EMQ) and the Functional Assessment of Cancer Therapy-Cog
iii

(FACT-Cog). The tool used to assess stress was the Perceived Stress Scale (PSS). Of the 171
participants of this study, they were predominately White/Caucasian (89.5%), college educated
(49.7%), and married or partnered (76%). Ages of participants in this study ranged from 24 to 80
years old (mean age was 53.8 years). For eligibility requirements, all participants in this sample
were female.
Results
The results of this study indicate that age had an impact on memory/cognition on this
sample, with EMQ, p = .01; Perceived Cognitive Impairments Subscale, p = .01; and Chi-square
(yes/no self-reported stress), p = .02. A statistically significant difference was shown in
Perceived Cognitive Abilities in those who had surgery versus those who did not, p = .05. Those
who received chemotherapy demonstrated a statistical difference than those who did not receive
chemotherapy using Chi-square (yes/no self-reports of stress), p = .01. There was a statistical
difference in those who received radiation and those who did not receive radiation on the EMQ,
p = .03; and Perceived Cognitive Impairments, p = .05. There was a statistical significance
between those who received hormonal therapy versus those who did not using Chi-square
(yes/no self-reports of stress), p = .02. Adriamycin was shown to be statistically significant using
Chi-square (yes/no self-reports of stress), p = .02. Those receiving Cytoxan were statistically
significant than those not receiving this medication on the EMQ, p = .01. Tamoxifen shown
statistically significant results in Perceived Cognitive Impairments, p = .05; and in Chi-square
self-reports of stress (yes/no), p = .05.
PSS meanings, indicating low, moderate, and high levels of stress demonstrated
significance on EMQ scores with p < .01. PSS raw scores (total non-categorical scores) were
statistically significant using both parametric correlations (Pearson product-moment correlation
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coefficient), p = < .01 and non-parametric correlations (Spearman’s rho), p < .01. Statistically
significant results were also found in the PSS meaning (low, moderate, high stress level) and
FACT-Cog scores, p = < .01.
Conclusions
In this study, age was shown to have an effect on both memory and cognition among the
sample utilizing the EMQ and the Perceived Cognitive Impairments Subscale of the FACT-Cog.
Participants who received chemotherapy and hormonal therapy had more self-reported memory
impairments than those who did not receive these treatment modalities. Those receiving
radiation had lower scores on the PCI subscale and thus more perceived cognitive impairments.
On the contrary, those who did not receive radiation were shown to have higher EMQ scores
indicating more memory problems than participants who did receive radiation.
Participants in this study experiencing moderate and high levels of stress had higher
EMQ scores, indicating more memory problems than those with low stress. The results from this
study indicate that many factors, including age, certain treatment modalities, particular
medications, and stress can have a negative impact on an individual’s memory or cognition. This
signifies an importance for future research to be conducted in relation to cognitive impairments
to distinguish and identify probable causes, increase awareness and education among healthcare
providers to directly benefit patients through knowledge, and the development of potentially
beneficial therapeutic treatments.
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Chapter 1: Statement of the Problem
Introduction
Breast cancer is the most common form of cancer and the leading cause of death by any
type of cancer among women. Breast cancer accounts for 25% or 1.68 million of the total
number of cancer cases and 15% or 520,000 of cancer deaths worldwide (Anampa et al., 2015;
Jemal et al., 2010; Torre et al., 2015). Women undergoing physical, emotional, and mental
transitions related to breast cancer and the accompanying treatment are forced to deal with a
multitude of changes. Surgically, a woman with breast cancer is left with the physical ruin of
scars and missing identifications of womanhood. Emotional scarring is evident in a woman’s
changing appearance, self-perception, and self-confidence during her emotional journey. Women
are plagued with symptoms that include nausea, vomiting, diarrhea, constipation, fatigue,
neuropathy, and myelosuppression. However, one side effect that has eluded the oncology world
is cognitive impairments associated with cancer and cancer treatment.
One group of side effects related to cancer and cancer treatment that remains largely
misunderstood and potentially overlooked is cognitive impairments. These changes have been
reported to occur both during and after cancer treatment. Cognitive impairments related to
chemotherapy are also known as “chemo-brain” or “chemo-fog” and encompasses deficits in
cognitive domains that include memory, verbal fluency, attention and concentration, and one’s
ability to recall information (Brewster et al., 2017).
This experience has been referenced in the literature for years and appears to be gaining
more attention as the occurrence becomes more prevalently reported among patients with cancer.
The lack of a clear-cut definition, a decreased ability to identify causative mechanisms, and
healthcare providers’ decreased confidence and lack of understanding of the phenomenon may
1

contribute to decreased reports of these symptoms by those experiencing them. Institutional
policies for assessing and addressing cancer- and treatment-related cognitive impairments are not
universal and, in some institutions, do not exist.
This chapter will outline this descriptive correlational study, providing a background and
significance of the problem of cognitive impairments as experienced by women with breast
cancer who are post-chemotherapy. The lack of clear-cut understanding of the effects of cancerand cancer-related treatment on memory leads to the purpose of this study, which is to determine
factors self-reported by participants that could potentially have a negative effect on memory,
including various demographics, breast cancer treatments, stress, and the COVID-19 pandemic.
Another concern is the lack of universal assessments aimed at determining the presence of these
impairments. Literature has demonstrated a disconnect between objective psychometric testing
and cancer- and treatment-related cognitive impairment diagnosis. Some institutions have no
policies in place to address the phenomenon or assess patients who may be experiencing it.
Background and Significance
Cancer- and treatment-related cognitive impairments is a complex phenomenon that
affects many cognitive domains. Cognitive decline has been shown to be present at diagnosis
(Allen et al., 2018), throughout and worsening with various treatments, and into survivorship
(Ahles et al., 2012; Allen et al., 2018). Impairments in cognition have been reported in breast
cancer as well as other types of cancers such as lymphoma, testicular cancer, and in cancer
patients after receiving stem cell transplants. The following will explain the background of
cancer- and treatment-related cognitive impairments and the significance of the problem among
breast cancer patients and survivors.
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Significant recognition of chemotherapy-related cognitive impairments (CRCI) did not
emerge with consistency until the late 1990s and it has only recently been addressed with more
frequency in the literature, although some recognition was published in the 1970s and early
1980s (Gordon, 2014; Myers, 2009). Gordon (2014) described cognitive impairments during
chemotherapy as a common condition, “one that physicians have only recently begun to
recognize as an actual consequence of cancer and its treatment” (p. 21). In the past, physicians
used to link problems with memory to causes such as fatigue, depression, anxiety, and stress
associated with the cancer diagnosis itself more so than to chemotherapy and other treatments.
However, researchers are conducting more rigorous studies that are including brain imaging
demonstrating a direct link between chemotherapy and decreased cognitive processes (Dietrich,
2012; Gordon, 2014). Janelsins et al. (2014) noted that up to 30% of patients with cancer exhibit
cognitive impairment prior to treatment, 75% might have measurable cognitive impairment
during treatment, and 35% of cancer survivors will continue to exhibit cognitive difficulties in
the months to years that follow treatment. This statistic demonstrates the worsening effects of
cancer treatments on patients’ memory that may already be impaired due to diagnosis, stress,
depression, and other factors that are present prior to starting treatment.
The President’s Cancer Panel and the National Coalition for Cancer Survivorship
formally recognized cognitive impairments after chemotherapy as a quality-of-life issue in the
1990s (Ferguson et al., 2010). Uncertainties surrounding memory problems related to cancer and
treatments also includes a lack of proper assessment tools that are universally accepted and
utilized. The multifaceted nature of cancer itself leads to an exponential quandary of potential
explanations of and causes for cognitive impairments related to cancer and its treatment.
Researchers studying this condition are seeking to demonstrate that there is not a single cause for
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this phenomenon, but rather it is various mechanisms that when combined, increase the
occurrences and severity of the symptoms. These mechanisms include the cancer diagnosis;
treatments including chemotherapy, radiation, and endocrine therapy; stress, anxiety, and
depression; and cell damage, cytokine release, inflammation, and resulting changes in brain
construction.
Cognitive impairments have been associated with malignant brain tumors and treatments
directly affecting the brain, including cranial surgery or brain radiation (Janelsins et al., 2011).
Although a direct cause has not been identified for cognitive impairments, systemic
chemotherapy treatments have shown to lead to more cognitive problems than locoregional
therapies such as surgery or radiation (Kohli et al., 2007; Quesnel et al., 2009). Additionally,
research has shown that cognition can be affected in children with cancer and adults with a
history of childhood cancer. More recently, Janelsins et al. (2011) studied cognition and
cognitive impairments in various solid tumors (i.e., breast, prostate, colon, and testicular cancer)
and non-central nervous system blood malignancies such as leukemia and lymphoma.
The number of patients and survivors who experience cognitive impairments varies
greatly. Wefel et al. (2015) estimated that 17% to 50% of breast cancer patients experience
symptoms related to cognitive decline in one or more cognitive domains. Other studies have
shown the incidence of cognitive impairments have been reported in up to 75% non-central
nervous system cancers (Amidi et al., 2015; Dwek et al., 2017; Janelsins et al., 2011; Vardy et
al., 2014; Vardy & Tannock, 2007). Approximately 25% of survivors report experiencing
symptoms of cognitive decline up to 20 years after the completion of treatment (Ahles et al.,
2012; Koppelmans et al., 2012). These variations in data can be due to a lack of understanding of
the phenomenon, symptoms not detected with objective neuropsychological testing, and vague
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reports or patients not reporting their symptoms. People often make light of their symptoms and
casually report that they feel like they are losing their minds, not realizing that what they are
experiencing is real, that it happens to others, and is a serious and sometimes long-lasting
complication of their disease and therapy. Gordon (2014) reported that cognitive impairments
can affect upwards of 75% of cancer patients while they are receiving treatment such as
chemotherapy. It is important to note that cognitive impairments have been reported in patients
during treatment and as long as months to years after the completion of therapy. Women with
breast cancer have reported experiencing this phenomenon up to two years after treatment in
prospective longitudinal studies (Mar Fan et al., 2005) and as a long as 21 years after treatment
in cross-sectional studies (Koppelmans et al., 2012).
Severity of cancer- and treatment-related cognitive impairments can vary among cancer
patients. Research has shown that perceived cognitive impairments are one of the most prevalent
symptoms reported by cancer patients over three phases of the disease (Bender et al., 2005). Mild
cognitive impairments are reported to be those that require more effort at concentration and
memory; however, there is no reported effect on activities of daily living and quality of life. On
the other hand, patients have reported more severe cognitive impairments that impair their
memory and daily functioning. The severity of cognitive impairments has been thought to be
influenced by many factors including, but potentially not limited to, personal characteristics of
patients, tumor etiology, treatment regimen, and environment supports (Jean-Pierre, 2010).
While the treatment may impact patients’ cognitive function, other factors, including
personal characteristics and other stressors, may also influence their memory. The COVID-19
pandemic impacted many women with breast cancer who had received chemotherapy or were
waiting for treatment when services were postponed or halted. This stress may have also
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contributed to their memory functioning or the perceived negative impact on their memory.
These are among the characteristics that need to be studied in order to understand what role they
may play in mild cognitive impairments such as concentration and memory problems that posttreatment cancer patients experience.
Problem Statement
Patients who experience cognitive impairments during and after cancer treatments,
chemotherapy in particular, are often afflicted with impaired executive functioning, problems
with memory and recall, loss of control and decreased sense of self, increased stress and
depression, role conflicts when returning to work, and impaired quality of life (Boykoff et al.,
2009; Myers, 2013). Of particular interest in this study are self-reported problems with memory.
The International Cognition and Cancer Task Force is an organization developed in 2006 to
guide in further understanding cancer- and treatment-related cognitive impairments in cancer
patients with non-central nervous system cancers (Pendergrass et al., 2018). Table 1 provides an
overview of cognitive domains that this organization recommends be assessed in patients with
reports of cognitive deficits or impairments. This overview is useful in understanding the
different cognitive domains, the roles they play, and the neuropsychological assessments that are
utilized for assessing impairments in each domain.
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Table 1
Recommended Tests to Assess Reportedly Affected Cognitive Domains
Reportedly Affected
Cognitive Domain to be
Assessed
Learning and Memory

Executive Functioning

Processing Speed

Reportedly Affected
Cognitive Domain to be
Assessed
Working Memory

Recommended Cognitive
Assessment Test

Similar Cognitive
Assessments

Hopkins Verbal Learning Test –
Revised (HVLT-R)

California Verbal Learning
Test-II (CVLT-II), Rey
Auditory Verbal Learning
Test (RAVT), Brief
Visuospatial MemoryRevised (BVMT-R, Visual
Learning and Memory)
Trail Making Test
Delis-Kaplan Executive
Function Scale (D-KEFS)
Trail Making
Controlled Oral Word Association Delis-Kaplan Executive
(COWA) (also known as FAS test) Function Scale (D-KEFS)
Verbal Fluency
Trail Making Test
Delis-Kaplan Executive
Function Scale (D-KEFS)
Trail Making, Wechsler
Adult Intelligence Scale-IV
(WAIS-IV) Coding, Symbol
Digit Modalities Test
(SDMT)
Additional Assessment
Recommended Cognitive Assessment Test
Auditory Consonant Trigrams (ACT)
Paced Auditory Serial Attention Test (PASAT)
Brief Test of Attention (BTA)
Wechsler Adult Intelligence Scale–IV (WAIS-IV) Letter Number
Sequencing

Schagen et al. (1999) described cognitive deficits related to chemotherapy as
neuropsychological symptoms, including memory and problems with concentration, that are
reported by patients who have been treated with chemotherapy. Ahles et al. (2003) described
changes in cognitive function following chemotherapy as being subtle in the domains of
memory, concentration, and executive function. These changes can hinder an individual’s selfconfidence, self-efficacy, value in self-abilities, and issues returning to work. Myers (2013)
pointed to issues with survivors’ self-confidence, social, relationships, and work-related
outcomes (Von Ah, 2013). In addition, Von Ah (2013) reported embarrassment and shame
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described by patients with cognitive problems related to their treatments as well as feelings of
frustration, anxiety, and guilt, all of which led the patients to have an increased lack of selfconfidence and overwhelming feelings, including loss of control.
The multifaceted nature of cancer itself leads to an exponential quandary of potential
explanations of and causes for cognitive impairments related to the disease and its treatment.
Dietrich (2012) explained that cognitive impairments related to chemotherapy have become the
most puzzling and concerning side effect of treatment due to the lack of definitive causes. In
addition to these concerns, another considerable concern described by Janelsins et al. (2014) is
that cognitive impairments can lead to treatment delays and adherence issues, impaired quality of
life, problems returning to work, and long-term cognitive impairments. Research has shown that
cognitive impairments as reported by breast cancer survivors have had significant and
detrimental consequences on various areas of survivorship including self-perceptions, social
networking, work ability, and overall quality of life (Boykoff et al., 2009; Mitchell, 2007; Munir
et al., 2010; Myers, 2013; Von Ah et al., 2013). Although there are recommended assessments to
date, none of these are considered the gold standard nor are any used universally among
oncology practitioners. This lack of standardized assessments can lead to problems in reporting
and diagnosing memory deficits. It is imperative for oncology providers to take patient reports or
concerns seriously and help the patient to navigate through these often-debilitating symptoms.
Assessing relationships between various factors such as demographics, treatments received and
time since treatment, and stress and memory could be the start to addressing this concern.
One area of concern for these patients in particular is the ability to identify and diagnose
these cognitive impairments or declines. Many psychometric, neuropsychological tests have been
developed to diagnose memory problems in various diseases and disorders. However, these
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objective tests are not always effective at determining the presence of impairments in various
cognitive domains related to cancer and cancer treatments. Along with the inability of many
standard neuropsychological tests to accurately pick up on the subtle changes associated with
these types of cognitive changes, these changes can be masked, worsened, or affected by
confounding variables such as stress, life events, fatigue, depression, and anxiety. Another
reason that neuropsychological tests may not fully grasp the scope of cognitive changes
associated with cancer and cancer therapy is that patients can utilize compensatory mechanisms
that enhance their performance outcomes on these tests (Janelsins et al., 2011).
Neuropsychological tests do not always detect the subtle cognitive changes that breast cancer
survivors experience, but they are often used due to the lack of a standardized battery of
assessments for this population (Jansen et al., 2007).
Purpose Statement
The purpose of this descriptive correlational study was to determine relationships
between women with breast cancer who are currently receiving or who have received at least one
type of treatment and the negative impact that these treatments and other factors have or have
had on their memory as reported by these participants. How stress influences their memory or
their self-report of negative impact on memory was explored. This study also seeks to explore
the memory of women who have received breast cancer treatment modalities pre- or during/postCOVID-19 lockdown to identify relationships. Assessing relationships between various factors
such as demographics, treatments received and time since treatment, and stress and memory
could be the start to addressing the lack of universally utilized assessments. This design served as
a first step to develop a memory support strategy using a web-based nursing intervention that
considers the impact of stress.
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Theoretical Framework
The theoretical framework of interest for this study is Lazarus and Folkman’s
Psychological Stress and Coping Theory. This theory, initially developed in 1966 and revisited
in 1984, describes stress as an interaction between a stimulus and response. In 1966, Lazarus
proposed a more dynamic transactional framework of stress, expressing that stress was more than
a single event but rather consisted of transactions between a person and his or her environment.
This transaction is one in which individuals are able to attribute a meaning to their environment,
allowing them to identify a transaction in which stress can arise. Lazarus and Folkman (1984)
expanded on this model by including the concept of coping. They believed that a coping
appraisal played the primary mediator in the person-environment transaction model. In essence,
this means that there are variations in how different people cope with a particular stressful event.
Lazarus and Folkman (1984) defined coping as “constantly changing cognitive and behavioral
effects to manage specific external and/or internal demands that are appraised as taxing or
exceeding the resources of the person” (as cited in Johansen et al., 2017). Jay et al. (2004)
demonstrated that stress has been shown to “exert a damaging effect” on brain regions affecting
cognition, such as the prefrontal cortex and the hippocampus.
The transactional process of stress is not unilateral, meaning “it is neither the individual
nor the environment alone that produces stress but a complex transaction between the two”
(Folkman, 1984; Lazarus & Folkman, 1984). Stress is formed through an appraisal process in
which an individual assesses stimuli as threatening, challenging, or harmful. This appraisal is a
process that occurs constantly. There are two primary features of this theory: cognitive appraisal
and coping. During a cognitive appraisal, an individual determines the meaning of events or
stimuli and applies this meaning to the intensity of a stress reaction. Appraisal of the individual
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and environmental transactions rely on two factors: an individual’s personal agenda and
environmental factors. An individual’s personal agenda may include the individual’s values,
goals, and beliefs. Environmental factors include demands and resources. During primary
appraisal, the transaction between an individual and environment as determined to be positive,
irrelevant, or stressful. The stressful transactions are those that are associated with having the
ability to inflict harm/loss, threat, or a challenge to one’s well-being. In secondary appraisal, the
main focus is what actions can help manage the stressor and mitigate the distress associated with
it. Primary and secondary appraisals are equally important and work concurrently. Coping,
within this theory, is brought into action when a situation or event is deemed to be stressful to an
individual. This process of coping helps determine what actions are needed for the individual to
overcome the stressful event/situation. Two types of coping strategies can be used to manage the
stress: problem-focused coping which focuses on the actions required to directly manage the
stressor, whereas emotion-focused coping focuses on regulation of the individual’s emotions that
result from the stressor. The appraisal of stress and the determination of coping with stressful
stimuli/events is a complex and bidirectional process. An individual needs to effectively appraise
stimuli as well as determine the appropriate coping mechanism in order to successfully approach
stressful situations (Biggs et al., 2017).
Research Questions
This descriptive correlational study aims to examine and compare factors that have been
reported to negatively affect memory among women with breast cancer. The general questions
that guide this study include:
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•

Q1 - What are the characteristics of women who have received treatment for breast cancer
(i.e., demographics) who indicate experiencing a negative impact on their
memory/cognition?

•

Q2 - What relationships exist between factors such as 1) treatment modality for breast
cancer received, 2) time since last treatment received, 3) treatment agents received and
memory among women with breast cancer who have received treatment?

•

Q3 - What life factors (i.e., divorce, job loss, pandemic, etc.) experienced by women while
receiving treatment for breast cancer have impacted their level of stress?

•

Q4 - What life factors (i.e., divorce, job loss, pandemic, etc.) experienced by women while
receiving treatment for breast cancer have negatively impacted their memory?

•

Q5a - What negative impact does stress have on memory among women who have received
treatment for breast cancer?

•

Q5b – What correlation exists between levels of stress and memory among women who
have received treatment for breast cancer?

•

Q6 - What differences exist in memory for women who received breast cancer treatment
pre- or during/post-COVID-19 pandemic “lockdown” date?

•

Q7 – What is the relationship between the stress state (Low, Moderate, and High on PSS)
and the FACT-Cog scores?

•

Q8 – Qualitative Component - What do women who have received treatment for breast
cancer report might have affected their memory?

Definition of Key Terms and Variables
Many people have attempted to define the complex constructs of chemotherapy-related
cognitive impairment. Although many simplistic definitions have been developed, the condition
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of chemotherapy-related cognitive impairments is a complex phenomenon that is difficult to
explain and to understand. Kannarkat et al. (2007) identified reasons that contribute to a lack of
clarity associated with these cognitive declines, including a lack of a clear definition and a lack
of understanding about the exact mechanisms that bring about cognitive changes (Kanaskie,
2012). Cognitive impairments related exclusively to chemotherapy are anecdotally known as
“chemo-brain,” “chemo fog,” “chemotherapy-related cognitive impairment,” and
“chemotherapy-related cognitive dysfunction.” Schagen et al. (1999) described cognitive
deficits related to chemotherapy as neuropsychological symptoms, including memory and
problems with concentration, that are reported by patients who have been treated with
chemotherapy for cancer. Schagen et al. (1999) also explained that these problems can be
experienced even years after the completion of treatment. Ahles et al. (2003) described changes
in cognitive function following chemotherapy as being subtle changes in the domains of
memory, concentration, and executive function.
As more light continues to be shed on chemotherapy-related cognitive impairments, more
complex definitions are being developed. Hess and Insel (2007) saw chemotherapy-related
cognitive impairments as being a problem with higher-level mental functioning, including one’s
information-processing abilities and speed. Hess and Insel (2007) described that these higherlevel functioning abilities required combined efforts from several areas of the brain and include
the domains of memory, psychomotor speed, and executive functioning (e.g., planning,
concentration, attention, decision making, initiation, task persistence, and abstract reasoning).
Dr. Lynne Taylor, a neuro-oncologist from Tufts Medical Center in Boston, MA, noted the
importance of acknowledging patient reports of cognitive impairments or deficits during or after
their treatment as reported by patients who are assessed for pain (Gordon, 2014).
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Dependent variables
The critical variable of this descriptive correlational study is the cognitive domain of
memory. Schagen et al. (1999) described cognitive deficits related to chemotherapy as
neuropsychological symptoms, including memory and problems with concentration, that are
reported by patients who have been treated with chemotherapy for cancer. Ahles et al. (2003)
described changes in cognitive function following chemotherapy as being subtle changes in the
domains of memory, concentration, and executive function. Cognitive function was operationally
defined as the main dependent variable as follows.
Cognitive Functioning - Memory: Memory was measured by the Functional Assessment of
Cancer Therapy-Cog (FACT-Cog, Ver 3), a 37-item Likert-type scale divided into 4 subscales
assessing Perceived Cognitive Impairments (20 items), Perceived Cognitive Abilities (9 items),
Comments from Others (4 items), and Impact on Quality of Life (4 items); and the Everyday
Memory Questionnaire, a 13-item Likert style modified version used by Royle and Lincoln
(2009) as a subjective measure of memory failures in everyday life.
Perceived Stress: Self-reported Perceived Stress may be a dependent variable or intermediary
variable to the outcome of memory that was tested. The Perceived Stress Scale (PSS; Cohen &
Williamson, 1988) was included in this questionnaire to assess stress levels experienced by study
participants allowing them to focus on factors that have been perceived as stressful over the past
month. The 10-Item PSS (Cohen et al., 1983; Cohen & Williamson, 1988) measures three issues
identified as the major components in experiencing stress: 1) unpredictable, 2) uncontrollable,
and 3) overloading life events. This measure was used to assess associations with the
demographic and treatment variables that may impact the dependent variable of memory.
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In addition to the operationally defined measures, there was also one open-ended
question and several specific demographic and treatment questions as other independent
variables. The one open-ended question asked participants to describe what factors they felt
negatively impacted their memory:
1. What factors do you feel have had an impact on your memory during your breast cancer
journey? Please be as specific as possible.
Operational variables
Operational definitions describe the variables and reflect how the dependent and
independent variables are measured. This descriptive correlational study assessed whether there
are any relationships between independent variables and memory among women with breast
cancer. The operational variable was used in the questionnaire administered to participants via
SurveyMonkey.
Independent Variables
The independent variables of this study were all factors listed as having a negative impact
on the participants’ memory as self-reported in the questionnaire. Variables of particular interest
included treatments received, duration of time since last treatment, how long the participant
experienced treatment, personal events that occurred during this time, anxiety, depression, stress,
and whether the participant was treated pre- or during/post-COVID-19 state of emergency as
indicated by the date of their last treatment prior to March 22, 2020. Additional predictor
variables included selected demographic characteristics as self-reported in the questionnaire. The
Perceived Stress variable also served as an independent predictor of memory.
Description of Cognitive Impairment Related to Cancer
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Walker and Avant (1995) defined antecedents as events or incidences that must occur
prior to the occurrence of the concept. In terms of cognitive impairments related to cancer
treatments, it can be difficult to determine antecedents due to a decreased universal knowledge of
the concept as a whole. Some antecedents of this phenomenon include particular chemotherapy
agents, hormonal therapy such as Tamoxifen and Letrozole, targeted biological therapies such as
Herceptin (trastuzumab), and psychological and biological factors.
Some chemotherapy agents have been shown to increase the risk of developing or
perpetuating cognitive impairments in cancer patients. Some agents commonly given to breast
cancer patients with particular increased risk include anthracyclines such as Adriamycin (Kesler
& Blayney, 2016), as well as Taxol (Paclitaxel), Carboplatin, Methotrexate, 5-fluorouracil,
Gemzar (Gemcitabine), and Navelbine (Vinorelbine) (McDougall et al., 2014). Survivors who
underwent hormonal therapy such as Tamoxifen or Letrozole and those who received targeted
biological therapies such as Herceptin have also reported symptoms of cognitive impairments
related to their treatments. Many physiologic and biologic factors should be considered as
influencing this phenomenon in combination with chemotherapy. Studies have shown that cancer
as well as surgical procedures associated with cancer may alter cognitive function in patients
(Ahles et al., 2008; Jansen et al., 2011). Ferguson et al. (2010) explained how major depressive
episodes and anxiety disorders are associated with short- and long-term memory deficits, as well
as deficits in psychomotor function, new learning, and naming. Some studies have shown that
estrogen has an enhancing effect on cognitive functioning, while other studies found little impact
(Ferguson et al., 2010).
Janelsins et al., (2014) found that cognitive impairments related to chemotherapy occurs
in both younger and older populations. The normal aging process is associated with cognitive
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decline. It is important to determine if a patient’s age is a sole determinant of cognitive decline or
if there is a correlation between age and chemotherapy at inducing or worsening cognitive
impairments. The connection between fatigue and cognitive impairments in cancer patients is
still undetermined. Ferguson et al. (2010) noted that fatigue associated with chemotherapy
receipt can compromise hemoglobin transport. This experience of fatigue differs from that of
chronic fatigue syndrome. Thus, more research needs to be conducted to determine if a causeand-effect relationship exists.
Components of Cognitive Impairment
Cognitive impairment is a complex condition that can be deconstructed into its
component parts. Critical attributes are components of a concept that when present identify the
concept as such. These attributes are the required describing factors that ultimately make the
concept what it is. In the absence of other neurological disorders such as Alzheimer’s disease,
dementia, head trauma, etc., symptoms of chemotherapy-related cognitive impairments such as
problems in executive functioning (attention, concentration, and problem solving), memory, and
verbal memory may be clinical attributes of this phenomenon. Trouble with attention and
concentrating associated with chemotherapy-related cognitive impairments can be as simple as
one forgetting what he or she was just about to say. It could become as complicated as the
inability to focus or problem-solve while following a recipe. Short-term memory is most
commonly affected by cognitive declines related to chemotherapy. Myers (2012) reported that
cognitive impairments in the domain of retention of information can occur in a variety of settings
including in casual conversations with friends or family, during work- or school-related
activities, and after reading or watching movies. Cancer patients and survivors explain that
problems in verbal fluency, speed of processing, and overall word-finding ability are decreased
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during and after treatments (Myers, 2012). They report having trouble remembering names,
completing sentences, and not being able to think of words they were looking to use (Myers,
2012).
Cognitive impairment is a complex condition that consists of declines in one or more
cognitive domains; of particular interest to this study is the cognitive domain of memory.
Problems with memory can be extremely scary and devastating. Problems with memory can also
be attributed to decreased quality of life among women with breast cancer. Although much
research is being done on cognitive impairments related to cancer and its treatment, there are still
gaps in knowledge. Research needs to be conducted to understand definitive causes and the
pathophysiology behind the decline in these cognitive domains. Effective assessments for cancer
and treatment-related cognitive impairments need to be studied and identified to be implemented
as standard practice. The purpose of this study is to explore the relationships between variables
such as individual characteristics, demographics, life events, and stress and the impact on
memory in women who have received at least one treatment for breast cancer. Time since last
treatment in accordance with the COVID-19 “lockdown” were also studied. In studying the
relationship between these variables and memory in this population, the researcher is utilizing
this study as a first step to develop a memory support strategy using a web-based nursing
intervention that considers the impact of stress.
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Chapter 2: Review of the Literature
This chapter presents a review of the literature for this study of improving memory for
women with breast cancer with self-reported cognitive impairments after chemotherapy. The
literature review is divided into several areas: (a) breast cancer overview, (b) history of breast
cancer treatments, (c) overview of cognition and cognitive domains, (d) cognitive impairments in
cancer patients, (e) cognitive impairment assessments, (f) potential mechanisms of cognitive
impairments, (g) measurement tools for cognitive impairments, and (h) possible interventions.
Breast Cancer Overview
It is important to note that while breast cancer incidence (or number of new cases) has
increased, the deaths related to breast cancer have declined over the past 20 years (Ely & Vioral,
2007). This is mainly due to the ability to screen for and diagnose breast cancer earlier and
advances in treatments. Cancer occurs when cells in the body begin to multiply and divide
rapidly. Cancer cells occur at a primary point, but they can also break off of the primary tumor
and spread to other locations, a process called metastasizing. This can occur at diagnosis,
anytime during treatment, or after one has been declared disease free after treatment completion.
Breast cancer is a malignant form of cancer diagnosed more often in women; however,
men can also be affected. This form of cancer occurs when the cancerous cells are present in the
breast tissue. Breast cancer is no longer viewed as a single disease but many diseases
differentiated by three characteristics: (1) histological, (2) biological, and (3) immunological
(Chapman & Moore, 2005). Survival of breast cancer is dependent on many factors, including
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growth rate of the tumor, age at diagnosis, and biological parameters that define the disease.
Diagnostic tests that may be involved in determining the presence of breast cancer include selfbreast exams, mammography, ultrasound, and magnetic resonance imaging (MRI). Breast cancer
is treated by multiple modalities depending on the size and staging of the tumor. Some potential
treatments include chemotherapy, radiation, hormonal therapy, and targeted therapy. These
treatments can be given as single regimens or in combination with one another (Chapman &
Moore, 2005).
History of Breast Cancer Treatments
Throughout the course of chemotherapy development for breast cancer, treatments have,
for the most part, remained the same. The main change of agents is how chemotherapy is
administered. Literature has discussed the progress made in adjuvant chemotherapy regimens for
the treatment of breast cancer. In the early 20th century, the standard surgical treatment for a
breast cancer diagnosis was a radical mastectomy, although research has more recently shown no
benefit of this procedure compared to less aggressive surgical interventions, and metastasis was
shown to occur despite which type of surgical procedure was performed (Anampa et al., 2015).
Through increased research studies, adjuvant therapies, such as chemotherapy, anti-HER2
directed therapy, and endocrine therapy, began to show promise when given in combination with
local therapies.
The success of the combination chemotherapy regimen CMF (Cytoxan, Methotrexate,
and 5-fluorouricil) at the Instituto Nazionale Tumori in Milan, Italy, helped demonstrate its
potential for success for patients who were status post-radical mastectomy. CMF quickly became
the first-line, first-generation chemotherapy treatment regimen due to its effectiveness at
reducing recurrence. Currently, CMF is still one of the chosen first-line treatments in patients
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followed by tamoxifen in patients with ER-positive, lymph node-negative disease and is
effective at improving 5-year disease-free survival.
Combination AC, which consists of Adriamycin and Cyclophosphamide every 3 weeks x
4 cycles, is a first-generation chemotherapy regimen that is still being used to date. This regimen
has improved the overall 3-year disease-free survival rate; AC-T, which consisted of Adriamycin
and Cyclophosphamide every 3 weeks x 4 cycles with or without being followed by Paclitaxel
(Taxol). The main difference between the first-generation AC and second-generation AC-T is the
potential to add Paclitaxel (Taxol) as well as escalating doses of Doxorubicin in the secondgeneration regimen (Anampa et al., 2015). An improvement came with the third-generation
chemotherapy regimen resulting from a study conducted by Citron et al. (2003), in which
researchers discovered more successful disease-free survival rates with dose-dense AC-T,
consisting of Adriamycin and Cyclophosphamide given every 2 weeks x 4 cycles, followed by
Paclitaxel (Taxol) every 2 weeks x 4 cycles followed by filgrastim. Dose-dense refers to
administering the same doses of chemotherapy at more frequent intervals. This regimen was
initially shown to improve the primary end-point disease-free survival and overall survival rates
in ER-negative disease but not ER-positive disease. A 2 x 2 factorial design was developed by
Citron et al. (2003) to determine the disease-free survival and overall survival rates of adjuvant
chemotherapy on node-positive primary breast cancer.
Results of this study indicated overall improvements of disease-free survival and overall
survival without any increase in experienced toxicities with the use of dose-dense AC-T and AT-C administered every two weeks and better outcomes than the conventional every three-week
administration of both the concurrent or sequential chemotherapy regimen. This study
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determined the effectiveness of dose-dense AC-T and dose-dense A-T-C, which are now both
considered first-line regimens chosen for node-positive primary breast cancer.
Women with breast cancer that is hormone-receptor-positive will usually be prescribed
hormonal therapy medicine, which has been shown to reduce the risk of recurrence. Hormonal
therapy helps lower the amount of estrogen in the body and it also blocks the action of estrogen
on breast cancer cells, decreasing the growth of cancerous cells for this population. There are
different types of hormonal therapy that are used for breast cancer patients at different
menopausal stages. Selective estrogen receptor modulators are used, such as Tamoxifen,
commonly in pre- and post-menopausal women with breast cancer. Aromatase inhibitors, such as
Arimidex (anastrozole), Aromasin (exemestane), and Femara (letrozole), are hormonal
medicines used to treat post-menopausal women. Previous standard of care comprised of
hormone-receptor-positive breast cancer was at least five years of hormone therapy after
chemotherapy or surgery. However, more recently, studies are being conducted demonstrating a
potential benefit to continuing hormone therapy for 10 years or more, rather than 5 years. Studies
have demonstrated conflicting reports about the benefits of staying on these medications longer,
so it is usually decided at the discretion of the doctor and patient (Al-Mubarak et al., 2014; Blok
et al., 2017; Davies et al., 2013; Goss et al., 2016; Mamounas et al., 2017; Tjan-Heijnen et al.,
2017).
The Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial was a worldwide
randomized control trial that demonstrated a lower risk of recurrence for those participants who
took Tamoxifen for 10 years, reduced breast cancer mortality, and reduced overall mortality
(Davies et al., 2013). This study shows there is a benefit to being on Tamoxifen longer than the
originally prescribed five years. A meta-analysis was conducted comparing the disease-free
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survival of women with early breast cancer treated with extended adjuvant therapy Tamoxifen to
those treated with standard of care Tamoxifen for five years. Overall, the results of this metaanalysis demonstrated some improvement in extended therapy, but not with enough significance
to warrant the benefit (Al-Mubarak et al., 2014).
The results of MA.17R, a randomized clinical trial of Letrozole, determined that taking
letrozole significantly improves disease-free survival and distant disease-free survival. The
overall survival was comparable in both arms except for participants with lymph-node positive
breast cancer, in which letrozole showed to improve their overall survival rates (Goss et al.,
2016). The NRG Oncology/National Surgical Adjuvant Breast and Bowel Project (NSABP) B42 Trial is one study that demonstrated significance in breast cancer-free interval event rate and
distant recurrence when using letrozole, an aromatase inhibitor for five years after five years of
endocrine therapy. This study did not note statistical significance in disease-free survival or
overall survival using these medications for extended therapy (Mamounas et al., 2017). In both
the DATA study (Tjan-Heijnen et al., 2017) and the IDEAL trial (Blok et al., 2017), aromatase
inhibitors after endocrine therapy failed to improve disease-free survival.
Extended aromatase inhibitor (AI) use has been shown to be more beneficial than
extended tamoxifen in breast cancer patients in some studies (van Hellemond et al., 2018).
Extended use of tamoxifen is recommended over AIs in particular subsets of patients, including
selected pre-menopausal women, those with intolerance to the extended use of AIs, and in areas
where AIs are more expensive and prohibits the ability of the patient to obtain it. Another issue
with the use of extended tamoxifen and AI medications is that of intolerable side effects leading
to patient discontinuance. Some women have been shown to discontinue the use of these
medications even before the standard five-year requirement (van Hellemond et al., 2018).
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Based on the mixed conclusions regarding the extended use of tamoxifen and AIs, many
oncologists are recommending the use of AIs or tamoxifen for at least 10 years. The use of these
AIs or tamoxifen may be suggested to be maintained longer then 10 years if the patient does not
have unpleasant side effects leading to a desire to discontinue use. It is because of these mixed
recommendations aforementioned that this study included women with breast cancer who have
completed chemotherapy no more than two years prior to enrollment but are continuing on AIs
or tamoxifen.
Cognitive Domain: Memory
Different areas of the brain help with different types of memory. Memory processing, one
of the largest areas of memory, is a function of the hippocampus located in the temporal lobe.
Memory is a process for encoding, storing, and retrieving experiences and knowledge. Figure 1,
from Lu and Woodruff (2018) from Queensland Brain Institute shows the lobes and
responsibilities of each lobe.
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Figure adapted from https://qbi.uq.edu.au/brain/brain-anatomy/lobes-brain

Figure 1 Lobes of the Brain and Their Responsibilities

There are two main types of memory: 1) short-term memory and 2) long-term memory. Longterm memory is then broken into smaller subsets seen in Figure 2 (adapted from Lu & Woodruff,
2018).
Types of Memory
Short Term

Long Term
Explicit (conscious)
Includes:

Implicit (unconscious)
Includes:

Episodic
(events that
happened to
you)

Priming

Semantic
(general
knowledge
of the
world)

Procedural
(e.g.
motor)

Figure 2 Types of Memory

Explicit memory is the role of the hippocampus, the neo-cortex, and the amygdala. Further, the
hippocampus is associated with episodic memory, which is formed by events in one’s life.
Semantic memory becomes one’s general knowledge, which are memories produced and moved
from the hippocampus to the neo-cortex. The amygdala is responsible for emotional memory, in
which the brain attaches an emotional significance to a memory. The basal ganglia and
cerebellum are responsible for implicit or unconscious memory. Implicit memory is more of a
procedural memory in which learned motor skills are stored for later use. One additional type of
memory is called working memory. This type of memory is present when activity is taking place
through the performance of tasks. Working memory is a job of the neo-cortex and is of particular
interest to study under neuroimaging such as MRIs (Lu & Woodruff, 2018). Cognitive domains
that are frequently reported as being affected by cancer and cancer treatments include attention
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(focused and sustained attention, selective attention, and distractibility); memory (immediate and
delayed memory, short-term/working memory, and visual and verbal memory); processing
speed; executive function (i.e., planning, organizing, problem solving, abstract thinking, mental
flexibility, and cognitive insight, ability to monitor or correct one’s own conviction; Jean-Pierre
et al., 2014).
Memory Compensation
The Memory Compensation Questionnaire measures self-reports of five everyday
memory compensation strategies utilized in older adults, which include external aids (e.g.,
notebooks or calendars), mnemonic strategies (e.g., imagery or rehearsal), increased effort
investment (e.g., concentrating harder to remember items), as well as other strategies. This has
been the only tool that has been deemed reliable and valid for assessing various forms of
everyday memory compensation (Garrett et al., 2010). Some argue that those with higher
cognitive reserve may experience less cognitive impairments over time because they have
participated in alternative memory strategies when previously used ones are no longer effective
(Stern, 2002). The utilization of varied memory strategies may enhance an individual’s cognitive
reserve through memory compensation although there is a need for more research.
Stress and Memory
The proof is building in the literature that stress can negatively impact both subjective
and objective memory (Belanoff et al., 2001; Lupien & McEwen, 1997; Lupien et al., 2009;
Neupert et al., 2006; Stawski et al., 2006; VonDras et al., 2005). In addition, when life stress
becomes too high to cope with, the ability to compensate may be hindered, even if one identifies
a deficit in memory ability. Along with stress, depression and anxiety could inhibit one’s ability
to compensate. On the other hand, one who experiences high levels of life stress as his or her
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normal functioning may be more capable of compensating compared to those with lower levels
of life stress due to the continual presence of these higher than usual levels.
Cognitive Impairments in Cancer Patients
Breast cancer
Women with breast cancer have reported effects in short-term memory, trouble with
word finding (verbal memory), lack of focus and inability to concentrate, and decreased work
performance (Myers 2012). Patients have complained of decreased productivity, problems
relating to their social roles, and the inability to utilize their community engagement capabilities
(Reid-Arndt et al., 2009). For patients who have completed chemotherapy treatments, the most
concerning report is that of a diminished ability to return to work in full or limited capacity, with
some women not being able to return at all depending on the severity of cognitive decline
(Bradley et al., 2005; Janelsins et al., 2014; Wefel, Lenzi, Theriault, Buzdar et al, 2004). Linda
James is a survivor of cancer and reported that she felt like she was losing her mind or going
crazy during her treatments. She explained her experience stating, “I can’t find the right words
when I’m having a conversation. I forget what I wanted to say by the time the other person
finishes talking” (as cited in Gordon, 2014, p. 21). In one qualitative study involving interviews
and focus groups of female breast cancer survivors, six major themes arose from the study,
including cognitive problems, effects on employment, emotional response, a search for answers,
coping mechanisms, and the providers’ roles (Becker et al., 2015).
The relationship between anxiety and cognitive impairment in breast cancer patients has
been commonly researched in the literature. In one study, results did not determine a statistical
significance between anxiety at baseline and cognitive impairment; however, participants
receiving chemotherapy did demonstrate an effect on cognitive impairment that differed
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according to anxiety levels assessed at the baseline (Ramalho et al., 2017). It is important to note
that those participants who received anthracycline-based chemotherapy regimens that included
doxorubicin and cyclophosphamide demonstrated a four-fold higher presence of cognitive
impairments than those who did not receive those drugs (Ramalho et al., 2017).
Cancers of Other Origins
Cognitive impairments were assessed in testicular cancer survivors who were 2 to 7 years
post-treatment to determine whether there were differences between those treated with
chemotherapy and those not treated with chemotherapy. Participants in this study reported an
effect in the same domains as breast cancer survivors, including verbal learning and memory,
visual learning, executive functioning, processing speed, and attention and working memory
(Amidi et al., 2015). There is much conflict in the literature regarding the use of
neuropsychological tests to diagnose cancer patients with cognitive decline. While they may
prove useful and this study provides evidence, conflicts in the literature tend to lead to a warning
about using these objective tests as definitive and conclusive in cancer patients with reports of
cognitive impairments. In another study, researchers found no significant differences between
group means scores on neuropsychological tests for testicular cancer patients treated with or not
treated with chemotherapy with reports of cognitive impairments (Schagen et al., 2008; Skaali et
al., 2011; Wefel et al., 2011).
Participants in their study with nonseminomatous germ cell tumors who were treated with
chemotherapy showed more of decline in cognitive functioning with elevations happening over
time (Wefel et al., 2014). While overall results of another study did not demonstrate a
significance in cognitive impairments between those who received chemotherapy and those who
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did not, in all, testicular cancer survivors, on average, did perform significantly lower on
neuropsychological tests than expected (Wefel et al., 2011).
Potential Mechanisms of Cognitive Impairments
Various mechanisms have been identified that may influence the onset and severity of
cognitive impairments, including chemotherapeutic agents that cross the blood-brain barrier;
direct cell injury; indirect call injury that leads to the release of cytokines causing inflammation
and oxidative stress; as well as confounding factors of fatigue, age-related cognitive decline,
hormone reduction, anemia, anxiety, and depression (Allen et al., 2018). Neuropathic
underpinnings could be responsible for increased cognitive impairments in patients with cancer,
including disrupted fronto-striatal networks and reduced frontal-occipital and parietal white
matter integrity (Damholdt et al., 2016).
Hormones
There has also been a link found between changes in levels of estrogen and testosterone
and cognitive decline. Varying levels of hormone release can be directly related to natural
menopause onset. The initiation of menopause can also be induced by hormonal therapy, which
is common among hormone receptor-positive breast cancer patients. This hormonal therapy is
given to patients to help suppress the production of estrogen and testosterone and is believed to
have an impact on cognition (Castellon et al., 2004; Zec & Trivedi, 2002).
The activation and deactivation of working memory was shown to be increased in preand peri-menopausal patients, whereas it was not increased in post-menopausal or health control
populations. This in turn means that working memory could be hindered in patients who were
not experiencing amenorrhea prior to starting chemotherapy and that chemotherapy-induced
amenorrhea could negatively affect cognitive functioning in the domain of working memory
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(Conroy et al., 2013). It could be fair to say that the decrease of estrogen production and release
caused by the initiation of amenorrhea with the start of chemotherapy treatments can lead to
increased problems in some cognition function in breast cancer patients.
Genotype
Various genetic components are thought to increase vulnerability for cognitive changes.
Apolipoprotein E is a complex glycoprotein that is responsible for the uptake, transport, and
distribution of lipids and has been shown to affect neural repair and plasticity after injury. It is
associated with cognitive problems in various disorders, including memory complaints in
otherwise normal patients, Alzheimer’s disease, and stroke and brain injury (McAllister et al.,
2004). Cancer survivors who were found to have at least one E4 allele were shown to score
significantly less on visual memory and in spatial ability domains than survivors who did not
have this gene (Ahles et al., 2003). COMT-Val is a single nucleotide polymorphism that allows
for quicker metabolism of dopamine and leaving less neurotransmitters available, which is
critical for cognitive functioning (McAllister et al., 2004). This gene carrier performed poorly in
domains of attention and executive function, and breast cancer patients in particular who have
this gene performed more poorly on attention tests than healthy controls carrying the gene (Small
et al., 2011).
Certain subgroups of patients may be more prone to experiencing cognitive problems or
have continued problems throughout the course of their AI treatments. These problems were
present prior to treatment initiation and continued through the 18-month treatment course
(Bender et al., 2018). Some characteristics that were shown to increase cognitive problems with
treatment include advancing age, greater levels of pre-therapy fatigue, and the presence of
cognitive problems prior to adjuvant treatment. Results also concluded that the effects of cancer
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and cancer treatment can extenuate cognitive problems related to aging neurons and damaging
DNA (Bender et al., 2018).
Fatigue, Depression, and Anxiety
Pretreatment worry in women with early-stage breast cancer was shown to affect
cognition more in those to be receiving chemotherapy treatments than radiation (Berman et al.,
2014). Researchers explain this result as being related to the worry of toxic effects that are more
associated with cytotoxic medications such as chemotherapy than effects of radiation, which are
known to be less devastating on patients (Berman et al., 2014). Researchers suggest that future
research be conducted on late-stage or patients with metastatic disease. Future research is
implicated to validate these results as worry remains an important component affecting cognitive
problems associated with cancer and cancer therapy (Berman et al., 2014).
Cytokines and Inflammation
Research has been and is continuing to explore the role of cytokines and chemotherapy
on cognitive changes experienced in patients with various types of cancer. In one study among
breast cancer patients, brain imaging demonstrated an increase in sTNF-RII in patients that
received chemotherapy compared to those who did not, which increased self-reported memory
impairments (Ganz, Bower, et al., 2013). In this study, researchers could not determine a
significant association between objective measures and pro-inflammatory cytokines (Ganz
Bower, et al., 2013). A cross-sectional study demonstrated decreased left hippocampal levels that
were associated with higher levels of TNF-ᵪ and lower levels of IL-6, both being significant
findings in the chemotherapy recipients and the health control group (Kesler et al, 2013). This
study determined that altered hippocampal volume and memory problems may be associated
with the elevated TNF-ᵪ and decreased IL-6 levels (Kesler et al, 2013).
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One study explored the relationship of three different cytokine levels (IL-6, IL-8, and
MCP-1) and the severity of self-reported cognitive complaints in breast cancer patients who
received one of following regimens: doxorubicin-based (with cyclophosphamide or
cyclophosphamide with 5-fluourouricil; AC/CAF) or cyclophosphamide, methotrexate, and 5fluourouricil (CMF). All three cytokine levels were elevated in the doxorubicin-based regimens
than CMF (Janelsins et al., 2011). However, MCP-1 changes were negatively correlated with
self-reports of forgetfulness (Janelsins et al., 2011). A case-control study demonstrated that there
were more self-reports of cognitive impairments in patients who received chemotherapy than
those who did not. On the other hand, those patients who had breast cancer and did not receive
chemotherapy showed more cognitive decline on objective cognitive testing than the other two
groups (Booth et al, 2006). Although there was increased frontal lobe activity in those with
increased levels of objective cognitive impairment, there was no significant correlation between
patient symptoms and cytokine levels (Booth et al, 2006).
One study of head and neck cancer patients exploring the effects of radiotherapy alone
versus the combination of radiotherapy and cisplatin-based chemotherapy on cognitive function
demonstrated that the patients who received the cisplatin-based chemotherapy in combination
with radiotherapy had poorer objective cognitive functioning than those who received
radiotherapy alone; the statistics were not significantly different (Ganz, Kwan et al., 2013). This
result indicates that there is not a strong enough correlation between objective cognitive
functioning and a patient’s cytokine level (Ganz, Kwan, et al., 2013). Treatment was shown to
not have a significant impact on cognition in patients with myelogenous leukemia and
myelodysplastic syndrome patients when measured at the baseline (prior to chemotherapy) and
one month later, although fatigue levels tended to increase (Meyers et al., 2005).
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Relationships between cytokines/receptors, including sTNFR1, sTNFRII, TNF-α, MCP1, IL-8, IL-6, and IL-6R, sought to determine if there was an association between them and
cognitive functioning in breast cancer patients currently receiving chemotherapy. Results
indicated a relationship between sTNFRI and sTNFRII receptors and short-term visual memory,
with declines in short-term visual memory being expressed when increased concentrations of
these receptors were present (Williams et al., 2018). Receptors MCP-1 and TNF-α were found to
have mixed results that need to be taken with caution, as some results show increased levels and
decreased levels have been associated with chemotherapy-related cognitive impairment (Meyers
& Perry 2008). Another potential role that cytokines play in chemotherapy-related cognitive
impairments development and expression is their role in dopamine and serotonin metabolism,
which is thought to help maintain cognitive function (Ahles & Saykin, 2007).
Cancer patients who receive Paclitaxel (Taxol) are thought to be at increased risk for
cognitive problems related to pro-inflammatory cytokine release, especially IL-6, which has
shown to be elevated three days after receiving the drug. These levels were not shown to be
elevated in patients who received 5-fluorouracil (5-FU), cyclophosphamide (Cytoxan), and
methotrexate in combination (Pusztai et al., 2004). This may indicate a need to determine if other
cytokines in particular are released with these drugs increasing inflammation and worsening
symptoms.
Fatigue severity was compared in lymphoma patients 4-10 years post-chemotherapy and
general population norms using the EORTC-QLQ-C30. Although more patients’ postchemotherapy reported having cognitive impairments and they had slightly more elevated serum
cytokine levels than the population norms, researchers did not explore the association between
cytokine levels and cognitive impairments (Knobel et al, 2000).
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Chemotherapy/Cancer Treatment Related
Although most chemotherapeutic agents do not cross the brain-blood barrier, cognitive
impairments are shown to be increased in patients who have received chemotherapy versus those
who have not received chemotherapy. Particular agents have been suspected of potentiating
cognitive impairments more so than others, as well as the dose and administration of agents.
Chemotherapy agents such as antimetabolites (i.e., methotrexate and fluorouracil), platinumbased agents or nitrosureas have all been associated with central nervous system neurological
toxicity or chemotherapy-related cognitive impairments (Meyers & Perry, 2008). The importance
of focusing on the type, dose, and administration route of chemotherapy needs to be stressed as
they are all variables that influence the onset and effect of cognitive impairments in this
population (Simo et al., 2013). Although most experiences of cognitive impairments have been
reported in patients while they were receiving chemotherapy, a sub-set of patients (17-34%)
report this effect as being a long-term effect of treatment (Ahles & Saykin, 2007).
In a prospective, longitudinal study, 61% of subjects treated with 5-fluorouracil (5FU),
doxorubicin, and cyclophosphamide (FAC) chemotherapy regimen had cognitive declines in
learning, attention, and processing speed. However, if this pre-treatment assessment had been
unavailable, the researchers reported that 46% of participants would not have had detectible
cognitive impairments because their post-treatment assessment scores were in the normal range
(Wefel, Lenzi, Theriault, Davis, et al., 2004). The significance of these results is that cognitive
declines associated with chemotherapy treatments can be intermittent and oftentimes subtle,
which can make it difficult to ascertain a clinically significant difference in cognitive ability
during testing. Cognitive declines related to chemotherapy treatments were seen in the cognitive
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domains of executive function, memory, psychomotor, speed, and attention (Janelsins et al.,
2014).
In cancer patients who received fluorouracil and oxaliplatin at two hospitals in South
Korea, self-reports of cognitive declines were more prevalent than when assessed through
objective measures (Oh, 2017). Results also pointed to possible predictors of cognitive decline in
this population as including fatigue levels, depression, age, and toxic effects from chemotherapy.
Participants showed mild cognitive declines in objective measures and increased self-reports of
cognitive decline (Oh, 2017). Differences in self-reported cognitive complaints, structural and
functional MRI images, and standard neuropsychological tests were explored between two twins,
one diagnosed and treated for breast cancer (Twin A) and the other twin who was not diagnosed
with breast cancer (Twin B), with Twin A having more self-reported cognitive impairments and
higher scores on short- and long-delay recall than Twin B (Ferguson et al., 2007).
Cognitive performance has been shown to worsen based on the number of chemotherapy
treatments (Collins et al., 2013). Significantly lower scores on verbal memory performance have
been seen in those treated with anthracycline-based regimens versus those treated with
nonanthracycline-based treatments or those who did not receive any chemotherapy (Kesler et al.,
2016). However, the same study showed that anthracycline-treated and nonanthracycline-treated
participants demonstrated lower executive function and increased distress and fatigue than
participants in the study who never received chemotherapy treatments (Kesler et al., 2016). A
meta-analysis showed differences between those who received chemotherapy and healthy
controls but not between chemotherapy and non-chemotherapy participants in cognitive
impairment (Ono et al., 2015).
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Results of one study indicated that while chemotherapy can influence the worsening of
cognitive functioning among some cognitive domains, it also showed that cognitive dysfunction
can occur with the onset of disease and disease development regardless of the introduction of
treatment (Winocur et al., 2018). This result is consistent with reports that only some people
suffer from cognitive impairments before starting treatment.
Brain Changes
The literature is beginning to shift attention to neuroimaging studies that are showing
changes in different parts of the brain, which demonstrates that this phenomenon is a tangible
problem. Just as cognitive changes are associated with cancer treatments, in particular,
chemotherapy can be subtle enough to not be detected with neuropsychological measures;
changes in brain functioning and neural changes all related to chemotherapy can be trivial and
hard to identify. Neuroimaging techniques currently being used to investigate these changes
provide a fine-grained examination of these subtle neural changes.
Breast cancer survivors more than 20 years post-chemotherapy had significantly less total
brain volume as well as less gray matter volume compared to the health control group
(Koppelmans et al., 2012). More gray and white matter loss has been shown in those treated with
chemotherapy as well as reduced white matter integrity and altered brain activation, all of which
have been shown to occur in many different parts of the brain, including the prefrontal lobe,
parietal, occipital, and temporal lobes and lasting between 12 months to 20 years after
completing treatment (Janelsins et al., 2014). These imaging studies demonstrate that cognitive
changes related to brain alterations can leave permanent changes in a subset of patients.
Dr. Marc Haut, a neuropsychologist from West Virginia University School of Medicine,
described symptoms of cognitive impairments related to chemotherapy as similar to changes that
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are seen in patients with subcortical white matter disease, which are small strokes that occur deep
inside the connecting fibers of that brain that affect a person’s cognitive domains of executive
functioning and processing speed (as cited in Gordon, 2014). Furthermore, Dr. Lynne Taylor, a
neuro-oncologist from Tuft’s Medical Center in Boston, Massachusetts, reported that
neuroimaging studies in patients reporting cognitive impairments have demonstrated white
matter changes particularly occurring in the hippocampus and prefrontal cortex, both of which
are responsible for higher-level cognitive functioning (as cited in Gordon, 2014).
Stress
Stress has been described as a response to an event perceived to be a pressure or threat
(Johansen et al., 2017). It is also a reactive process to the unknown or a cognitive, behavioral, or
emotional responses to events deemed by an individual as stressful. A stressor is what causes an
individual to become stressed, and the stressful event is the experience associated with the
exposure to a stressor. Human beings have always risked experiencing stress when faced with
the unknown or when the present is unpredictable. There has been much research to determine
the existence of a relationship between stress and disease processes, focusing on the mind-body
relationship. One disease of particular and current interest in the literature is stress and cancer.
While studies have not established a definitive causal relationship of stress to cancer
development, many researchers continue to study this possible connection between the two.
What may be of bigger relevance to this study is the concept of stress as a prognostic
factor in cancer, which focuses on a cancer patient’s ability to cope with cancer diagnosis,
treatment, and disruption in life. This concept is also explored on the basis of one’s ability to
cope with the psychological stress associated with cancer and its impact on survival. Women
with cancer who used “fighting spirit” had better survival outcomes than those using other
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coping mechanisms (Greer et al., 1979). Those who have less ability to use coping skills and thus
focus more on feeling helpless or hopeless have shown poorer outcomes. There has been
increased interest in studying coping mechanisms that can benefit cancer patients. If stress has an
impact on memory, this study can also be a first step to developing a memory intervention that
can equip patients to cope with their cancer and have better outcomes along with improving
one’s memory.
Women diagnosed with breast cancer deal with many different types of stress related to
their diagnosis as well as to treatment-related side effects (Papanastasiou et al., 2019). In two
case-control studies identified by researchers, breast cancer patients who are undergoing
treatment have increased levels of stressed as compared to healthy individuals (Hinnen et al.,
2008; Hoskins, 1997). These studies showed a correlations between stress and a decline in
cognitive functioning demonstrated through self-completed questionnaires or psychometric
testing or both in younger patients with breast cancer.
The ability of one’s brain to regulate and adapt to stress is called allostasis. The overuse
or disruptions in this system can lead to a dysregulation contributing to allostatic load, which has
been shown to lead to disease over long periods of time. Increased allostatic load has also been
associated with a decrease in hippocampal size. Memory functioning is a function controlled by
the hippocampus, and with decreased size, memory can be negatively influenced. Individuals
with high levels of allostatic load at diagnosis may be at increased risk for cognitive decline
associated with their cancer (Andreotti et al., 2014). Thus, it can be said that there is a significant
relationship between stress and memory.
Another factor that researchers explored was glucocorticoid levels and cognitive
functions, with cortisol levels relating to memory ability. High levels of glucocorticoid secretion

38

suppress the excitability of the hypothalamic pituitary adrenal axis leading to impaired memory
and attention (Myers, 2014) and increased and prolonged excitability of neuron activity can
cause atrophy of both prefrontal and hippocampal brain regions, leading to decreases in memory
and attention (McEwen & Gianaros, 2011). Psychological stress, in particular, that is associated
with cancer diagnosis and treatment has been shown to increase allostatic load. Psychological
stress has also been shown to increase cortisol levels with an inability for the body to regulate
these levels. Both of these factors can lead to impairments in memory, thus demonstrating a
connection between psychological stress and memory impairment.
Assessing for Cognitive Impairments
To date, the literature has failed to identify a standardized assessment for cognitive
impairments. Oncology practices and centers are left to develop their own assessments and
protocols for assessing for these side effects. This can be daunting in that no standardization in
assessment can leave some patients undiagnosed and thus untreated. Two main categories of
assessing cognitive impairments include objective measures in terms of using psychometric tests
and subjective measures in terms of self-reports and perceived cognitive impairments from those
experiencing the symptoms.
Cognitive decline may not always be measurable or observable by people other than
those experiencing them because they are subtle. This becomes even more frustrating to those
with cognitive impairments when the reports do not corroborate with neuropsychological tests
and are thus rejected as a true experience related to cancer or cancer treatment. The National
Comprehensive Cancer Network (NCCN) Survivorship Guidelines have recently focused on
cognitive impairments and the need to assess for this phenomenon in patients; however, they
have not identified any assessment tool of benefit. Rather, the National Comprehensive Cancer
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Network stresses the importance of discovering or developing proper assessment tools for
cognitive impairment. The network also emphasizes the importance of performing a
comprehensive clinical assessment that includes family members and their experience with the
patient’s cognitive functioning. It is also important for the healthcare providers to assess for
potential causes of cognitive impairments other than cancer and cancer treatments such as
hypercalcemia, metabolic disturbances, multisystem failure, emotional stress, anxiety, and
depression. Patients reporting cognitive impairments should be assessed for comorbidities that
may affect their cognition prior to starting cancer treatments, including diabetes, cardiovascular
disease, and neurological conditions (i.e., stroke and Alzheimer’s disease). Medication
reconciliation should also be performed to assess one’s cognition such as antidepressants,
antipsychotics, antiepileptics, opioids, and sedatives.
Objective Measures and Psychometric Testing
There is debate in the literature as to whether objective measures and neuropsychological
testing is adequate in assessing for cognitive impairments in breast cancer patients due to the
subtle nature of these symptoms. While these cognitive impairments can remain in normal limits,
they have a remarkable impact on everyday functioning (Tannock et al., 2004). Everyday
functioning can be measured by the Everyday Memory Questionnaire (EMQ). Cognitive reserve
may result in discrepancies between objective testing and subjective reporting of cognitive
impairments related to cancer and cancer treatments (Moore, 2014). Cognitive reserve accounts
for increased activity in areas of the brain that allows for cognitive compensation, leading to
more perceived cognitive impairments than those detected on objective testing (Moore, 2014).
Cognitive performance of women undergoing chemotherapy and those 6-12 months post
chemotherapy completion showed declines in various neuropsychological assessment measures
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(Freeman, et al., 2002). This article supports the need for more research in this field to determine
the best measures of assessment as well as treatment options. A standard neuropsychological
battery is difficult to pinpoint for cancer patients due to their lack of validity and reliability
among this population (Jean-Pierre et al., 2014). The complexity of cancer- and treatment-related
cognitive impairments and the need to assess the integrity of all major cognitive domains lead to
in-depth testing, which could be compromised by clinical time constraints and patient fatigue.
Neuropsychological tests also may not be reimbursed by insurance companies for this population
reporting cognitive impairments (Jean-Pierre et al., 2014). With no “gold standard” in
assessments for cancer- and treatment-related cognitive impairments, subtle changes in cognition
are left to self-report and patient and family member perceptions.
Self-Reported or Perceived Cognitive Impairments
The Patient’s Assessment of Own Functioning Inventory is a 33-item tool measuring
domains found to be impaired in breast cancer patients, including higher level cognitive and
intellectual functions (executive functioning), memory, language, and motor/sensory-perceptual
area. This tool had been previously found to be reliable in other populations, but Van Dyk et al.
(2016) established both reliability and construct validity for this tool to assess cognitive
complaints among this population. Literature has found a relationship between self-reported
cognitive impairment after chemotherapy but not in the first 18 months of AI alone, possibly
because AI therapy may potentiate, worsen, or lengthen cognitive impairment that can be
experienced with or after chemotherapy (Merriman et al., 2017). Another explanation of this
result is that while AI therapy may lead to disturbances in cognitive functioning, these changes
may not be experienced early in therapy (Merriman et al., 2017).
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Some objective psychometric tests are unable to measure for the subtly associated with
cognitive impairments and also, some lack to ability to measure daily function limitations
experienced and reported by cancer patients. The main problem is associated with the ecological
validity of objective measures to adequately diagnose the subtle nature and particularity of
symptoms experienced by cancer patients. Ecological validity explains the applicability of a
study’s results to real-life experiences (Bender et al., 2008). It becomes even more important to
encourage patients to report these symptoms and help healthcare providers provide intervention.
Due to the documented differences between subjective and objective measures of cognitive
impairment, it becomes hard to determine the best clinically diagnostic approach to identifying
cognitive impairment. While changes in mood, in particular the presence of anxiety or depressive
symptoms, have been associated with cognitive impairments, it is important to note that not
everyone experiencing cognitive changes are depressed or anxious. Some studies have
determined relationships between objective measurements and certain domains of cognitive
function experiencing dysfunction (Matotek et al., 2001; Poppelreuter et al., 2004).
Differences have been explored in the subjective reporting of memory problems in breast
cancer survivors related to prospective memory and retrospective memory as well as to
comparing breast cancer survivors to healthy controls (Paquet et al., 2018). Prospective memory
involves the ability to execute a previously formulated intention at the appropriate moment.
Retrospective memory involves remembering past events or facts. Research conducted has
shown that breast cancer survivors have more difficulty with their prospective memory than
retrospective memory. Problems associated with memory failures are often not picked up by
neuropsychological tests because these tests tend to measure retrospective memory, a deficit not
common among this population (Kent, 2016). It has been shown that women, whether healthy or
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not, have increasingly poorer metacognitive efficiency as they get older (Collins et al., 2017;
Volz-Sidiropoulou & Gauggel, 2012).
Self-reports of cancer- and treatment-related cognitive impairments have more of a
detrimental impact on quality of life than impairments detected on objective neuropsychological
cognitive tests (Moore, 2014). While many studies have focused on objective measures of
cognitive impairments or have included neuropsychological tests as a component of the study,
many of them suggest the importance of focusing on the self-reports and perceived cognitive
impairments. More research needs to be done in this area. It is for that purpose that this current
study focused solely on self-reported and perceived cognitive impairments and did not include
neuropsychological measures.
Review of Measurement Tools for Cognitive Impairments
Through the qualitative data determined from one study, researchers began to devise a
psychometric tool to evaluate cognitive declines. This psychometric tool is now what is referred
to as the Functional Assessment of Cancer–Cognitive Function Instrument (Wagner et al., 2009).
In developing the tool, researchers found that patients reported cognitive problems as affecting
their work and daily life activities as either the inability to complete tasks or spending more time
to complete the tasks. These participants also reported that their cognitive decline was noticed by
family and friends with a significance of 75% (Wagner et al., 2009).
The Functional Assessment of Cancer Therapy-Cog (FACT-Cog-Ver. 3) was correlated
with the European Organization for Research and Treatment of Cancer Quality of Life Core
Questionnaire 30 cognitive functioning scale (Cheung, Lim, Ho, et al., 2013). The correlations
between the FACT-Cog and EORTC-QLQ-C30 were determined strong (r = .725 and .646),
whereas correlations with fatigue, anxiety, and global health status were determined to only be
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weak to moderate (r = .376-.589). Similar results have been determined from previous studies
(Jacobs et al., 2007). This could be a result of the multifactorial composition of cognitive
impairments and the various mechanisms that could be potentiating the phenomenon. It was
assessed using the Evaluation of Everyday Memory questionnaire that self-awareness of
everyday memory problems is important, especially since poor awareness can lead to an inability
to decide when and which compensatory strategies to use and/or the need to use assistive
techniques or devices (Tropp et al., 2015).
Von Ah and Tallman (2015) investigated the relationships between perceived cognitive
impairments using the FACT-Cog and its subscales and objective cognitive measure
performance; specifically, verbal memory, speed of processing, and executive functioning were
investigated in one study (Von Ah et al., 2015). Results of this study demonstrated that the total
score of the FACT-Cog questionnaires were directly correlated with the immediate verbal
memory component of the Rey Auditory Verbal Learning Test (AVLT) (r = .29; p <0.01);
delayed verbal memory component of the Rivermead Behavioral Memory Test Paragraph Recall
test (r = .30; p <0.01) (Von Ah et al., 2015).
The Patient Assessment of Own Functioning Inventory was tested and found to be valid
and reliable among post-menopausal women with early-stage breast cancer who were pretreatment (Bell et al., 2013). Studies are now revealing that women may experience cognitive
changes prior to starting adjuvant therapy, thus relating cognitive impairments to not only
chemotherapy (known anecdotally as “chemo brain”) and other cancer treatments but also
relating it to the cancer itself (Bell et al., 2013). Biological changes in cognitive function may
include changes in blood-brain barrier integrity, DNA damage, cytokine overproduction, genetic
susceptibility, and reduced estrogen related to cancer therapy (Ahles & Saykin, 2007). Authors
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continue to note that cognitive changes related to cancer and cancer therapies remain subtle in
nature and may not be identified on psychometric tests. They point to the ecological validity of
these tests and their ability to translate into daily functions (Chaytor & Schmitter-Edgecombe,
2003).
As evidenced by the literature, cancer and treatment-related cognitive impairments is a
complex phenomenon, one in which we can continue to learn about with increased research. This
phenomenon affects many domains of cognitive functioning, including executive functioning,
memory and recall, word processing, and attention. Cancer and treatment-related cognitive
impairments have been reported from individuals with many different cancers, but, it is most
frequently reported in women with breast cancer. Although there are many causes being explored
and identified as mechanisms behind this phenomenon, factors such as the cancer diagnosis,
cytokine release, inflammatory process, stress, and chemotherapy have been associated with
causation. This study served as a precursor to understanding what impacts memory in order to
begin to develop a memory-support strategy in the future.
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Chapter 3: Methods

This chapter focuses on the methods that were utilized for this descriptive correlational
study. The design of the study, setting, and sample are described, including the eligibility
criteria. In this chapter, the process for obtaining the sample, including the recruitment and
selection of participants as well as the procedure of the study, are presented.
Design
A quantitative, descriptive correlational study with a qualitative component was done
using a web-based survey on a sample of breast cancer patients that have or are currently
receiving at least one treatment. This study aims to determine relationships between various
independent variables (such as demographics, cancer treatments received, life events experienced
during treatment, and stress) and the dependent variable of memory. A one-time questionnaire
(which can be found, in full, in Appendix A) was sent via email to participants including two
instruments to assess memory, one measure of stress and questions obtaining demographics,
information related to treatments received, and the negative impact of these factors on memory.
One open-ended question asked participants to describe what factors they felt negatively
impacted their memory using the dependent variable of memory:
•

Do you feel your memory has been affected since your treatment? (Yes/No). If
so, what factors do you feel have negatively affected your memory during your
breast cancer journey? Please be as specific as possible.

Memory was measured by the Functional Assessment of Cancer Therapy-Cog (FACTCog, Ver 3), a 37-item Likert-type scale divided into 4 subscales assessing Perceived Cognitive
Impairments (20 items), Perceived Cognitive Abilities (9 items), Comments from Others (4
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items), and Impact on Quality of Life (4 items); and the Everyday Memory Questionnaire, a 13item Likert-type modified version used by Royle and Lincoln (2009) as a subjective measure of
memory failures in everyday life. Stress was assessed through the Perceived Stress Scale (Cohen,
Kamarck, & Mermelstein, 1983). Time since last treatment was assessed to determine whether
last treatment received was pre- or concurrent to the COVID-19 pandemic determined by March
22, 2020, at 8:00 p.m., the date and time established when the New York State Governor, by
executive order, limited services to essential and emergency only (New York State, 2020) in
order to determine this event’s impact on stress and memory.
Collecting quantitative and qualitative data concurrently enriches the study by adding
depth to the quantitative findings through the open-ended qualitative question without leading
the participants’ responses (Borkan, 2004). Using this approach provides a comprehensive
understanding of the impact of various variables, including demographics, treatment modalities,
time since last treatment, stress, life events, and the COVID-19 pandemic on memory among
women with breast cancer who have received at least one treatment. Demographics were
collected in the survey and consent was waived with information about the study and instructions
that, by completion and submission of the survey, subjects are giving their consent.
Setting
The setting for this study was internet based. The questionnaire was distributed to
participants via a link directing them to SurveyMonkey.
Sample
The sample for this study was women with breast cancer who have received at least one
treatment modality and are either currently receiving treatment or have completed treatment no
more than five years prior to study enrollment. Treatment modalities for breast cancer included
in this study are surgery alone, surgery with another treatment modality, chemotherapy alone or
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with another treatment modality, and radiation with or without another treatment modality. The
sample was recruited directly or indirectly from a private practice in Long Island, NY, and
through social network recruitment and individual invitations through community contacts for
potential participants who met the criteria for inclusion. The use of snowballing and social media
to recruit from breast cancer interest groups including word of mouth may also be used as
strategies to supplement the returns. From this population, a convenience sample was identified
of respondents and then stratified to seek out those who meet the inclusion criteria.
Eligibility
The eligibility requirements assessed demographics including age, race, education,
relationship status, as well as other factors that could affect the cognitive domain of memory
including types of treatments received, length of time since receiving last treatment, duration of
treatments, and year of initial diagnosis. Another factor taken into consideration for comparative
purposes included whether the participants received their treatments pre- or during/post the
COVID-19 pandemic “lockdown” date in New York state when non-essential services were
stopped.

48

Age. Participants in this study had to be women who are between the ages of 18 and 80.
Although literature supports the presence of cognitive decline as a component of normal aging, it
is still yet unclear if increased age has a negative or positive correlation with increased cognitive
impairments. Changes in cognitive processes, including declines, are common with normal
aging. The actual ages that these declines and plateaus vary with each cognitive domain and
process. Murman (2015) reported that while some cognitive processes have been shown to
decline after age 30 (auditory acuity), others occur later in life. Of particular importance to this
study include the cognitive processes of memory, retention, and executive functioning.
Increasing age has demonstrated declines in new learning abilities and the retrieval of newly
learned material. While studies have shown that “sensory memory” is stable with aging, the
storage capacity for older adults is limited and difficult to exceed. Howieson (2015) described
how memory declines over time, worsening with normal aging in the following manner:
information recall has been shown to peak early and decline after the age of 40; language and
recall becomes harder after the age of 70; information processing becomes hindered in the older
adult; and visual perceptual abilities decline around the age of 80.
The American Cancer Society (2020) publishes statistics related to breast cancer
diagnoses yearly. According to their most recent publication 2019-2020, the incidence of breast
cancer diagnosis has been shown to increase until women reach their 70s. Incidence after 80
years slowly decreases. The median age of breast cancer diagnosis from 2012-2016 was 62.
When measured in 10-year age groups, the probability of a breast cancer diagnosis is highest for
women in their 70s (4.1%). With this data, the researcher feels it is important that this study aims
to recruit a sample more reflective of the population.
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Diagnosis and Treatments. Participants included in this study were women with a
diagnosis of breast cancer, including those with metastatic breast cancer, who have received any
treatment including surgery alone, surgery with another treatment modality, chemotherapy alone
or with another treatment modality, and radiation with or without another treatment modality.
Participants were considered eligible for this study regardless of whether they have completed
treatment, are metastatic breast cancer patients, or are currently receiving treatment. Participants
were considered ineligible if they have completed treatments in whole more than 2 years prior to
study enrollment. Chemotherapy agents of particular interest for this study include Adriamycin
(Doxorubicin), Cyclophosphamide (Cytoxan), Paclitaxel (Taxol), Methotrexate, 5-fluorouracil
(5-FU), Taxotere (Docetaxel), or Carboplatin. Justification for using these agents is based on
strong literature noting the potential role these particular medications play in cognitive
impairments in cancer patients. However, the study was open to include any chemotherapy
agent, including oral medications. Women currently receiving hormonal or endocrine therapy
were eligible for participation in this study.
Inclusion and Exclusion Criteria. Table 2 provides the eligibility and ineligibility
criteria for participants for this study.
Table 2
Inclusion and Exclusion Criteria

50

Inclusion Criteria

Exclusion Criteria

Women ages 18-80

Men
Women Below 18 or above 80 years of age

Diagnosed with breast cancer and received at least
one form of treatment modality

Diagnosed and treated for any other cancer with no
breast cancer diagnosis OR with breast cancer
diagnosis and treatment more than 5 years prior to
study enrollment

Received any treatment for breast cancer including:
surgery alone, surgery with another treatment
modality, chemotherapy alone or with another
treatment modality, and radiation with or without
another treatment modality

Neurological disorders or diseases including:
dementia, Alzheimer’s, brain injury not limited to
traumatic injury, seizure disorder, or stroke.
Psychiatric diagnoses or disease including: major
depressive disorder, schizophrenia, bipolar disease,
psychotic disorders or episodes. Heart disease,
congestive heart disease, or heart attack. Multiple
sclerosis (MS). History or current reports of
Alcoholism or Substance Abuse.

May be currently receiving treatment modalities for
breast cancer

Taking medications including: anti-epileptic
medications, medications for dementia or Alzheimer’s
disease, bipolar medications, anti-schizophrenic
medications, anti-psychotic medications

Completed chemotherapy regimen no more than five
years prior to study enrollment.
May be currently receiving treatment for metastatic
breast cancer.

Recruitment
Aforementioned participants for this study were recruited from a free-standing health
organization on Long Island, New York. Additionally, to more accurately represent the
population, the researcher may seek to recruit additional participants through the assistance of a
larger organization helping to support breast cancer patients. The organization was asked to
assist with the distribution of the researcher-developed recruitment flyer (found in Appendix B)
that directed potential participants to the survey link. In addition, other organizations such as
local breast cancer support groups were considered to increase the sample to supplement the
returns in order to meet the minimum amount required to prevent a Type II error from occurring.
These additional returns were also stratified and reviewed for inclusion criteria. The use of

51

snowballing and social media to recruit from breast cancer interest groups including word of
mouth were also used as strategies to supplement the returns (Figure 3).

Figure 3 Study Schema

Selection
An investigator-developed questionnaire was used to collect demographic information, including
age, education level, and limited medical information (to be used to determine eligibility).
Questions surrounding medical information determined coding treatment modalities received,
time since last treatment, and any current or past neurological or psychological history or
treatments. Participants were required to complete this questionnaire to determine if they met
inclusion criteria for this study as well as for the research purposes of this study. This
investigator-developed questionnaire was the first page of the SurveyMonkey questionnaire.
Two instruments to assess memory, the FACT-Cog, Ver. 3 and the EMQ, and one instrument to
measure stress, the PSS, were a part of the SurveyMonkey questionnaire. The questionnaire also
assessed characteristics including demographics, information related to treatments received, and
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the impact of these factors on memory. One open-ended question asked participants what factors
they felt negatively impacted their memory. Time since last treatment were assessed and
participants responded to their last treatment date to determine whether treatment received was
before, during, or after the COVID-19 pandemic determined by the date established when the
New York Governor limited services to essential and emergency personnel only.
Procedures
This descriptive correlational study was conducted through the distribution of the
questionnaire via SurveyMonkey to a sample of women with breast cancer who have received at
least one treatment modality and express problems with memory. This research aimed to identify
relationships between various factors and their negative effects on memory among this sample.
This online survey served as a first step to identify influential variables that may impact
cognitive function in order to develop a memory-support strategy using a web-based nursing
intervention that considers the impact of stress.
For the quantitative component of the study, the researcher collected demographic
information as well as other pertinent information regarding treatments the participants have
received, and time since last treatment received. Memory was measured by the FACT-Cog, Ver
3, a 37-item Likert-type scale divided into 4 subscales assessing Perceived Cognitive
Impairments (20 items), Perceived Cognitive Abilities (9 items), Comments from Others (4
items), and Impact on Quality of Life (4 items); and the EMQ, a 13-item Likert style modified
version used by Royle and Lincoln (2009) as a subjective measure of memory failures in
everyday life. The researcher also used the revised PSS from Cohen and Williamson (1988), a
10-item, Likert-type questionnaire developed to ask questions focused on acquiring respondents’
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feelings and thoughts surrounding the previous month in an attempt to assess their stress levels
and factors that increase their stress.
The questionnaire consisted of one open-ended question to elicit narrative, personalized
responses to the following question:
1. Do you feel that your memory has been affected since your treatment? (Yes/No) If so,
what factors do you feel have negatively affected your memory during your breast cancer
journey? Please be as specific as possible.
This question provided an opportunity for the respondents to answer, in their own words, about
their personal views about what factors in their life during their cancer journey have negatively
affected their memory. These narrative responses served as qualitative data to be triangulated to
corroborate the quantitative responses.
Consents were sent along with the SurveyMonkey questionnaire link. By submitting the
responses, the participants were made aware that they are providing their consent for the research
study. They were made aware that their participation is voluntary and that they could withdraw
from the study at any time, free of penalty. There was no review needed of medical records or
contact with the physicians regarding individual patients’ progress in the study.
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Instruments
Functional Assessment of Cancer Therapy-Cog (Ver 3). The FACT-Cog is from a
family of questionnaires used to assess various symptoms of cancer therapy. This particular scale
focuses on areas to assess cognition as it relates to patients receiving treatment for cancer. The
questionnaire (found in Appendix C) consists of 37 Likert-type items that are divided into 4
subscales: Perceived Cognitive Impairments (20 items), Perceived Cognitive Abilities (9 items),
Comments from Others (4 items), and Impact on Quality of Life (4 items). The context for all
subscales of this questionnaire is “In the past 7 days.” Content areas that items focus on include
mental acuity, concentration, memory, verbal fluency, multi-tasking/interruption, interference,
and functional change; all of which are all the identified domains reported to be affected. FACTCog (Ver. 3) has both negatively worded items (I have trouble with…) and positively worded
items (My mind is as sharp as it has always been) used for scoring. The FACT-Cog (Ver 3) had
been found to be reliable, with a Crohnbach’s alpha of 0.86 for the total score, and subscale
scores ranging from 0.77 to 0.86 (Von Ah and Tallman, 2015).
The FACT-Cog measurement tool was developed to assess the perceptions of cognitive
impairments and cognitive abilities during and after cancer treatments. This tool is also interested
in exploring the phenomenon of cancer therapy effects on patients as well as the impact on their
quality of life. Perceived cognitive impairments and comments from others are answered as
never, about once a week, two to three times a week, nearly every day, and several times a day.
Perceived cognitive abilities and impact on quality-of-life responses include not at all, a little bit,
somewhat, quite a bit, and very much. Individual items are scored from 0 to 4, and the process of
interpreting the score requires performing reversals (for negatively worded questions) as
indicated on the scoring sheet and then determining the sum of those scores in each subscale.
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The sum of the items is then multiplied by a particular number provided on the scoring sheet and
then that number is divided by the number of items in the subscale. The higher the scores on the
FACT-Cog in total or of the independent subscales, the less perceived cognitive impairments.
Low scores represent more cognitive impairments and a poorer quality of life.
Cheung, Lim, Shwe, et al. (2013) assessed the psychometric properties of the FACT-Cog
(Ver 3) in English- and Chinese-speaking cancer patients in Singapore. Researchers assessed and
correlated the FACT-Cog (Ver 3) with the European Organization for Research and Treatment of
Cancer Quality of Life C30 Questionnaire (EORTC-QLQ-C30) cognitive functioning scale and
the association with fatigue, global health status, and anxiety. The correlations between FACTCog (Ver. 3) and the EORTC-QLQ-C30 was determined to be strong (r = .725 and .646),
whereas correlations with fatigue, anxiety, and global health status were weak to moderate (r =
.376–.589). Cheung, Lim, Shwe et al. (2013) determined that the FACT-Cog (Ver. 3) internal
consistencies within the cognitive domains were high (Cronbach’s α = 0.707–0.929), and testretest reliability was satisfactory for both versions (intra-class correlation coefficient = 0.762 and
0.697).
Everyday Memory Questionnaire. Royle and Lincoln (2009) sought to confirm the
previously reported factor structure of the EMQ, to determine the internal consistency and
criterion validity of the scale and to develop a shortened version. After their study, the
researchers were able to modify the questionnaire to consist of 13-item, Likert-type questions.
The 13 items provided examples of things that happened in everyday life, whether frequent or
rarely. These items were measures by respondents and reported to have occurred as one of the
following parameters: A. Once or less in the last month; B. More than once a month but less than
once a week; C. About once a week; D. More than once a week or less than once a day; or E.
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Once or more in a day. The higher the total score on the EMQ, the more problems with memory
for respondents. The EMQ can be found in Appendix D.
Perceived Stress Scale. Along with the researcher-developed questions to collect
demographic information and information regarding participants’ treatment, the researcher also
utilized the revised 10-item PSS from Cohen and Williamson (1988). The Perceived Stress Scale
(Cohen, Kamarck, & Mermelstein, 1983; Cohen and Williamson, 1988) measures three issues
that they identified as the major components in experiencing stress: 1) unpredictable, 2)
uncontrollable, and 3) overloading life events. This scale also aims at assessing current levels of
stressed through more direct questions. This questionnaire is short, can be administered quickly,
and is easy to score. Results can be categorized into “low stress,” “moderate stress,” and “high
stress” groups. This tool was designed to be utilized in community populations with at least a
junior high education.
The original PSS (Cohen et al., 1983) was a 14-item tool and provided strong reliability
with a coefficient alpha reliability of .84, .85, and .86 in each of the three samples tested.
However, Cohen and Williamson (1988) determined that 4 items on this scale performed poorly
on exploratory factor analysis, leading to the development of the 10-item scale. By dropping the
4 poorly scoring items, Cohen and Williamson (1988) were able to maintain a good reliability (α
= .78) among the population studied as well as demonstrate that the PSS10 has a tighter factor
structure and slightly stronger internal reliability and thus suggest using this version of the tool.
The PSS can be found in Appendix E and a letter of permission for use can be found in
Appendix F.
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Methodology
Demographic variables including age, race, ethnicity, and education level were collected.
Participant diagnosis, treatment modalities received, time since treatment completion, and selfreports of memory problems were also measured as variables through the questionnaire.
Analysis
Data management (i.e., cleaning, coding) was done using Excel. Then, analyses were
conducted using the statistical software program SPSS. Descriptive analyses of demographic
variables including age, race, ethnicity, education level, diagnosis, treatment modalities received,
time since treatment completion, and stress and memory were performed.
Further, preliminary analyses were conducted to test for common assumptions before
proceeding with inferential analyses regarding the main hypothesis: Various factors, including
demographic characteristics, factors associated with treatments, and stress will have a negative
impact on memory among women with breast cancer who have received at least one treatment
modality.
Human Subject Protection
The research study received approval from the IRB committee at Molloy College (found
in Appendix G). During the recruitment meeting, participants were informed that study
participation is voluntary and that individual results would not be shared with anyone not directly
involved in the study. Participants were told they could withdraw from the study at any time
without penalty. Participants were recruited through referrals from their oncologist or physician
assistant. In addition, other organizations such as local breast cancer support groups were
considered to increase the sample to supplement the returns in order to meet the minimum
amount required to prevent a Type II error from occurring. These additional returns were also
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stratified and reviewed for inclusion criteria. The use of snowballing and social media to recruit
from breast cancer interest groups, including work of mouth, were also used as strategies to
supplement returns. The links to the SurveyMonkey questionnaire and tool were sent via email
or the link was distributed to interested participants. Participants consented at the time of
responding to the questionnaire.
Data Handling
•

Locked in a password-protected file and stored electronically.

Data Storage and Protection
•

Locked in a password-protected file and stored electronically.

Data Analysis
•

Appropriate statistics were used with guidance from a statistician. A combination of

inferential statistics, including t-tests, correlation, and analysis of variance (ANOVA) with Post
hoc analyses were performed.
Summary
This descriptive correlational study was conducted to determine the relationships between
memory problems and independent variables. An email with the survey link was sent to
participants, or the email link was distributed in the recruitment web-posting. This questionnaire
contained questions pertaining to the participants’ demographics, information related to
treatment, and one open-ended question asking participants to identify factors that have
negatively impacted their memory. The questionnaire included the FACT-Cog (Ver. 3), the
EMQ, and the PSS. Descriptive and inferential analyses were conducted at the completion of
data collection.
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Chapter 4: Findings

The purpose of this study was to determine relationships between women with breast
cancer who are currently receiving or who have received at least one type of treatment and the
negative impact that these treatments and other factors have or have had on their memory as
reported by these participants. This study also explored how stress influences participants’
memory or their self-report of negative impact on memory. This design serves as a first step to
develop a memory support strategy using a web-based nursing intervention that considers the
impact of stress. The findings reflect responses from women who have been or are currently
being treated for breast cancer. There were no clinicians interviewed for this study. Therefore,
perceptions of impairments in memory/cognition are patient focused.
Psychometrically tested instruments were used to examine relationships such as stress
(PSS), everyday memory (EMQ) and cognition function (FACT-Cog, Ver. 3), comprised of
perceived cognitive impairments, perceived cognitive abilities, and everyday memory. Research
has focused on utilizing both objective and subjective measurements to assess for cognitive
impairments; however, much of the literature has shown that many of the objective psychometric
tests have not resulted in positive correlations with subjective reports from women with breast
cancer with self-perceived cancer and treatment-related cognitive impairments. For this reason,
this study focused on self-perceived, subjective instruments and self-reports from participants.
Research Question 1 - What are the characteristics of women who have received treatment
for breast cancer (i.e., demographics) who indicate experiencing a negative impact on their
memory/cognition?
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A total of 217 individuals entered the online Cancer and Memory PhD Study Survey
posted on SurveyMonkey between August 26th, 2020, and December 27th, 2020. Of the 217
individuals, all agreed to participate, yet 46 did not complete the survey enough to meet
inclusion for statistical analysis. Therefore, 171 surveys from participants with complete data
were separated by seven sections: introduction question (confirming they have received
treatment for breast cancer), demographics, cancer treatments, PSS, FACT-Cog, Ver. 3, EMQ,
and in your own words.
A pattern was identified indicating individuals fluctuating response rate for the various
psychometric tools utilized in the survey. This reflects a completion rate of demographics (age: n
= 170; race/ethnicity: n = 170; educational attainment: n = 171; marital status: n = 171); PSS, n =
167; EMQ, n = 152; Perceived Cognitive Impairments Subscale of the FACT-Cog, n = 171;
Comments by Others Subscale of the FACT-Cog, n = 171; Perceived Cognitive Abilities
Subscale of the FACT-Cog, n = 170; and Quality of Life Subscale of the FACT-Cog, n = 171.
For analysis purposes, missing data for examining relationships were excluded by pairwise
deletion, so for analysis purposes, sample size may vary according to the analysis. Included in
the analysis were 171 participants.
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Figure 1 Survey Progression and Participation

For pairwise comparisons, the final number of subjects analyzed for this study was 171
individuals. The age range of participants was between 24 and 80 years old. Ages of individuals
was broken into three groups for analysis: <49 years (n = 64, 37.65%), 50-58 years (n = 52,
30.59%), and 59+ (n = 54, 31.76%). For the eligibility of study inclusion, all individuals were
female (n = 171). In terms of race/ethnicity, the response was 153 (97%) White/Caucasian, 2
(1.18%) Black/African American, 6 (3.53%) Hispanic, 6 (3.53%) Asian/Pacific Islander, 3
(1.76%) Multiple Ethnicity/Other. There were no American Indian/Alaskan respondents to this
survey. There was 1 missing response for race/ethnicity. The level of education reported by
participants was 9 (5.26%) high school graduate, diploma or equivalent, 7 (4.09%)
trade/technical/vocational programs, 12 (7.02%) some college, 17 (9.94%) with an associate’s
degree; 68 (39.77%) with a bachelor’s degree, 51 (21.82%) with a graduate degree, and 7
(4.09%) with a doctoral degree. Their partnership status was reported as 2 (1.17%) separated; 6
(3.51%) widowed; 14 (8.19%) single, never married; 19 (11.11%) divorced; and 130 (76.02%)
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married or in a domestic partnership. Where appropriate, items with smaller sample sizes were
collapsed as described under each section.
The survey included questions focused on treatment modalities received, particular
agents received, time since initial diagnosis, time since last treatment, and type of last treatment
received. Participants were asked to identify which treatment modalities they have or currently
are receiving (multiple responses permitted) with 97.7% (n = 167) responding surgery, 77.8% (n
= 133) responding chemotherapy, 68.4% (n= 117) responding radiation, 20.5% (n = 35)
responding immunotherapy, and 76% (n = 130) responding hormonal therapy. Participants were
asked to identify which specific chemotherapy agent(s) they have or are currently receiving
(multiple responses permitted), with 39.8% (n = 68) receiving Adriamycin; 53.8% (n = 92)
receiving Cytoxan; 1.2% (n = 2) receiving Methotrexate; 6.4% (n = 11) receiving 5-Fluorouracil
(5-FU); 36.3% (n = 62) receiving Taxol; 11.7% (n= 20) receiving Carboplatin; 33.9% (n = 58)
receiving Taxotere; 1.8% (n = 3) receiving Abraxane; 3.5% (n = 6) receiving Epirubicin; 0.6% (n
= 1) receiving Ibrance; and 0.6% (n = 1) receiving Xeloda.
Participants were asked to identify which immunologic agent(s) they received (multiple
responses permitted), if any, with 16.4% (n = 28) receiving Herceptin; 12.3% (n = 21) receiving
Perjeta; 2.9% (n = 5) receiving Kadcylca; 1.8% (n = 3) receiving Nerlynx; and 1.8% (n = 3)
receiving Verzinio. Participants were asked to identify which hormonal agent(s) they received
(multiple responses permitted), if any, with 10.5% (n = 18) receiving Lupron; 0.6% (n = 1)
receiving Faslodex; 32.7% (n = 56) receiving Tamoxifen; 30.4% (n = 52) receiving Letrozole;
32.2% (n = 55) receiving Anastrazole; 5.3% (n = 9) receiving Zoladex; and 4.7% (n = 8)
receiving Aromasin.
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Participants were asked if they completed all of their treatments and when the date (or
approximate date) of their last treatment was. Responses were collapsed into groups due to small
sample sizes among responses with 51.46% receiving treatment within the last year (2020),
17.54% receiving treatment within 1-2 years of this survey (2019), and 30.99% receiving
treatment prior to the study by 2+ years (2018 and earlier). Participants were asked to report
what treatment they received last with 15.20% reporting immunotherapy; 16.96% reporting
surgery; 25.73% reporting chemotherapy; and 41.25% reporting radiation as the last treatment
received. This analysis did not account for those receiving hormonal medications (i.e.,
Aromatase inhibitors) as these medications are started after the completion of chemotherapy or
surgery (whichever is the later) and continues for 5-10 years dependent on the individual’s
ability to tolerate side effects. Research shows that some providers are prescribing these
medications for life depending on patient tolerance. Figure 6 shows the sample (n= 171) split
into three groups: those completing treatment prior to the COVID-19 mandate with no aromatase
inhibitors prescribed or having completed them (12.28%), those completing treatment before the
COVID-19 mandate but receiving aromatase inhibitors (47.95%), and those receiving treatment
during/after the COVID-19 mandate and aromatase inhibitors (39.77).
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Figure 2 Treatments According to COVID-19 Mandate

Statistical Analysis
Baseline variables were compared between groups to assess for distribution imbalances
using means/medians or proportions for continuous and categorial variable, respectively. To
address missing data for relationship testing, method of case wise-pair deletion was utilized.
Questionnaire Psychometrics
For the purpose of this study, each questionnaire used for the study was measured for
their reliability of internal consistency with a Cronbach’s alpha coefficient. An alpha coefficient
of ≥ 0.70 was considered an acceptable value of instrument reliability for this study. In this
sample of individuals who completed all questions on each survey to provide a total score, the
Cronbach’s alpha coefficients for continuous scales are reported as: PSS (n = 167), .866; EMQ
(n = 152), .934; FACT-Cog (Ver. 3) Full Scale (n = 160), .965. The Cronbach’s alpha
coefficients were also run for the subscales of the FACT-Cog (Ver. 3) reported as: Perceived
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Cognitive Impairments subscale (n = 165), .951; Comments by Others subscale (n = 168), .838;
Perceived Cognitive Abilities subscale (n = 168), .896; and Quality of Life subscale (n = 169),
.934. All scales and subscales were evaluated for reliability and deemed acceptable to use in this
sample of breast cancer participants.
Relationship Analysis
For the purposes of exploring relationships, Chi-square was used to determine categorical
variables of interest with categorical outcome variables. One-way analysis of variance was used
for categorical variables of interest and continuous outcome variables. Pearson’s correlation was
used to analyze relationships between continuous variables.
Age and Everyday Memory Questionnaire. The relationship between age and selfreported memory and cognitive impairments was analyzed through both Chi-square and one-way
analysis of variance. A one-way between-groups analysis of variance was conducted to explore
the impact of age on levels of memory, as measured by the EMQ. Participants were divided into
three groups according to their age (Group 1: 49yrs or less; Group 2: 50-58yrs; and Group 3:
59yrs and older). There was a statistically significant difference at the p < .05 level in EMQ
scores for the three groups F(2, 148) = 4.57, p= .01. The effect size, calculated using eta
squared, was .06. Post hoc comparisons using the Tukey HSD test indicated mean score for
<49yrs (M=20.02, SD=12.648) was statistically significant from age group 59+ (M=14.06,
SD=11.58). A mean score for age group 50-58 (M=21.30, SD=13.341) was statistically
significant from age group 59+ (n=48, M=14.06). There was no statistical significance between
<49yrs and 50-58yrs age groups (Table 3 and Table 4).
Table 3
Significance and Effect Size: ANOVA of Age and Everyday Memory Questionnaire
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Table 4
Post Hoc Tests: ANOVA of Age and Everyday Memory Questionnaire

Age and Perceived Cognitive Impairment Subscale. A one-way between-groups
analysis of variance was conducted to explore the impact of age on levels of cognitive
impairment, as measured by the Perceived Cognitive Impairment subscale of the FACT-Cog
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(Ver. 3). Participants were divided into three groups according to their age (Group 1: 49yrs or
less; Group 2: 50-58yrs; and Group 3: 59yrs and older). There was a statistically significant
difference at the p < .05 level in Perceived Cognitive Impairment scores for the three groups F(2,
167) = 4.51, p = .01. The effect size, calculated using eta squared, was, .05 (Table 5).
Table 5
Significance and Effect Size: ANOVA of Age and Perceived Cognitive Impairments Subscale

Post hoc comparisons using the Tukey HSD test indicated mean score for 50-58 age group
(M=37.96, SD=15.774) was significantly different than 59+ age group (M=28.82, SD=2.220).
The < 49 age group did not differ significantly from the other two age groups (Table 6).
Table 6
Post Hoc Tests: ANOVA of Age and Perceived Cognitive Impairments Subscale
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Age and Perceived Cognitive Abilities Subscale. A one-way between-groups analysis
of variance was conducted to explore the impact of age on levels of cognitive impairment, as
measured by the Perceived Cognitive Abilities subscale of the FACT-Cog (Ver. 3). Participants
were divided into three groups according to their age (Group 1: 49yrs or less; Group 2: 50-58yrs;
and Group 3: 59yrs and older). There was a no statistically significant difference at the p < .05
level in Perceived Cognitive Abilities scores between the groups F(2, 166) = 2.30, p = .10. The
effect size, calculated using eta squared, was, .03.
Age and Self-Reports of Memory Impairment. Self-reports of memory impairment
were analyzed through the responses of the survey question, “Do you feel your memory has been
affected since your treatment?” with a simple ‘yes’ or ‘no’ answer. A chi-square test for
independence for a 3x2 table indicated a significant association between the three age categories
and self-reports of negative effects on memory by respondents, c2(4, n = 112) = p = .02,
Cramer’s V = .198. Fisher-Freeman-Halton Exact Test run for assumptions (larger than 2x2
table), p = .02 demonstrating significance (Table 7).
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Table 7
Fisher-Freeman-Halton Exact Test for Assumptions: Age and Self-Reports of Memory
Impairment

Of the participants reporting a negative effect on memory (n= 94), participants <49 years old
reported the highest percentage of memory impairment (93.5%, n= 43), compared to those 50-58
years old (85.7%, n= 24), and those 59 years or older (71.1%, n= 27) reporting the least negative
effect on memory (Table 8).
Table 8
Negative Impact on Memory and Age Comparison
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Ethnicity and Everyday Memory Questionnaire. A one-way between-groups analysis
of variance was conducted to explore the impact of ethnicity on levels of memory, as measured
by the EMQ. Participants were divided into five groups according to their race/ethnicity
(White/Caucasian, Black/African American, Hispanic, Asian/Pacific Islander, and Multiple
ethnicity/Other). No respondents indicated being American Indian/Alaskan, so this was removed
from analysis. There was a no statistically significant difference at the p < .05 level in EMQ
scores between the groups, F(4, 150) = .865, p = .49. The effect size calculated using eta squared
was .027.
Ethnicity and Perceived Cognitive Impairments Subscale. A one-way between-groups
analysis of variance was conducted to explore the impact of ethnicity on levels of cognitive
impairment, as measured by the Perceived Cognitive Impairments Subscale of the FACT-Cog
(Ver. 3). Participants were divided into five groups according to their race/ethnicity
(White/Caucasian, Black/African American, Hispanic, Asian/Pacific Islander, and Multiple
ethnicity/Other). No respondents indicated being American Indian/Alaskan, so this was removed
from analysis. There was no statistically significant difference at the p < .05 level in Perceived
Cognitive Impairment scores between the groups, F(4, 169) = 1.887, p = .12. The effect size
calculated using eta squared was .044.
Ethnicity and Perceived Cognitive Abilities Subscale. A one-way between-groups
analysis of variance was conducted to explore the impact of ethnicity on levels of cognitive
impairment, as measured by the Perceived Cognitive Abilities Subscale of the FACT-Cog (Ver.
3). Participants were divided into five groups according to their race/ethnicity (White/Caucasian,
Black/African American, Hispanic, Asian/Pacific Islander, and Multiple ethnicity/Other). No
respondents indicated being American Indian/Alaskan, so this was removed from analysis. There
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was no statistically significant difference at the p < .05 level in Perceived Cognitive Abilities
scores between the groups, F(4, 168) = .593, p = .67. The effect size calculated using eta squared
was .014.
Ethnicity and Self-Reports of Memory Impairment. Self-reports of memory
impairment were analyzed through the responses of the survey question, “Do you feel your
memory has been affected since your treatment?” with a simple ‘yes’ or ‘no’ answer. A chisquare test for independence for a 5x2 table indicated no significant association between the five
ethnicity categories and self-reports of negative effects on memory by respondents, c2(8, n =
170) = p = .72, Cramer’s V = .198. Fisher-Freeman-Halton Exact Test run for assumptions
(larger than 2x2 table), p = .77 demonstrated no significance.
Educational Attainment and Everyday Memory Questionnaire. A one-way betweengroups analysis of variance was conducted to explore the impact of educational attainment on
levels of memory, as measured by the EMQ. Participants were divided into three groups
according to their educational attainment (Group 1: High School, Some College, and
Trade/Technical/Vocational; Group 2: College Graduate; Group 3: Graduate or Doctoral
Degree). There was no statistically significant difference at the p < .05 level in Everyday
Memory Questionnaire scores between the groups, F(2, 149) = .378, p = .69. The effect size
calculated using eta squared was .005.
Educational Attainment and Perceived Cognitive Impairments Subscale. A one-way
between-groups analysis of variance was conducted to explore the impact of educational
attainment on levels of cognitive impairment, as measured by the Perceived Cognitive
Impairments Subscale of the FACT-Cog (Ver. 3). Participants were divided into three groups
according to their educational attainment (Group 1: High School, Some College, and
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Trade/Technical/Vocational; Group 2: College Graduate; Group 3: Graduate or Doctoral
Degree). There was no statistically significant difference at the p < .05 level in Perceived
Cognitive Impairment scores between the groups, F(2, 168) = .417, p = .66. The effect size
calculated using eta squared was .005.
Educational Attainment and Perceived Cognitive Abilities Subscale. A one-way
between-groups analysis of variance was conducted to explore the impact of educational
attainment on levels of cognitive impairment, as measured by the Perceived Cognitive Abilities
Subscale of the FACT-Cog (Ver. 3). Participants were divided into three groups according to
their educational attainment (Group 1: High School, Some College, and
Trade/Technical/Vocational; Group 2: College Graduate; Group 3: Graduate or Doctoral
Degree). There was no statistically significant difference at the p < .05 level in Perceived
Cognitive Abilities scores between the groups, F(2, 167) = 2.239, p = .11. The effect size
calculated using eta squared was .026.
Educational Attainment and Self-Reports of Memory Impairment. Self-reports of
memory impairment were analyzed through the responses of the survey question, “Do you feel
your memory has been affected since your treatment?” with a simple ‘yes’ or ‘no’ answer. A chisquare test for independence for a 3x2 table indicated no significant association between the
three groups (Group One: High School, Some College and Trade/Technical/Vocational; Group 2:
College Graduate; Group 3: Graduate or Doctoral Degree) and self-reports of negative effects on
memory by respondents, c2(4, n = 171) = p = .40, Cramer’s V = .109. Fisher-Freeman-Halton
Exact test run for assumptions (larger than 2/2 table), p = .22 indicated no significance.
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Marital Status and Everyday Memory Questionnaire. A one-way between-groups
analysis of variance was conducted to explore the impact of marital status on levels of memory,
as measured by the EMQ. Participants were divided into two groups (partnered or not partnered).
There was no statistically significant difference at the p < .05 level in EMQ scores between the
groups, F(1, 150) = 2.001, p = .16. The effect size calculated using eta squared was .013.
Marital Status and Perceived Cognitive Impairments Subscale. A one-way betweengroups analysis of variance was conducted to explore the impact of marital status on levels of
cognitive impairment, as measured by the Perceived Cognitive Impairments Subscale of the
FACT-Cog (Ver. 3). Participants were divided into two groups (partnered or not partnered).
There was a no statistically significant difference at the p < .05 level in Perceived Cognitive
Impairments scores between the groups F(1, 169) = .257, p = .61. The effect size calculated
using eta squared was .002.
Marital Status and Perceived Cognitive Abilities Subscale. A one-way betweengroups analysis of variance was conducted to explore the impact of marital status on levels of
cognitive impairment, as measured by the Perceived Cognitive Abilities Subscale of the FACTCog (Ver. 3). Participants were divided into two groups (partnered or not partnered). There was
no statistically significant difference at the p < .05 level in Perceived Cognitive Abilities scores
between the groups, F(1, 168) = 1.863, p = .17. The effect size calculated using eta squared was
.011
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Marital Status and Self-Reports of Memory Impairment. Self-reports of memory
impairment were analyzed through the responses of the survey question, “Do you feel your
memory has been affected since your treatment?” with a simple ‘yes’ or ‘no’ answer. A chisquare test for independence for a 2x2 table indicated no significant association between two
groups (partnered or not partnered) and self-reports of negative effects on memory by
respondents, c2(2, n = 171) = p = .73, Cramer’s V = .061. Fisher’s Exact Test run for
assumptions (2x2 table), p = .76 demonstrated no significance.
Although participant characteristics including race/ethnicity, education completed, and
marital status did not demonstrate significance in this study, age proved to have a strongly
associated negative effect on both cognition and memory. This particular result is strongly
correlated with previous literature as will be discussed in chapter 5. Table 9 shows a summary of
statistics for Research Question 1.
Table 9
Summary of Statistics: Research Question 1 – Age, Ethnicity, Education, and Marital Status
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Research Question 2 - What relationships exist between factors such as 1) treatment
modality for breast cancer received, 2) time since last treatment received, 3) treatment
agents received and memory among women with breast cancer who have received
treatment?
Treatment Modalities
Individuals participating in this study were asked to indicate which of the following
treatment modalities they have received or are currently receiving, including surgery,
chemotherapy, radiation, immunotherapy, and hormonal therapy. Multiple responses were
allowed as many breast cancer treatment regimens utilize a mix of treatment modalities
dependent on stage and hormone receptor status. Figure 7 demonstrates the number of
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individuals who reported receiving each treatment modality with surgery n= 167, chemotherapy

Volume Reported

n= 133, radiation n= 117, immunotherapy n= 35, and hormonal therapy n= 130.
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Figure 3 Treatment Modalities Reported

Surgery and Everyday Memory Questionnaire. A one-way between-groups analysis of
variance was conducted to explore the impact of undergoing surgery for breast cancer on levels
of memory, as measured by the EMQ. Participants were divided into two groups (yes received or
no did not receive). There was no statistically significant difference at the p < .05 level in EMQ
scores between the groups, F(1, 150) = .15, p = .70. The effect size calculated using eta squared
was < .01.
Surgery and Perceived Cognitive Impairments. A one-way between-groups analysis of
variance was conducted to explore the impact of undergoing surgery for breast cancer on levels
of cognitive impairment, as measured by the Perceived Cognitive Impairments Subscale of the
FACT-Cog (Ver. 3). Participants were divided into two groups (yes received or did not receive).
There was no statistically significant difference at the p < .05 level in Perceived Cognitive
Impairments scores between the groups, F(1, 169) = .01, p = .94. The effect size calculated using
eta squared was < .01.
Surgery and Perceived Cognitive Abilities. A one-way between-groups analysis of
variance was conducted to explore the impact of undergoing surgery for breast cancer on levels
of cognitive impairment, as measured by the Perceived Cognitive Abilities Subscale of the
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FACT-Cog (Ver. 3). Participants were divided into two groups (yes received or did not receive).
There was a statistically significant difference at the p < .05 level in Perceived Cognitive
Abilities scores between the groups after running Welch and Brown-Forsythe for assumptions at
a p value of .05. The effect size calculated using eta squared was .01 (Table 10).
Table 10
One-way Analysis of Variance with Welch Test for Assumptions – Surgery and Perceived
Cognitive Abilities

The mean score for those receiving surgery (M=14.31, SD= 5.952) was significantly different
than those who did not receive surgery (M=17.00, SD= 1.826) (Table 11).
Table 11
Mean Scores and Standard Deviations – Surgery and Perceived Cognitive Abilities
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Surgery and Self-Reports of Memory Impairment. Self-reports of memory
impairment were analyzed through the responses of the survey question, “Do you feel your
memory has been affected since your treatment?” with a simple ‘yes’ or ‘no’ answer. A chisquare test for independence for a 2x2 table indicated no significant association between two
groups (yes received or did not receive) and self-reports of negative effects on memory by
respondents, c2(1, n= 113) = .000, p = 1.00, phi = -.05. Fisher’s Exact Test, p = .51 for
assumptions indicating no statistical significance.
Chemotherapy and Everyday Memory Questionnaire. A one-way between-groups
analysis of variance was conducted to explore the impact of receiving chemotherapy for breast
cancer on levels of memory, as measured by the EMQ. Participants were divided into two groups
(yes received or no did not receive). There was no statistically significant difference at the p <
.05 level in EMQ scores between the groups, F(1, 149) = .66, p = .73. The effect size calculated
using eta squared was < .01.
Chemotherapy and Perceived Cognitive Impairments. A one-way between-groups
analysis of variance was conducted to explore the impact of receiving chemotherapy for breast
cancer on levels of cognitive impairment, as measured by the Perceived Cognitive Impairments
Subscale of the FACT-Cog (Ver. 3). Participants were divided into two groups (yes received or
did not receive). There was no statistically significant difference at the p < .05 level in Perceived
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Cognitive Impairments scores between the groups, F(1, 168) = .97, p = .33. The effect size
calculated using eta squared was .01.
Chemotherapy and Perceived Cognitive Abilities. A one-way between-groups analysis
of variance was conducted to explore the impact of receiving chemotherapy for breast cancer on
levels of cognitive impairment, as measured by the Perceived Cognitive Abilities Subscale of the
FACT-Cog (Ver. 3). Participants were divided into two groups (yes received or did not receive).
There was no statistically significant difference at the p < .05 level in Perceived Cognitive
Abilities scores between the groups, F(1, 167) = .07, p = .79. The effect size calculated using eta
squared was < .01.
Chemotherapy and Self-Reports of Memory Impairment. Self-reports of memory
impairment were analyzed through the responses of the survey question, “Do you feel your
memory has been affected since your treatment?” with a simple ‘yes’ or ‘no’ answer. A chisquare test for independence for a 2x2 table indicated a significant association between the two
categories (yes received and no did not receive) and self-reports of negative effects on memory
by respondents, c2(1, n= 112) = 6.13, p = .01, phi = -.26. Fisher’s Exact Test, p = .01 for
assumptions indicated a statistical significance in those reporting memory problems and
receiving chemotherapy or not (Table 12 and Table 13).
Table 12
Chi-square: Significance of Chemotherapy and Self-Reports of Memory Impairment
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Table 13
Effect Size Using Cramer’s V: Chemotherapy and Self-Reports of Memory Impairment

Radiation and Everyday Memory Questionnaire. A one-way between-groups analysis
of variance was conducted to explore the impact of receiving radiation on levels of memory, as
measured by the EMQ. Participants were divided into two groups (yes received or no did not
receive). There was a statistically significant difference at the p < .05 level in EMQ scores for the
two groups, F(1, 149) = 5.03, p = .03. The effect size calculated using eta squared was .03. The
mean score for those indicating yes, they received radiation (M=17.14, SD=12.436), was
significantly different than those indicating no, they did not receive radiation (M= 22.11, SD=
12.932) (Table 14 and Table 15).
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Table 14
Significance and Effect Size: ANOVA for Radiation and Everyday Memory Questionnaire

Table 15
Means and Standard Deviations: ANOVA on Radiation and Everyday Memory Questionnaire

Radiation and Perceived Cognitive Impairments. A one-way between-groups analysis
of variance was conducted to explore the impact of receiving radiation on levels of cognitive
impairment, as measured by the Perceived Cognitive Impairments Subscale of the FACT-Cog
(Ver. 3). Participants were divided into two groups (yes received or no did not receive). There
was a statistically significant difference at the p < .05 level in Perceived Cognitive Impairments
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scores for the two groups, F(1, 168) = 3.89, p = .05. The effect size calculated using eta squared
was .02. The mean score for those indicating yes, they received radiation (M= 32.16, SD=
15.891), was significantly different than those indicating no, they did not receive radiation (M=
37.32, SD= 15.592) (Table 16 and Table 17).
Table 16
Significance and Effect Size: ANOVA on Radiation and Perceived Cognitive Impairments

Table 17
Means and Standard Deviations: ANOVA for Radiation and Perceived Cognitive Impairments
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Radiation and Perceived Cognitive Abilities. A one-way between-groups analysis of
variance was conducted to explore the impact of receiving radiation therapy for breast cancer on
levels of cognitive impairment, as measured by the Perceived Cognitive Abilities Subscale of the
FACT-Cog (Ver. 3). Participants were divided into two groups (yes received or did not receive).
There was no statistically significant difference at the p < .05 level in Perceived Cognitive
Abilities scores between the groups, F(1, 167) = 3.21, p = .08. The effect size calculated using
eta squared was .02.
Radiation and Self-Reports of Memory Impairments. Self-reports of memory
impairment were analyzed through the responses of the survey question, “Do you feel your
memory has been affected since your treatment?” with a simple ‘yes’ or ‘no’ answer. A chisquare test for independence for a 2x2 table indicated no significant association between two
groups (yes received or did not receive) and self-reports of negative effects on memory by
respondents, c2(1, n= 112) = < .001, p = 1.00, phi = .017.
Immunotherapy and Everyday Memory Questionnaire. A one-way between-groups
analysis of variance was conducted to explore the impact of receiving immunotherapy for breast
cancer on levels of memory, as measured by the EMQ. Participants were divided into two groups
(yes received or no did not receive). There was no statistically significant difference at the p <
.05 level in EMQ scores between the groups, F(1, 150) = .42, p = .52. The effect size calculated
using eta squared was < .01.
Immunotherapy and Perceived Cognitive Impairments. A one-way between-groups
analysis of variance was conducted to explore the impact of receiving immunotherapy for breast
cancer on levels of cognitive impairment, as measured by the Perceived Cognitive Impairments
Subscale of the FACT-Cog (Ver. 3). Participants were divided into two groups (yes received or

84

did not receive). There was no statistically significant difference at the p < .05 level in Perceived
Cognitive Impairments scores between the groups, F(1, 169) = .02, p = .90. The effect size
calculated using eta squared was < .01.
Immunotherapy and Perceived Cognitive Abilities. A one-way between-groups
analysis of variance was conducted to explore the impact of receiving immunotherapy for breast
cancer on levels of cognitive impairment, as measured by the Perceived Cognitive Abilities
Subscale of the FACT-Cog (Ver. 3). Participants were divided into two groups (yes received or
did not receive). There was no statistically significant difference at the p < .05 level in Perceived
Cognitive Abilities scores between the groups, F(1, 168) = 1.75, p = .19. The effect size
calculated using eta squared was .01.
Immunotherapy and Self-Reports of Memory Impairments. Self-reports of memory
impairment were analyzed through the responses of the survey question, “Do you feel your
memory has been affected since your treatment?” with a simple ‘yes’ or ‘no’ answer. A chisquare test for independence for a 2x2 table indicated no significant association between two
groups (yes received or did not receive) and self-reports of negative effects on memory by
respondents, c2(1, n= 113) = 1.91, p = .17, phi = -.160. Fisher’s Exact Test, p = .115 for
assumptions indicated no statistical significance between groups.
Hormonal Therapy and Everyday Memory Questionnaire. A one-way betweengroups analysis of variance was conducted to explore the impact of receiving hormonal therapy
for breast cancer on levels of memory, as measured by the EMQ. Participants were divided into
two groups (yes received or no did not receive). There was no statistically significant difference
at the p < .05 level in EMQ scores between the groups, F(1, 150) = .55, p = .46. The effect size
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calculated using eta squared was < .01. Welch and Brown-Forsythe were run for assumptions, p=
.53, indicating no significant difference.
Hormonal Therapy and Perceived Cognitive Impairments. A one-way betweengroups analysis of variance was conducted to explore the impact of receiving hormonal therapy
for breast cancer on levels of cognitive impairment, as measured by the Perceived Cognitive
Impairments Subscale of the FACT-Cog (Ver. 3). Participants were divided into two groups (yes
received or did not receive). There was no statistically significant difference at the p < .05 level
in Perceived Cognitive Impairments scores between the groups, F(1, 169) = 1.35, p = .25. The
effect size, calculated using eta squared, was .01.
Hormonal Therapy and Perceived Cognitive Abilities. A one-way between-groups
analysis of variance was conducted to explore the impact of receiving hormonal therapy for
breast cancer on levels of cognitive impairment, as measured by the Perceived Cognitive
Abilities Subscale of the FACT-Cog (Ver. 3). Participants were divided into two groups (yes
received or did not receive). There was no statistically significant difference at the p < .05 level
in Perceived Cognitive Abilities scores between the groups, F(1, 168) = .14, p = .71. The effect
size calculated using eta squared was < .01.
Hormonal Therapy and Self-Reports of Memory Impairments. Self-reports of
memory impairment were analyzed through the responses of the survey question, “Do you feel
your memory has been affected since your treatment?” with a simple ‘yes’ or ‘no’ answer. A chisquare test for independence for a 2x2 table indicated a significant association between the two
categories (yes received and no did not receive) and self-reports of negative effects on memory
by respondents, c2(1, n= 113) = 5.22, p = .02, phi = -.24. Fisher’s Exact Test, p = .02 for
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assumptions indicates a statistical significance between those who have received at least one
hormonal medication and those who reported memory problems (Table 18).
Table 18
Chi-square: Hormonal Therapy and Self-Reports of Memory Problems

Time Since Last Treatment
Time since last treatment was assessed by asking individuals in the study when they last
received any type of treatment by date or approximate date. For this analysis, results were group
based on the year of last treatment and items with small sample sizes were collapsed into three
groups (Group 1: 1 year or less – 2020, Group 2: 1 year to 2 years – 2019, Group 3: 2 years or
more – 2018 or before). All individuals participating in the study responded to this question (n =
171) with 51.46% (n = 88) responding receiving their last treatment 1 year or less (within the
year 2020), 17.54% (n = 30) responding receiving their last treatment between 1 to 2 years ago
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(within the year 2019), and 30.99% (n = 53) responding receiving their treatment 2 years or more
prior to this study (2018 or earlier) (Table 19 and Figure 8).
Table 19
Descriptives: Last Treatment by Year

Figure 4 Last Treatment by Year

A one-way between-groups analysis of variance was conducted to explore the impact of
time since last treatment for breast cancer on levels of memory, as measured by the EMQ. There
was no statistically significant difference at the p < .05 level in EMQ scores between the three
groups (Group 1: 1 year or less – 2020, Group 2: 1 year to 2 years – 2019, Group 3: 2 years or
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more – 2018 or earlier), F(2, 149) = .77, p = .46. The effect size calculated using eta squared was
.01.
A one-way between-groups analysis of variance was conducted to explore the impact of
time since last treatment for breast cancer on levels of cognitive impairment, as measured by the
Perceived Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically
significant difference at the p < .05 level in Perceived Cognitive Impairments scores between the
three groups (Group 1: 1 year or less – 2020, Group 2: 1 year to 2 years – 2019, Group 3: 2 years
or more – 2018 or earlier), F(2, 168) = 1.19, p = .30. The effect size calculated using eta squared
was .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
time since last treatment for breast cancer on levels of cognitive impairment, as measured by the
Perceived Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically
significant difference at the p < .05 level in Perceived Cognitive Abilities scores between the
three groups (Group 1: 1 year or less – 2020, Group 2: 1 year to 2 years – 2019, Group 3: 2 years
or more – 2018 or earlier), F(2, 167) = .86, p = .42. The effect size calculated using eta squared
was .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 3x2 table indicated no significant
association between three groups (Group 1: 1 year or less – 2020, Group 2: 1 year to 2 years –
2019, Group 3: 2 years or more – 2018 or earlier) and self-reports of negative effects on memory
by respondents, c2(2, n= 113) = .08, p = .69, phi = .08. Fisher-Freeman-Halton Exact Test, p =
.83 for assumptions indicated no statistical significance between groups.
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Treatment Agents
The treatment modalities utilizing particular agents, including chemotherapy,
immunology, and hormonal therapy, were analyzed using Chi-square and one-way variance to
explore relationships between these agents and memory/cognition. Individuals participating in
this study were able to choose from a provided list of agents as well as add other medications not
on the list in the “other” free-text box provided. Agents were broken into three groups for
individual analysis of agents according to chemotherapeutic agents, immunological agents, or
hormonal therapy agents (Figure 9).

Modalities Using Medications
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Figure 5 Modalities Using Medications

Chemotherapeutic Agent – Adriamycin. A one-way between-groups analysis of
variance was conducted to explore the impact of receiving Adriamycin on levels of memory, as
measured by the EMQ. Participants were divided into two groups (yes received or no did not
receive). There was a statistically significant difference at the p < .05 level in EMQ scores for the
two groups, F(1, 149) = 4.05, p = .05. The effect size calculated using eta squared was .03. The
mean score for those indicating yes, they received Adriamycin (M=20.90, SD=13.612) was
significantly different than those indicating no they did not receive Adriamycin (M= 16.70, SD=
11.918) (Table 20 and Table 21).
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Table 20
Significance and Effect Size: ANOVA for Adriamycin and Everyday Memory Questionnaire

Table 21
Means and Standard Deviations: Adriamycin and Everyday Memory Questionnaire

A one-way between-groups analysis of variance was conducted to explore the impact of
Adriamycin for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
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(yes received or did not receive), F(1, 168) = .96, p = .33. The effect size calculated using eta
squared was .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Adriamycin for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive), F(1, 167) = .84, p = .36. The effect size calculated using eta
squared was .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated a significant
association between the two categories (yes received and no did not receive) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = 5.30, p = .02, phi = -.24. Pearson
Chi-Square, p = .01 with continuity correction, p = .02 indicates a statistical significance
between women who reported memory problems and those who received Adriamycin or not
(Table 22).
Table 22
Chi-square: Adriamycin and Self-Reports of Cognitive Impairment
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Chemotherapeutic Agent – Cytoxan. A one-way between-groups analysis of variance
was conducted to explore the impact of receiving Cytoxan on levels of memory, as measured by
the EMQ. Participants were divided into two groups (yes received or no did not receive). There
was a statistically significant difference at the p < .05 level in EMQ scores for the two groups,
F(1, 149) = 6.93, p = .01. The effect size calculated using eta squared was .04. The mean score
for those indicating yes, they received Cytoxan (M=20.82, SD=13.159) was significantly
different than those indicating no, they did not receive Cytoxan (M= 15.41, SD= 11.674) (Table
23 and Table 24).
Table 23
Significance and Effect Size: ANOVA for Cytoxan and Everyday Memory Questionnaire
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Table 24
Means and Standard Deviations: Cytoxan and Everyday Memory Questionnaire

A one-way between-groups analysis of variance was conducted to explore the impact of
Cytoxan for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive), F(1, 168) = 2.92, p = .09. The effect size calculated using eta
squared was .02.
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A one-way between-groups analysis of variance was conducted to explore the impact of
Cytoxan for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive), F(1, 167) = .29, p = .59. The effect size calculated using eta
squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Cytoxan) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = 1.55, p = .21, phi = -.14. Pearson
Chi-Square, p = .13 with continuity correction, p = .21 indicated no statistical significance
between groups.
Chemotherapeutic Agent – Methotrexate (MTX). A one-way between-groups analysis
of variance was conducted to explore the impact of Methotrexate for breast cancer on levels of
memory, as measured by the EMQ. There was no statistically significant difference at the p < .05
level in EMQ scores between the two groups (yes received and did not receive Methotrexate),
F(1, 149) = .79, p = .38. The effect size calculated using eta squared was .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Methotrexate for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
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(yes received or did not receive), F(1, 168) = .44, p = .51. The effect size calculated using eta
squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Methotrexate for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive) F(1, 167) = .46, p = .50. The effect size calculated using eta
squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Methotrexate) and self-reports
of negative effects on memory by respondents, c2(1, n= 113) = .125, p = .72, phi = .13. Fisher’s
Exact Test, p = .29 indicated no statistical significance between groups.
Chemotherapeutic Agent – 5-Fluorouracil (5-FU). A one-way between-groups
analysis of variance was conducted to explore the impact of 5-Fluorouracil for breast cancer on
levels of memory, as measured by the EMQ. There was no statistically significant difference at
the p < .05 level in EMQ scores between the two groups (yes received and did not receive 5Fluorouracil), F(1, 149) = .39, p = .53. The effect size calculated using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
5-Fluorouracil for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
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(yes received or did not receive 5-Fluorouracil), F(1, 168) = .05, p = .83. The effect size
calculated using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
5-Fluorouracil for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive 5-Fluorouracil), F(1, 167) = .01, p = .94. The effect size
calculated using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive 5-Fluorouracil) and self-reports
of negative effects on memory by respondents, c2(1, n= 113) = < .01, p = 1.00, phi= -.04.
Fisher’s Exact Test 1.00 indicated no statistical significance between groups.
Chemotherapeutic Agent – Taxol. A one-way between-groups analysis of variance was
conducted to explore the impact of Taxol for breast cancer on levels of memory, as measured by
the EMQ. There was no statistically significant difference at the p < .05 level in EMQ scores
between the two groups (yes received and did not receive Taxol), F(1, 149) = 2.46, p = .12. The
effect size calculated using eta squared was .02. The Welch and Brown-Forsythe were run for
assumptions p = .14, indicating no statistical significance.
A one-way between-groups analysis of variance was conducted to explore the impact of
Taxol for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
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difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Taxol), F(1, 168) = .28, p = .60. The effect size calculated using
eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Taxol for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Taxol), F(1, 167) = .05, p = .83. The effect size calculated using
eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. Yates continuing correction was used for a 2x2 table with p = .09 indicated
no statistical significance between groups.
Chemotherapeutic Agent – Carboplatin. A one-way between-groups analysis of
variance was conducted to explore the impact of Carboplatin for breast cancer on levels of
memory, as measured by the EMQ. There was no statistically significant difference at the p < .05
level in EMQ scores between the two groups (yes received and did not receive Carboplatin), F(1,
150) = .20, p = .65. The effect size calculated using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Carboplatin for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
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(yes received or did not receive Carboplatin), F(1, 169) = .86, p = .35. The effect size calculated
using eta squared was .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Carboplatin for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Carboplatin), F(1, 168) = 2.19, p = .14. The effect size calculated
using eta squared was .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Carboplatin) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = 2.521, p = .11, phi = -.18. Fisher’s
Exact Test .07 indicatied no statistical significance between groups.
Chemotherapeutic Agent – Taxotere. A one-way between-groups analysis of variance
was conducted to explore the impact of Taxotere for breast cancer on levels of memory, as
measured by the EMQ. There was no statistically significant difference at the p < .05 level in
EMQ scores between the two groups (yes received and did not receive Taxotere), F(1, 150) =
.03, p = .85. The effect size calculated using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Taxotere for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
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(yes received or did not receive Taxotere) F(1, 169) = .65, p = .42. The effect size calculated
using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Taxotere for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Taxotere) F(1, 168) = .41, p = .52. The effect size calculated
using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Taxotere) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = 1.72, p = .11, phi = -.15. Pearson
Chi-Square, p = .11 with continuity correction, p = .19 indicated no statistical significance
between groups.
Chemotherapeutic Agent – Abraxane. A one-way between-groups analysis of variance
was conducted to explore the impact of Abraxane for breast cancer on levels of memory, as
measured by the EMQ. There was a no statistically significant difference at the p < .05 level in
EMQ scores between the two groups (yes received and did not receive Abraxane), F(1, 150) =
1.55, p = .22. The effect size calculated using eta squared was .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Abraxane for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
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difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Abraxane), F(1, 169) = .30, p = .58. The effect size calculated
using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Abraxane for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Abraxane), F(1, 168) = .23, p = .63. The effect size calculated
using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Abraxane) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = < .01, p = 1.00, phi = -.04. Fisher’s
Exact Test, p = 1.00 indicated no statistical significance between groups.
Chemotherapeutic Agent – Epirubicin. A one-way between-groups analysis of
variance was conducted to explore the impact of Epirubicin for breast cancer on levels of
memory, as measured by the EMQ. There was no statistically significant difference at the p < .05
level in EMQ scores between the two groups (yes received and did not receive Epirubicin), F(1,
150) = 2.03, p = .16. The effect size calculated using eta squared was .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Epirubicin for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
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difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Epirubicin), F(1, 169) = .89, p = .35. The effect size calculated
using eta squared was .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Epirubicin for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Epirubicin), F(1, 168) = 1.4, p = .24. The effect size calculated
using eta squared was .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Epirubicin) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = < .01, p = 1.00, phi = -.07. Fisher’s
Exact Test, p = 1.00 run for assumptions indicated no statistical significance between groups.
Immunotherapy Agent – Herceptin. A one-way between-groups analysis of variance
was conducted to explore the impact of Herceptin for breast cancer on levels of memory, as
measured by the EMQ. There was no statistically significant difference at the p < .05 level in
EMQ scores between the two groups (yes received and did not receive Herceptin), F(1, 150) =
.87, p = .35. The effect size calculated using eta squared was .01. Welch and Brown-Forsythe run
for assumptions p = .28 indicated no statistical difference between groups.
A one-way between-groups analysis of variance was conducted to explore the impact of
Herceptin for breast cancer on levels of cognitive impairment, as measured by the Perceived
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Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Herceptin), F(1, 169) = .03, p = .86. The effect size calculated
using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Herceptin for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Herceptin), F(1, 168) = .63, p = .43. The effect size calculated
using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Herceptin) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = 2.52, p = .11, phi = -.18. Fisher’s
Exact Test, p = .07, indicated no statistical significance between groups.
Immunotherapy Agent – Perjeta. A one-way between-groups analysis of variance was
conducted to explore the impact of Perjeta for breast cancer on levels of memory, as measured
by the EMQ. There was no statistically significant difference at the p < .05 level in EMQ scores
between the two groups (yes received and did not receive Perjeta), F(1, 150) = .52, p = .47. The
effect size calculated using eta squared was < .01. Welch and Brown-Forsythe run for
assumptions, p = .37, indicating on statistical significance between groups.
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A one-way between-groups analysis of variance was conducted to explore the impact of
Perjeta for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Perjeta), F(1, 169) = .21, p = .64. The effect size calculated using
eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Perjeta for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Perjeta), F(1, 168) = 3.10, p = .08. The effect size calculated
using eta squared was .02.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Perjeta) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = 1.60, p = .21, phi = -.16. Fisher’s
Exact Test, p = .12 indicating no statistical significance between groups.
Immunotherapy Agent – Kadcyla. A one-way between-groups analysis of variance was
conducted to explore the impact of Kadcyla for breast cancer on levels of memory, as measured
by the EMQ. There was no statistically significant difference at the p < .05 level in EMQ scores
between the two groups (yes received and did not receive Kadcyla), F(1, 150) = 1.05, p = .31.
The effect size calculated using eta squared was .01.
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A one-way between-groups analysis of variance was conducted to explore the impact of
Kadcyla for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Kadcyla), F(1, 169) = .14, p = .71. The effect size calculated
using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Kadcyla for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Kadcyla), F(1, 168) = .16, p = .69. The effect size calculated
using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. Fisher’s Exact Test, p = 1.00, indicated no statistical significance between
groups.
Immunotherapy Agent – Verzinio. A one-way between-groups analysis of variance
was conducted to explore the impact of Verzinio for breast cancer on levels of memory, as
measured by the EMQ. There was no statistically significant difference at the p < .05 level in
EMQ scores between the two groups (yes received and did not receive Verzinio), F(1, 150) =
.88, p = .35. The effect size calculated using eta squared was .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Verzinio for breast cancer on levels of cognitive impairment, as measured by the Perceived

105

Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Verzinio), F(1, 169) = .58, p = .45. The effect size calculated
using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Verzinio for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Verzinio), F(1, 168) = .61, p = .44. The effect size calculated
using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. Fisher’s Exact Test, p = 1.00, indicated no statistical significance between
groups.
Immunotherapy Agent – Nerlynx. A one-way between-groups analysis of variance was
conducted to explore the impact of Nerlynx for breast cancer on levels of memory, as measured
by the EMQ. There was no statistically significant difference at the p < .05 level in EMQ scores
between the two groups (yes received and did not receive Nerlynx), F(1, 150) = 1.25, p = .27.
The effect size calculated using eta squared was .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Nerlynx for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
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(yes received or did not receive Nerlynx), F(1, 169) = < .01, p = .10. The effect size calculated
using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Nerlynx for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Nerlynx), F(1, 168) = .25, p = .62. The effect size calculated
using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Nerlynx) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = < .01, p = 1.00, phi = -.06. Fisher’s
Exact Test, p = 1.00, indicated no statistical significance between groups.
Hormonal Therapy Agent – Lupron. A one-way between-groups analysis of variance
was conducted to explore the impact of Lupron for breast cancer on levels of memory, as
measured by the EMQ. There was no statistically significant difference at the p < .05 level in
EMQ scores between the two groups (yes received and did not receive Lupron), F(1, 150) = .29,
p = .59. The effect size calculated using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Lupron for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
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(yes received or did not receive Lupron), F(1, 169) = .04, p = .85. The effect size calculated
using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Lupron for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Lupron), F(1, 168) = .76, p = .38. The effect size calculated
using eta squared was .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Lupron) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = 1.18, p = .28, phi = -.14. Fisher’s
Exact Test, p = .21, indicated no statistical significance between groups.
Hormonal Therapy Agent – Tamoxifen. A one-way between-groups analysis of
variance was conducted to explore the impact of Tamoxifen for breast cancer on levels of
memory, as measured by the EMQ. There was no statistically significant difference at the p < .05
level in EMQ scores between the two groups (yes received and did not receive Tamoxifen), F(1,
150) = .08, p = .77. The effect size calculated using eta squared was < .01. Welch and BrownForsythe were run for assumptions, p = .77, indicating no statistical significance between groups.
A one-way between-groups analysis of variance was conducted to explore the impact of
Tamoxifen for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was statistical significance
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difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Tamoxifen), F(1, 169) = 4.10, p = .05. The effect size calculated
using eta squared was .02. The mean score for those indicating yes, they received Tamoxifen
(M= 37.14, SD= 15.725) was significantly different than those indicating no, they did not receive
radiation (M= 31.91, SD= 15.917) (Table 25 and Table 26).
Table 25
Significance and Effect Size: ANOVA for Tamoxifen and Perceived Cognitive Impairment

Table 26
Means and Standard Deviations: ANOVA for Tamoxifen and Perceived Cognitive Impairments
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A one-way between-groups analysis of variance was conducted to explore the impact of
Tamoxifen for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Tamoxifen), F(1, 168) = .57, p = .45. The effect size calculated
using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated a significant
association between two groups (yes received or did not receive Tamoxifen) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = 3.74, p = .05, phi = -.21. Pearson
Chi-Square was p = .03 with continuity correction, p = .05.
Hormonal Therapy Agent – Letrozole. A one-way between-groups analysis of variance
was conducted to explore the impact of Letrozole for breast cancer on levels of memory, as
measured by the EMQ. There was no statistically significant difference at the p < .05 level in
EMQ scores between the two groups (yes received and did not receive Letrozole), F(1, 150) = <
.01, p = .97. The effect size calculated using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Letrozole for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Letrozole), F(1, 169) = .01, p = .94. The effect size calculated
using eta squared was < .01.
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A one-way between-groups analysis of variance was conducted to explore the impact of
Letrozole for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Letrozole), F(1, 168) = .05, p = .83. The effect size calculated
using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Letrozole) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = 2.85, p = .09, phi = -.19. Fisher’s
Exact Test, p = .07 indicated no statistical significance between groups.
Hormonal Therapy Agent – Arimidex. A one-way between-groups analysis of variance
was conducted to explore the impact of Arimidex for breast cancer on levels of memory, as
measured by the EMQ. There was no statistically significant difference at the p < .05 level in
EMQ scores between the two groups (yes received and did not receive Arimidex), F(1, 150) =
.37, p = .55. The effect size calculated using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Arimidex for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Arimidex), F(1, 169) = < .01, p = .99. The effect size calculated
using eta squared was < .01.
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A one-way between-groups analysis of variance was conducted to explore the impact of
Arimidex for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Arimidex), F(1, 168) = .35, p = .55. The effect size calculated
using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Arimidex) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = < .01, p = .97, phi = -.03. Fisher’s
Exact Test, p = .068 indicated no statistical significance between groups.
Hormonal Therapy Agent – Aromasin. A one-way between-groups analysis of
variance was conducted to explore the impact of Aromasin for breast cancer on levels of
memory, as measured by the EMQ. There was no statistically significant difference at the p < .05
level in EMQ scores between the two groups (yes received and did not receive Aromasin), F(1,
150) = .52, p = .47. The effect size calculated using eta squared was < .01.
A one-way between-groups analysis of variance was conducted to explore the impact of
Aromasin for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Aromasin), F(1, 169) = .95, p = .33. The effect size calculated
using eta squared was .01.
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A one-way between-groups analysis of variance was conducted to explore the impact of
Aromasin for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Aromasin), F(1, 168) = .85, p = .36. The effect size calculated
using eta squared was .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Aromasin) and self-reports of
negative effects on memory by respondents, c2 (1, n= 113) = .14, p = .71, phi = -.09. Fisher’s
Exact Test, p = 1.00 indicated no statistical significance between groups.
Hormonal Therapy Agent – Zoladex. A one-way between-groups analysis of variance
was conducted to explore the impact of Zoladex for breast cancer on levels of memory, as
measured by the EMQ. There was no statistically significant difference at the p < .05 level in
EMQ scores between the two groups (yes received and did not receive Zoladex), F(1, 150) = .40,
p = .53. The effect size calculated using eta squared was < .01. Welch and Brown-Forsythe were
run for assumptions, .33, indicating no statistical significance.
A one-way between-groups analysis of variance was conducted to explore the impact of
Zoladex for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Impairments Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Impairments scores between the two groups
(yes received or did not receive Zoladex), F(1, 169) = .06, p = .80. The effect size calculated
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using eta squared was < .01. Welch and Brown-Forsythe were run for assumptions, .72,
indicating no statistical significance.
A one-way between-groups analysis of variance was conducted to explore the impact of
Zoladex for breast cancer on levels of cognitive impairment, as measured by the Perceived
Cognitive Abilities Subscale of the FACT-Cog (Ver. 3). There was no statistically significant
difference at the p < .05 level in Perceived Cognitive Abilities scores between the two groups
(yes received or did not receive Zoladex), F(1, 168) = .03, p = .89. The effect size calculated
using eta squared was < .01.
Self-reports of memory impairment were analyzed through the responses of the survey
question, “Do you feel your memory has been affected since your treatment?” with a simple
‘yes’ or ‘no’ answer. A chi-square test for independence for a 2x2 table indicated no significant
association between two groups (yes received or did not receive Zoladex) and self-reports of
negative effects on memory by respondents, c2(1, n= 113) = .14, p = .71, phi = -.09. Fisher’s
Exact Test, p = 1.00, indicated no statistical significance between groups.
Summary of Findings
Treatment modalities, including chemotherapy, radiation and hormonal therapy were
shown to be significant in this study. Adriamycin and Cytoxan are two chemotherapeutic
medications commonly utilized for the treatment of breast cancer. These were shown to have
relationships with cognitive impairments and memory problems in this study. The hormonal
therapy agent, Tamoxifen, also was shown to have an effect on self-reports of memory in this
study, which is consistent with more recent literature looking at aromatase inhibitors and other
estrogen receptor medications. Time since last treatment was not shown to have an effect on
memory/cognition, but it is suggested that this concept be investigated further in future research.
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Tables summarizing of statistics on treatment modality (Table 27), chemotherapy agents (Table
28), immunotherapy agents (Table 29), hormonal agents (Table 30), and time since treatment
(Table 31) are shown below.
Table 27
Summary Statistics: Research Question 2 – Treatment Modality

Table 28
Summary Statistics: Research Question 2 – Chemotherapy Agents
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Table 29
Summary of Statistics: Research Question 2 – Immunotherapy Agents
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Table 30
Summary of Statistics: Research Question 2 – Hormonal Agents
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Table 31
Summary of Statistics: Research Question 2 – Time Since Treatment

Research Question 3 - What life factors (i.e., divorce, job loss, pandemic, etc.) experienced
by women while receiving treatment for breast cancer have impacted their level of stress?
To approach this research question, individuals participating in this study were asked to
identify factors, if any, that they believe had an impact on their stress level. Individuals were first
asked to respond with a “yes” or “no” to the following question: “Do you feel your memory has
been affected since your treatment?” The total number of responses were 171, with 55.56% (n =
95) individuals who responding “yes,” 10.53% (n = 18) individuals responding “no,” and those
who did not respond were 33.92% (n = 58) (Figure 10)
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Figure 6 Do you feel your memory has been affected since your treatment?

An open-ended question asked, “If you feel your memory was impacted, what additional factors
do you feel have negatively affected your memory during your breast cancer journey? Please be
as specific as possible.” Qualitative responses were grouped into categories and quantified for
analysis with Chi-square and one-way analysis of variance for the purpose of answering
Research Question 3.
Four main groups arose in reviewing the narrative responses of factors that affected the
participants’ memories (Group 1: Cancer and Cancer Treatment Related
Stress/Anxiety/Depression, Group 2: General Stress/Anxiety/Depression, Group 3: Cancer
Treatments and Medications, Group 4: Miscellaneous). Those falling into Group 1 mentioned
stress, anxiety, or depression, specifically relating them to cancer and/or cancer treatments such
as trauma from diagnosis and stress the cancer can return. Participant responses categorized in
Group 1 specifically mentioned stress/anxiety/depression or worry as it relates exclusively to
their cancer diagnosis or treatment(s). Those categorized into Group 2 were responses
mentioning stressful events, generalized anxiety, and depression not specified as cancer or cancer
treatment related. Factors considered as generally stressful events included factors such as job
loss, divorce, or loss of a spouse. Participants who specifically mentioned the COVID-19
pandemic as impacting their memory were also clustered into this generalized
stress/anxiety/depression group. Group 3 included any responses that were focused specifically
on cancer medications or treatments. These included reports that chemotherapy, aromatase
inhibitors, surgery, and anesthesia, etc., were perceived to have had a negative effect on the
respondent’s memory. Group 4 included miscellaneous factors reported in the open-ended
question as impacting the individual’s memory that were not reported as stressful or directly
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related to cancer and treatment. These included factors such as mental health issues (not
specified as related to cancer or treatment), sleep and fatigue, pain and discomfort, lack of
socialization and isolation (not reported to be related to COVID-19), menopause, and no
cognitive assessments performed at baseline. (i.e., mental health issues, trauma not related to
cancer diagnosis or other medical issues independent of breast cancer). To answer Research
Question 3, descriptive statistics were run on the four groups to demonstrate how they ranked on
the PSS meaning of low, moderate, or high stress, with Group 3 (cancer medications and
treatments) having higher levels of moderate stress (n = 24) (Figure 4.6)
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Figure 7 Descriptives Demonstrating Grouped Life Factors on Perceived Stress Scale Meaning

A deeper investigation into the impact of the COVID-19 mandate on stress was
conducted with a chi-square test for independence for a 3x2 table. There was no significant
association between the three mandate groups (Group 1: treatment completed before mandate
with no aromatase inhibitors or completed aromatase inhibitors; Group 2: treatment completed
before mandate but still on aromatase inhibitors; Group 3: treatment during or after mandate with
the use of aromatase inhibitors) and PSS meanings (low, moderate, or high stress). A FisherFreeman-Halton Exact Test .59 was run for assumptions, indicating no statistical significance
between groups.
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Individual narratives were also examined for the specific mention of stress and two
groups were created, those specifically mentioning stress affecting memory and those not
indicating stress as a factor affecting memory. A chi-square test for independence for a 3x2 table
indicating no significant association between the groups (stress indicated versus stress not
indicated) and PSS meanings (low, moderate, or high stress). A Fisher-Freeman-Halton Exact
Test .44 was run for assumptions indicating no statistical significance between groups.
The relationship between the COVID-19 mandate and those indicating
stress/anxiety/depression as factors affecting memory was examined with a chi-square test for
independence for a 3x2 table. There was no significant association between the three mandate
groups (Group 1: treatment completed before mandate with no aromatase inhibitors or completed
aromatase inhibitors; Group 2: treatment completed before mandate but still on aromatase
inhibitors; Group 3: treatment during or after mandate with the use of aromatase inhibitors) and
stress/anxiety/depression indicated versus stress/anxiety/depression not indicated. A FisherFreeman-Halton Exact Test, p = .08 was run for assumptions, indicating no statistical
significance between groups.
A one-way analysis of variance was conducted on the categorical variable stress versus
no stress indicated and the continuous variable of the PSS total score. There was no statistically
significant difference at the p < .05 level in PSS scores between the two groups (yes, stress
indicated; and no, stress not indicated), F(1, 68) = .40, p = .53. The effect size calculated using
eta squared was .01. However, when the individual items from the PSS were run with a one-way
analysis of variance with stress versus no stress, there was a statistically significant difference at
the p < .05 level in Question 3 of the PSS (PSS3value - “In the last month, how often have you
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felt nervous and stress?”) between the two groups (yes, stress indicated; and no, stress not
indicated) F(1, 69) = 5.89, p = .02 (Table 32 and Table 33).
Table 32
Significance: ANOVA for Perceived Stress Scale PSS3 Value and Stress/No Stress

Table 33
Effect Size: ANOVA for PSS3 Value and Stress/No Stress
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The mean score for those indicating yes stress (M= 2.24, SD= 1.033) was significantly different
than those indicating no stress (M= 1.57, SD= .964) (Table 34).
Table 34
Means and Standard Deviations for PSS3 Value and Stress/No Stress

A one-way analysis of variance was conducted on the categorical variable stress versus no stress
indicated and the continuous variable of the EMQ total score. There was no statistically
significant difference at the p < .05 level in EMQ scores between the two groups (yes, stress
indicated; and no, stress not indicated), F(1, 61) = .163, p = .69. The effect size calculated using
eta squared was < .01. However, when the individual items from the EMQ were run with a oneway analysis of variance with stress versus no stress, there was a statistically significant
difference at the p < .05 level in Question 9 of the EMQ (EMQ9value - “When reading a
newspaper or magazine, being unable to follow the thread of the story, losing track of what is
about”) between the two groups (yes stress indicated and no stress not indicated), F(1, 61) =
3.95, p = .05. The mean score for those indicating yes stress (M = 17, SD = .71) was significantly
different than those indicating no stress (M = 52, SD = 1.48) (Table 35).
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Table 35
Significance, Means and Standard Deviations: ANOVA for Everyday Memory Questionnaire
EMQ9value and Stress/No Stress

Research Question 4 - What life factors (i.e., divorce, job loss, pandemic, etc.) experienced
by women while receiving treatment for breast cancer have negatively impacted their
memory?
As with Research Question 3, the narrative open-ended responses inquiring about factors
that have negatively impacted participants’ memory was quantified into groups for the purpose
of analyzing relationships between reported stressful life factors and memory. A one-way
analysis of variance was conducted on the categorical variable stress versus no stress indicated
and the continuous variable of the EMQ score. There was no statistically significant difference at
the p < .05 level in EMQ scores between the two groups (yes, stress indicated; and no, stress not
indicated), F(1, 61) = .16, p = .69. The effect size calculated using eta squared was < .01.
Individual items from the EMQ were run via a one-way analysis of variance and stress/no stress
indicated. There were no statistically significant differences at the p < .05 level except for item
nine “When reading a newspaper or magazine, being unable to follow the thread of the story;
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losing track of what it is about” from the EMQ indicated a statistically significant difference at
the p = < .05 level in the EMQ scores between the two groups (yes, stress indicated; and no,
stress indicated), F(1, 57) = 3.95, p = .05 (Table 36). The effect size calculated using the Eta
square was .06.
Table 36
Significance and Effect Size: ANOVA for Item 9 of Everyday Memory Questionnaire and
Stress/No Stress
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The mean score for those indicating yes stress (M= .71, SD= 1.488) was significantly different
than those indicating no stress (M= 1.48, SD= 1.379) (Table 37).
Table 37
Means and Standard Deviations for Item 9 on Everyday Memory Questionnaire and Stress/No
Stress

A one-way analysis of variance was conducted on the categorical variable stress versus
no stress indicated and the continuous variable of the FACT-Cog (Ver. 3) score. There was no
statistically significant difference at the p < .05 level in FACT-Cog scores between the two
groups (yes stress indicated and no stress not indicated), F(1, 69) = .75, p = .39. The effect size
calculated using eta squared was .01.
A one-way analysis of variance was conducted on the categorical variable stress versus
no stress indicated and the continuous variable of the Perceived Cognitive Impairments Subscale
score of the FACT-Cog (Ver. 3). There was no statistically significant difference at the p < .05
level in Perceived Cognitive Impairment scores between the two groups (yes stress indicated and
no stress not indicated), F(1, 69) = .31, p = .58. The effect size calculated using eta squared was
< .01.
A one-way analysis of variance was conducted on the categorical variable stress versus
no stress indicated and the continuous variable of the Perceived Cognitive Abilities Subscale
score of the FACT-Cog (Ver. 3). There was no statistically significant difference at the p < .05
level in Perceived Cognitive Abilities scores between the two groups (yes stress indicated, and
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no stress not indicated) F(1, 69) = 1.31, p = .26. The effect size calculated using eta squared was
.02.
Individual items of the FACT-Cog (Ver. 3) scale were run via a one-way analysis of
variance conducted on the categorical variable stress and the FACT-Cog scale. There were no
statistically significant differences at the p < .05 level between the two groups (yes stress
indicated, and no stress indicated). While no statistically significant differences were indicated
between groups, clinical relevance may be indicated on two items from the FACT-Cog with item
5 on the Perceived Cognitive Impairments subscale, p= .06 and CogPM1, p= .06. Item 5 on the
Perceived Cognitive Impairments subscale states, “I have had trouble remembering where I put
things, like my keys or my wallet.” Item CogPM1 is the third item on the Perceived Cognitive
Abilities subscale and states, “I have been able to remember things, like where I left my keys or
wallet.” The clinical relevance of these questions may elicit a relation between stress and the
effect on memory, which should be explored further in future studies as will be discussed in
Chapter 5.
Research Question 5a - What negative impact does stress have on memory among women
who have received treatment for breast cancer?
This research question sought to explore the relationship between stress and memory
among the individuals who participated in this study having received treatment for breast cancer.
A one-way analysis of variance was conducted on the PSS meaning (low, moderate, and high
stress levels) and the EMQ score. There was a statistically significant difference at the p < .05
level in EMQ scores between the three groups (low stress, moderate stress, and high stress), F(2,
145) = 8.29, p = < .01. The effect size calculated using eta squared was .10 (Table 38 and Table
39).

128

Table 38
Significance and Effect Sizes: ANOVA for Low, Moderate, and High Stress and Everyday
Memory Questionnaire

Table 39
Means and Standard Deviations: ANOVA for Low, Moderate, and High Stress and Everyday
Memory Questionnaire

Post hoc comparisons using the Tukey HSD test indicated that the mean score for Moderate
Stress group (M = 19.93, SD = 12.271) was statistically different from Low Stress group (M =
13.81, SD = 11.995). The mean score for High Stress group (M = 31.50, SD = 13.137) was
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statistically different from Low Stress group (M = 13.81, SD = 11.995). The mean score for High
Stress group (M = 31.50, SD = 13.137) was statistically different from Moderate Stress group (M
= 19.93, SD = 12.271) (Table 40).
Table 40
Post Hoc Tests: ANOVA for Everyday Memory Questionnaire and Low, Moderate, and High
Stress Levels

Research Question 5b - What correlation exists between levels of stress and memory among
women who have received treatment for breast cancer?
The relationship between stress (as measured by the raw scores of the PSS) and the
impact on memory (as measured by the EMQ) was investigated using Pearson product-moment
correlation coefficient. There was a positive correlation between the two variables, r = .373, n=
148, p < .01, with higher levels of stress (PSS) associated the more memory problems (EMQ).
Non-parametric correlations were also conducted using Spearman’s rho, also indicating a
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positive correlation between the two variables, r = .361, n = 148, p < .01 (Table 41 and Table
42).
Table 41
Correlations between Perceived Stress Scale Raw Score and Everyday Memory Questionnaire

Table 42
Nonparametric Correlations between Perceived Stress Scale Raw Score and Everyday Memory
Questionnaire
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To explore the relationship between stress and memory among participants in this study,
correlations were run using the PSS meaning (low, moderate, and high stress levels) and the
EMQ score. Further correlations were run on stress (as measured by the raw scores of the PSS)
and the impact on memory (as measured by the EMQ) using Pearson product-moment
correlation coefficient. Strong positive correlations were demonstrated between stress and
memory. A summary of statistics can be found below (Table 43).
Table 43
Summary of Statistics: Research Question 5a and 5b – Correlations on Stress and Memory

Research Question 6 - What differences exist in memory for women who received breast
cancer treatment pre- or during/ post-COVID-19 pandemic “lock-down” date?
A one-way analysis of variance was conducted on the COVID-19 mandate and the
continuous variable of the EMQ. There was no statistically significant difference at the p < .05
level in EMQ scores between the three groups (Group 1: treatment completed before mandate
with no aromatase inhibitors or completed aromatase inhibitors; Group 2: treatment completed
before mandate but still on aromatase inhibitors; Group 3: treatment during or after mandate with
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the use of aromatase inhibitors), F(2, 149) = .38, p = .69. The effect size calculated using eta
squared was .01.
A one-way analysis of variance was conducted on the COVID-19 mandate and the
continuous variable of the FACT-Cog (Ver. 3). There was no statistically significant difference
at the p < .05 level in FACT-Cog scores between the three groups (Group 1: treatment completed
before mandate with no aromatase inhibitors or completed aromatase inhibitors; Group 2:
treatment completed before mandate but still on aromatase inhibitors; Group 3: treatment during
or after mandate with the use of aromatase inhibitors), F(2, 167) = .62, p = .54. The effect size
calculated using eta squared was .01.
A one-way analysis of variance was conducted on the COVID-19 mandate and the
continuous variable of the Perceived Cognitive Impairment subscale of the FACT-Cog (Ver. 3).
There was no statistically significant difference at the p < .05 level in Perceived Cognitive
Impairment scores between the three groups (Group 1: treatment completed before mandate with
no aromatase inhibitors or completed aromatase inhibitors; Group 2: treatment completed before
mandate but still on aromatase inhibitors; Group 3: treatment during or after mandate with the
use of aromatase inhibitors), F(2, 168) = .55, p = .58. The effect size calculated using eta squared
was .01.
A one-way analysis of variance was conducted on the COVID-19 mandate and the
continuous variable of the Perceived Cognitive Abilities subscale of the FACT-Cog (Ver. 3).
There was no statistically significant difference at the p < .05 level in Perceived Cognitive
Abilities scores between the three groups (Group 1: treatment completed before mandate with no
aromatase inhibitors or completed aromatase inhibitors; Group 2: treatment completed before
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mandate but still on aromatase inhibitors; Group 3: treatment during or after mandate with the
use of aromatase inhibitors), F(2, 167) = 1.08, p = .34. The effect size calculated using eta
squared was .01.
A one-way analysis of variance was conducted on the COVID-19 mandate and the
individual items of the FACT-Cog (Ver. 3). There was a statistically significant difference at the
p < .05 level in item 13 of the Perceived Cognitive Impairment Subscale (labelled on the FACTCog as CogF24), “I have forgotten names of people soon after being introduced” between the
three groups (Group 1: treatment completed before mandate with no aromatase inhibitors or
completed aromatase inhibitors; Group 2: treatment completed before mandate but still on
aromatase inhibitors; Group 3: treatment during or after mandate with the use of aromatase
inhibitors), F(2, 168) = 3.21, p = .04. The effect size calculated using eta squared was .04 (Table
44).
Table 44
Significance and Effect Size: ANOVA for COVID-19 Mandate and Perceived Cognitive
Impairment Subscale Item13
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Post hoc comparisons using the Tukey HSD test indicated mean score for treatment completed
before mandate on AIs (M = 2.06, SD = 1.137) was statistically significant from treatment
during/after mandate with aromatase inhibitors (M = 1.59, SD = 1.123) (Table 45).
Table 45
Post Hoc Tests: ANOVA for COVID-19 Mandate and Perceived Cognitive Impairment Subscale
Item 13

A one-way analysis of variance was conducted on the COVID-19 mandate and the
individual items of the FACT-Cog (Ver. 3). There was a statistically significant difference at the
p < .05 level in item 5 of the Perceived Cognitive Abilities Subscale (labelled on the FACT-Cog
as CogPF1), “I am able to pay attention and keep track of what I am doing without extra
effort…” between the three groups (Group 1: treatment completed before mandate with no
aromatase inhibitors or completed aromatase inhibitors; Group 2: treatment completed before
mandate but still on aromatase inhibitors; Group 3: treatment during or after mandate with the
use of aromatase inhibitors), F(2, 167) = 3.59, p = .03. The effect size calculated using eta
squared was .04 (Table 46).
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Table 46
Significance and Effect Size: ANOVA for COVID-19 Mandate and Perceived Cognitive Abilities
Subscale Item 5 (CogPF1)

Post hoc comparisons using the Tukey HSD test indicated mean score for treatment completed
before mandate on AIs (M= 1.25, SD = 1.070) was statistically significant from treatment before
mandate no treatment with AI’s or done with AI’s (M= 1.99, SD= 1.149). A mean score for
treatment during/after mandate with AIs (M= 2.01, SD = 1.240) was statistically significant from
treatment before mandate no AI or done (M = 1.25, SD = 1.070) (Table 47).
Table 47
Post Hoc Tests: ANOVA for COVID-19 Mandate and Perceived Cognitive Abilities Subscale
Item 5 (CogPF1)
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Research Question 7 - What is the relationship between the stress state (Low, Moderate,
and High on PSS) and the FACT-Cog scores?
The relationship between stress state, as measured by the PSS, categorizes stress into
three levels: low, moderate, and high stress. A one-way analysis of variance was conducted on
the PSS meanings and the FACT-Cog (Ver. 3). There was a statistically significant difference at
the p < .05 level in the FACT-Cog between the three groups (low, moderate, and high stress),
F(2, 163) = 20.05, p = < .01. The effect size calculated using eta squared was .20 (Table 48).
Table 48
Significance and Effect Size: ANOVA for FACT-Cog and Perceived Stress Scale Meanings
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Post-hoc comparisons using the Tukey HSD test indicated that the mean score for Moderate
Stress group (M = 61.75, SD = 22.675) was significantly different from the Low Stress group (M
= 41.10, SD = 24.301) and the High Stress group (M = 85.11, SD = 24.796) was statistically
significant from the Low stress group (M = 41.10, SD = 24.301) and the High Stress group (M =
85.11, SD = 24.796) was statistically significant from the Moderate Stress group (M = 61.75, SD
= 22.675) (Table 49).
Table 49
Post Hoc Tests: ANOVA for FACT-Cog and Perceived Stress Scale Meanings
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Research Question 8 - What do women who have received treatment for breast cancer
report that might have affected their memory?
Participants of this study did report memory and cognition problems in the survey, many
of whom reported that treatments, especially chemotherapy, surgery, and aromatase inhibitors
contributed to memory and cognition problems. This was investigated more by assessing
participant narrative statements of the individuals who self-reported having memory/cognitive
impairments responding to the question: “If you feel your memory was impacted, what
additional factors do you feel have negatively affected your memory during your breast cancer
journey? Please be as specific as possible.” Responses were analyzed and collapsed into
prevalent categories. Five major categories arose from analysis: 1) Treatment-related, 2)
Stress/anxiety/depression, 3) Lack of knowledge, 4) The struggles are real, and 5) Other
comments.
Treatment-Related
This category highlighted the narratives that identified one or more treatments received
for breast cancer as negatively affecting the participants’ memory. Many of the responses
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reflected that chemotherapy, surgery, anesthesia from surgery, and aromatase inhibitors were the
more reported culprits of the respondent’s memory or cognitive impairments. Some of the
comments also reflected that side effects of these medications, especially lack of natural estrogen
production coupled with taking hormone therapy (to block estrogen and progesterone from
binding to cancer cells, inhibiting growth) may have influenced memory and cognition
negatively. This is not to be confused with hormonal replacement therapy that uses supplemental
hormones in lieu of those not naturally occurring in the body, which is not intended for breast
cancer patients to prolong remission. For the purpose of this study, comments were not altered
for grammar or spelling, as this could reflect the nature of cancer- and treatment-related
cognitive impairments.
Comments from Narratives – Treatment-related Category
Comment 1 “Immediate withdrawal of estrogen for my system. Stopped HRT 9/6/18, SMX
immediate DIEP 9/28/18 and started Letrozole 11/4/18. Lasted on letrozole til
2/28/29, started tamoxifen 4/10/19. I used to cry because of loss of cognitive
function, forgetting from the refrigerator to 3 steps away. At the
counter/stove/sink. I just laugh now and think of myself as a bobble head. (I
majored in math in college) I’m now 65”
Comment 2 “Tamoxifen. Lack of working and socializing. Anesthesia. It has severely
impacted my life. I’m not the same person that I was before.”
Comment 3 “My hormone therapy has greatly impacted my cognitive function too.”
Comment 4 “I really feel it was the chemo. I had no other side effects from the chemo but
my memory has been definitely altered for the worse.”
Comment 5 “No additional factors. All chemo and hormone therapy related.”
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Comment 6 “I think it was the chemo’s, I was on 4 different types of chemo and I had every
side effects that they listed , I can remember names of people I have known or
known of most of my life. The littlest thing I will foget. Wasn’t like that before
and one friend said you have chemo brain and I laughed I though she made the
word up. Lord and behold I believe I have it..and I hope it goes away like the
lymphedema I got also.”
Comment 7 “I definitely think my memory has been impacted but I am not certain of or if
there are any other factors that affected my memory besides treatments.”

These statements are representative that women with breast cancer do identify with
having some variation of memory or cognitive impairment.
Stress/Anxiety/Depression
In this theme, individual respondents who used the terms “stress,” “anxiety,” or
“depression” were immediately grouped together. Also, after analyzing the participant narratives,
stressful live events such as loss of a spouse, divorce, trauma of diagnosis, and finances were
categorized in this group. Many of the respondents’ comments were directly stated as stress,
anxiety or depression. Other comments included the following:
Comments from Narratives – Stress/Anxiety/Depression Category
Comment 1 “I believe the stress of my diagnosis and the stress of COVID has negatively
impacted my memory.”
Comment 2 “I think aromatase inhibitors have added to the problem, as well as the constant
background stress that a large part of my cancer wasn't seen on any imaging and
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could likely be far more advanced than scans show. I still have young children at
home.”
Comment 3 “The trauma of going through the diagnosis and treatment I think affects
memory and mood. Also of note, I am taking two different meds for depression anxiety at this time. Depression also affect memory and mood”
Comment 4 “COVID caused stress in every step of treatment and the isolation creates a lack
of socialization which is damaging.”
Comment 5 “Stress (almost dying, finances, divorce, treatment)”
Comment 6 “The loss of my husband a week after my diagnosis and no real support system
close by”

Lack of Knowledge
The theme of “lack of knowledge” was generated by comments from respondents that
either directly related healthcare provider’s lack of knowledge or lack of cognitive testing for
cancer- and treatment-related cognitive impairments. Although there were not many of these
comments, it would be of interest for future research to investigate this concept further, which
will be further discuss in chapter 5.
Comments from Narratives – Lack of Knowledge Category
Comment 1 “The lack of concern by my oncologist when I expressed my worry about
‘chemo brain’. I was told it would just slowly go away but didn’t.”
Comment 2 “being given tamoxifen when oncology pharmacist warned oncologist I could
NOT take as interacts with other meds I take but onc did it anyway, I googled it
to find out this danger and stopped taking. all oncs have confirmed I could not
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do that treatment so did it effect me permanently. doctor was wrote up upon
discovery.”
Comment 3 “No cognitive assessment done prior to treatments so no baseline available. Now
told I am within normal range for my ages/etc but I am not as sharp as I was
prior to treatments!”

The struggles are real
This thematic category was generated through the statements of respondents who
described their symptoms. A handful of participants responded with what their memory or
cognitive impairments look like in their personal and professional lives. Many of these responses
have been mentioned in the literature conducted to assess patients’ self-reports of cancer- and
treatment-related cognitive impairments.
Comments from Narratives – The struggles are real Category
Comment 1

“I'm an attorney who speaks often in court, I have found that words I routinely
use will completely escape me. Also, spelling words has become increasingly
difficult. Even if I attempt to sound out a word, I do not identify oblivious
sounds and will misspell the word. I forget how to drive to a location I've been
to before. If I have several places to go, I struggle with organizing my route.”

Comment 2

“Struggle to recall words - bit of a problem being a teacher ;) Struggle
concentrating - again a problem when data crunching. Tried to order resources
but couldn't think of the word 'cellophane' - asked for acetate???”

Comment 3

“Because I have to write down a “to do” list every single day or post reminders
of particularly important dates or events and keep a calendar now, my brain just
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isn’t as active as it once was. I have been seen and treated by physicians and
cognitive therapists since ending chemotherapy and have been diagnosed with
chemotherapy induced cognitive impairment. The neurologist said it was likely
a permanent problem at this point. My oncologist also said my age at the time
of the dose dense chemotherapy treatment has not helped But I am alive!”
Comment 4

“As a once avid reader and crossword puzzle player, I believe the lack of ability
to focus on these activities has affected my memory.”

Comment 5

“It takes longer to recall something when asked...sometimes not until the next
day. Sometimes I vaguely recall a story or tv show I’ve already heard or seen
and needed to be reminded of it.”

Comment 6

“It’s just annoying. It’s been simple things like forgetting to be my load in my
basket and not in the dryer and somehow piling up clean dry clothes on top of
my damp clothes. Forgetting items on my grocery list. Forgetting
conversations...”

Comment 7

“Just having to keep track of all the new immediate things.”

Comment 8

“Just feel muddled and not like myself. Struggle to read articles I normally
would, to help kids with homework, to get around to doing things.”

Other comments
This group of statements comprised comments that could not be classified into any of the
above. Many of these responses were generic in nature and did not go into deep details.
Responses that fell into this group included lack of socialization, mental health issues
(independent of cancer), fatigue, and other medical issues (independent of cancer diagnosis).
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Comments from Narratives – Other comments Category
Comment 1

“I’m reduced”

Comment 2

“Distraction due to pain or discomfort.”

Comment 3

“Being tired. I think general fatigue adds to my memory issues.”

Comment 4

“Menopause”

Comment 5

“Age”

Comment 6

“Awareness”

Comment 7

“Difficulty sleeping.”

Conclusion
In this chapter, a comprehensive assessment was conducted to investigate relationships
between individual characteristics and memory and cognitive problems in women with breast
cancer who have or are currently receiving treatment. Data were organized and described. The
analysis consisted of Chi-square, one-way analysis of variance (ANOVA), Pearson’s product
moment correlations, and qualitative analysis of participants’ narratives. Participants were
predominately White/Caucasian (89.5%), college educated (49.7%), and married or partnered
(76%). All participants, for the purpose of this study, were female. Ages of participants in this
study ranged from 24 to 80 years old (mean age was 53.8 years). Reliability testing demonstrated
that instruments were valid for use in this sample. Reporting Cronbach’s alpha: PSS = .866 (n=
167), EMQ = .934 (n= 152), FACT-Cog complete scale = .965 (n= 160), FACT-Cog subscale
Perceived Cognitive Impairments = .951 (n= 165), FACT-Cog subscale Comments from Others
= .838 (n= 169), FACT-Cog subscale Perceived Cognitive Abilities = .896 (n= 168), FACT-Cog
subscale Quality of Life = .934 (n= 169).
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Statistically significant results demonstrating relationships between various factors and
memory and cognition were found throughout the study. There was a statistically significant
difference between age and memory/cognition in those who reported having memory problems
than those who reported not having memory problems among the three age groups (p = .01).
Participants 50-58 years of age had statistically significant differences in mean scores on the
Perceived Cognitive Impairments subscale than those aged 59 and older (p = .01). On the EMQ
there were statistically significant differences in the mean scores between those 49 years of age
or less and those 59 years and older as well as between those 50-58 years of age and those 59 and
older (p = .01).
There were some statistically significant results among the therapeutic modalities that
participants received and memory/cognition scores. There was a statistically significant
difference between those reporting memory problems and receiving chemotherapy or not (p =
.01). There was a significance between Perceived Cognitive Impairments subscale scores of
those who received radiation and those who did not (p = .05) and a significance between EMQ
scores of those who received radiation than those who did not (p = .03). There was a statistically
significant difference between those who received hormonal therapy and memory/cognition in
those who reported having memory problems than those who reported not having memory
problems (p = .02).
Two chemotherapeutic agents demonstrated statistical significance on affecting memory
and cognition. There was statistical significance for those receiving the chemotherapy agent,
Adriamycin, on two tests. There was a statistical significance between women who reported
memory problems and those who received Adriamycin and those who did not (p = .02). A
statistically significant difference was observed between those who received Adriamycin and
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those who did not on the EMQ subscale (p = .05). A statistical significance between participants
who received Cytoxan and those who did not receive Cytoxan on the EMQ (p = .05). The
frequently utilized hormonal agent, Tamoxifen, resulted in a statistically significant difference in
those who did receive it and those who did not on the Perceived Cognitive Impairment subscale
(p = .05).
Individuals who reported stress, anxiety, depression, stressful life events, diagnosis, or
treatment-related stress or side effects causing memory impairment were shown to have
moderate stress levels on the PSS (57.63%). Although reports of having or not having stress and
scores on the PSS did not demonstrate any statistically significant differences between groups,
individual items from the PSS did demonstrate significance. Question 3 from the PSS
demonstrated a statistically significance in those who reported having stress than those who did
not have stress (p = .02). Question 3 states, “In the last month, how often have you felt nervous
and stress?” Reports of experiencing stress or not experiencing stress and the EMQ scores did
not differ significantly between groups. However, item 9 on the EMQ stating, “When reading a
newspaper or magazine, being unable to follow the thread of the story; losing track of what it is
about” did demonstrate a statistical difference among those who reported stress than those who
did not have stress (p = .05).
There was a statistically significant difference among levels of stress meanings from the
PSS (low, moderate, and high stress) and EMQ scores (p = < .01). There is a positive correlation
using the Pearson product-moment correlation coefficient between the two variables indicating
that the higher the levels of stress (PSS), the more memory problems (EMQ) (p = < .01).
Individual items on the FACT-Cog demonstrated significance, including item 13 (CogF24) on
the Perceived Cognitive Impairments subscale and item 5 (CogPF1) on the Perceived Cognitive
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Abilities subscale. Item 13 from the Perceived Cognitive Impairments indicated a statistical
difference between treatment completed before mandate on aromatase inhibitors and treatment
during/after mandate with aromatase inhibitors (p = .04). Item 5 on the Perceived Cognitive
Abilities subscale indicated a statistical difference between two groups: 1) treatment completed
before mandate on aromatase inhibitors and treatment before mandate no aromatase inhibitors or
done and 2) treatment during/after mandate with aromatase inhibitors and before mandate no
aromatase inhibitors or done (p = .03). There was a statistically significant difference between
stress levels (low, moderate, and high stress on the PSS) and the FACT-Cog scores (p < .01).
A qualitative analysis was conducted on the open-ended question, “What factors do you
feel have had an impact on your memory during your breast cancer journey? Please be as
specific as possible.” Individual participant responses were examined for commonalities. Five
themes arose from the analysis: 1) treatment related, 2) stress/anxiety/depression, 3) lack of
knowledge, 4) the struggle is real, and 5) other comments.
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Chapter 5: Discussion and Recommendations

While the phenomenon of cancer- and treatment-related cognitive impairments is not a
new concept, it is currently being widely researched in the literature. The multifaceted nature of
cancer itself leads to a multitude of potential explanations of and causes for cognitive
impairments related to cancer and its treatment. Researchers studying this condition are seeking
to demonstrate that there is not a single cause for this phenomenon, but rather, it is various
mechanisms that when combined, increase the occurrences and severity of the symptoms. It has
been reported by cancer patients and survivors to be a debilitating side effect experienced from
treatments received as well as from the stressors triggered by the cancer journey, starting from
diagnosis, through treatment, and well into survivorship. Cancer patients and survivors have
reported struggling with these impairments for months to years after the completion of treatment,
reporting negative effects in memory, recall, verbal fluency, executive functioning, and difficulty
in managing tasks both personally and professionally, which is consistent in this study’s
findings.
The lack of clear-cut understanding of the effects of cancer- and cancer-related treatment
on memory led to the purpose of this study, which was to determine self-reported factors that
have potentially had a negative effect on memory of participants, including demographics, breast
cancer treatments, stress, and the COVID-19 pandemic. Uncertainties surrounding memory
problems related to cancer and treatments also includes a lack of proper assessment tools that are
universally accepted and utilized. Although there are recommended assessments, to date, none of
these are considered the gold standard, nor are any used universally among oncology
practitioners. This lack of standardized assessments can lead to problems in reporting and
diagnosing memory deficits as well as diversity in assessment results in the literature. The lack
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of universal assessments aimed at determining the presence of these impairments was also
mentioned in participant narratives analyzed in this study. The literature has demonstrated a
disconnect between objective psychometric testing and cancer- and treatment-related cognitive
impairment diagnosis. For this study, the researcher utilized two instruments to assess memory
(EMQ and the FACT-Cog) and one measure of stress (PSS), all of which have been utilized in
previous research among cancer patients.
While some of the treatment modalities examined in this study showed a statistical
significance in impacting patients’ cognitive function, other factors including personal
characteristics and other stressors were shown to also influence their memory including age and
specific medications. The COVID-19 pandemic impacted many women with breast cancer who
were receiving chemotherapy or were waiting for other treatment modalities when these services
were postponed or halted due to restrictions and mandates. This stressor was examined in this
study to determine if there was a relationship with memory functioning or a perceived negative
impact on their memory.
Assessing relationships between various factors such as demographics, treatments
received and time since treatment, stress and memory as done in this study can lead to future
studies that may benefit this population. This online survey served as a first step to identifying
influential variables that may impact cognitive function in order to develop a memory support
strategy using a web-based nursing intervention that considers the impact of stress in a future
study.
This study determined that in this sample (n= 171), the individual characteristics such as
age, particular treatment modalities (i.e., chemotherapy, radiation, hormonal therapy), certain
medications (i.e., Adriamycin, Cytoxan, Tamoxifen), as well as life factors were shown to have
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statistical significance on stress and memory. Stress was also seen to have a statistical
significance on memory. Variables of race/ethnicity, educational attainment, marital status
(partnered/not partnered), time since last treatment, COVID-19 mandate were not shown to have
a statistical significance on stress and memory. This study was guided by the question: “What
factors influence and negatively affect memory and cognition among women with breast
cancer?” The purpose of this descriptive correlational study was to determine relationships
between women with breast cancer who are currently receiving or who have received at least one
type of treatment and the negative impact that these treatments and other factors have or have
had on their memory as reported by these participants. This study also explored how stress
influenced their memory.
Discussion
Established Measures
This study utilized established measures in a unique way, executing them as part of a
one-time web-based online survey. Future developers can utilize the quantitative results from
this study to gain insight into what factors have a potential to cause or worsen the effect of
cognitive and memory problems in women with breast cancer. By utilizing an open-ended
question in this study, future studies can use the qualitative data to gain new insights into the
individual experiences of women living with cognitive and memory problems related to their
cancer and/or their cancer treatments, as well as other life factors that can influence these
symptoms. By utilizing the EMQ and the subscales of the FACT-Cog in this study, the
researcher was able to collect and analyze data regarding the relationships between identified
factors and perceived problems with both memory and cognition independently. Utilizing the
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PSS enabled the researcher to collect and analyze data regarding the impact of the presence and
severity of stress, memory, and cognition.
Subject Characteristics
Participants of this study were predominately White/Caucasian (89.5%), college educated
(49.7%), and married or partnered (76%). This may not be representative of the race, ethnicity,
education, or marital status of all women with breast cancer in treatment. Ages of participants in
this study ranged from 24 to 80 years old (mean age was 53.8 years). For eligibility
requirements, all participants in this sample were female.
In this study, a relationship was shown to exist between age and memory/cognition on
two measurements, the EMQ and the Perceived Cognitive Impairments subscale of the FACTCog. Higher scores on EMQ indicate more frequently experienced and self-reported memory
problems while lower scores indicate less frequent memory problems. Here, mean differences
were seen between age groups indicating that participants in age group < 49 years and those in
the 50-58-year age group had more memory problems than those 59+ years. Lower scores on the
PCI subscale indicates more self-perceived cognitive problems and poorer quality of life.
Participants 59 and older had lower PCI scores and thus more self-perceived cognitive
impairments than those age 50-58 years. This study found that there was an association between
self-reports of memory impairments (by answering yes or no to the presence of memory
impairments) and age groups. Participants with self-reported memory impairments were high
among all age groups.
In summary, younger participants from this study had more perceived memory problems
and older participants reported more cognitive problems, reflecting that the other cognitive
domains may be hindered at increased levels among older patients. This could be due to the
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assumptions of natural effects of aging on the domain of memory. Previous literature has shown
that less stress among older populations have been correlated with better cognitive functioning
(Papanastasiou et al., 2019). The results of this current study as well as those previously done
backs the notion that more research is needed with particular emphasis on the particular
cognitive domains that tend to decline with age, including memory and executive functions,
reasoning, and processing speed.
It is an assumption that older participants may feel affected memory is relatable to natural
maturation and aging and less associated with cancer and cancer treatments. Those in the less
than 49-year age group may recognize memory impairments related to impaired executing
functioning secondary to work-related issues. Studies have explored the negative impact of
cancer and treatment-related cognitive impairments of breast cancer patients and survivors in
returning to work (Becker et al., 2015; Bradley et al., 2005; Janelsins et al., 2014; Myers 2012;
Reid-Arndt et al., 2009; Wefel, Lenzi, Theriault, Davis, et al., 2004).
There were no other statistically significant differences shown in this study among the
other subject characteristics, including race/ethnicity, educational attainment, and marital status
(partnered or not partnered). Using a sample with a more diverse population in regard to these
characteristics might be beneficial in future studies. Age was shown to have statistically
significant results on the EMQ indicating that younger cancer patients/survivors demonstrated
more self-reported or perceived memory problems. However, older patients/cancer survivors
were shown to have more perceived cognitive impairments on the Perceived Cognitive
Impairment subscale.
Treatment Modalities
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Results from this study demonstrated statistically significant differences between four
treatment modalities and memory/cognition, including surgery, chemotherapy, radiation, and
hormonal therapy. Participants in this study who had surgery had more self-perceived
impairments as measured by the Perceived Cognitive Abilities subscale than those who did not
have surgery. This matches some of the narrative responses in this study mentioning surgery and
anesthesia to memory problems. There was a statistically significant difference between selfreports of memory impairments and those who received chemotherapy. In this sample, 84.8%
reported their memory was affected. Within this group, 89.9% of participants who received
chemotherapy reported that their memory was affected whereas individuals who did not receive
chemotherapy reported 66.7% memory affected. This result is consistent with the literature
demonstrating chemotherapy’s effect on memory and other cognitive domains (Ahles et al.,
2007; Bernstein et al., 2017; Collins et al., 2013; Ferguson et al., 2007; Janelsins et al., 2014; Jim
et al., 2012; Kesler, et al., 2016; Meyers et al., 2008; Oh et al., 2017; Ono et al., 2015; Simo et
al., 2013; Wefel, Lenzi, Theriault, Davis, et al., 2004; Winocur et al., 2018).
Participants in this study who received radiation had more self-perceived cognitive
impairments as measured on the Perceived Cognitive Impairments subscale than those who did
not receive radiation. On the other hand, participants in this study who did not receive radiation
had more problems with memory than those who did receive radiation when utilizing the EMQ.
These results could indicate that the other factors, including other treatments not measured, could
have been influencing the changes in cognition and memory among all groups. Another reason
for the differences between those receiving radiation and those not receiving radiation on
memory and cognition could be explained through the unequal distribution of groups for those
indicating having received radiation or not. In future studies, having more equally representative
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groups (received or did not receive radiation) may provide statistical results. Current literature
has demonstrated an effect on central nervous system related cancers involving brain and spine
radiation, directly damaging the processes involving different cognitive domains (Butler et al.,
2006; Cramer et al., 2019; Dietrich et al., 2008). In non-central nervous system related cancers
such as breast cancer, it is thought that localized radiation can increase inflammation as well as
heighten the release of cytokines, both of which are thought to have negative effects on cognition
(Shibayama et al., 2014).
There was a statistically significant difference between self-reports of memory problems
in those who received hormonal therapy and those who did not. In this sample, 84.1% reported
their memory was affected. Within this group, 89.3% of participants who received hormonal
therapy reported that their memory was affected whereas individuals who did not receive
hormonal therapy reported 69% memory affected.
Specific Agents
This study looked at potential relationships between specific medications under each type
of treatment modalities and memory/cognitive impairments. Two chemotherapy agents,
Adriamycin and Cytoxan, and one hormonal agent, Tamoxifen, were shown to be associated
with memory and cognitive impairments. In this study, those receiving Adriamycin had higher
EMQ scores and thus more memory impairments than those who did not receive this drug. There
was also a statistically result between self-reports of memory impairments and those who
received Adriamycin. In this sample, 84.1% reported their memory was affected. Within this
group, 95.3% of participants who received Adriamycin reported that their memory was affected
whereas individuals who did not receive Adriamycin reported 77.1% memory affected.
Participants who received Cytoxan had higher EMQ scores and thus more memory impairments
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than those who did not receive this medication. This is in line with previous research that has
established causal relationships between both Adriamycin and Cytoxan, received in combination
and independently of each other, and cognitive impairments including the domain of memory.
Studies have shown that upwards of 70% of patients have experienced cognitive dysfunction
with severe deficits in attention and memory (Ahles et al., 2002; Brezden et al., 2000; Schagen et
al., 1999; van Dam et al., 1998; Wefel, Lenzi, Theriault, Buzdar, et al., 2004).
Results from this study indicate that participants who reported receiving Tamoxifen had
less cognitive impairments than those who did not receive Tamoxifen. This result varies from
previous research demonstrating that women receiving Tamoxifen had difficulties in verbal
memory, fluency, and cognitive impairment as compared to both the surgical
operation/radiotherapy group and the healthy control group (Boele et al., 2015).
Results from this study showed that there was a statistically significant difference
between self-reports of memory impairments in those who did and did not receive Tamoxifen. In
this sample, 84.1% reported their memory was affected. Within this group, 94.7% received
Tamoxifen and reported that their memory was affected, whereas 78.7% did not receive
Tamoxifen and reported their memory being affected. This discrepancy between objective
measurements and subjective reports is similar to previous research results reflecting the limited
nature of psychometric tools in assessing and diagnosing cognitive impairments in cancer
patients (Jean-Pierre et al., 2014; Moore, 2014; Tannock et al., 2004). One study utilizing
psychometric testing, including the clock drawing task, box copying task, and the narrative
writing task, was unable to determine a relationship between women who received Tamoxifen
for breast cancer and cognitive problems. However, results from that study also showed that
participants who received Tamoxifen were twice as likely to visit their physicians with
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complaints of memory problems than those who never took this medication (Paganini-Hill et al.,
2000). These results can indicate the lack of standardized psychometric testing successful of
detecting these types of cognitive changes and support a need to focus on patient reports of
memory and cognitive decline associated with treatments.
Stress and Memory/Cognition
This study also explored relationships between levels of stress (low, moderate, and high)
and memory. Results indicated that those with both moderate stress and high stress had more
memory problems than those with low stress as measured by the EMQ. The high stress group
also had higher EMQ scores and more memory problems than those with moderate stress. As a
result, it is shown that experiencing higher levels of stress results in higher EMQ scores and
more memory problems. This result was also demonstrated by determining positive correlations
between stress and memory. This result demonstrates that the higher the levels of stress on the
PSS, the more memory problems measured by the EMQ, which was confirmed using both
parametric and non-parametric correlations.
The relationship between stress and memory was further analyzed utilizing levels of
stress (low, moderate, or high stress) and the FACT-Cog total scores. Participants from this study
experiencing moderate stress were found to have less perceived cognitive impairments and better
quality of life than those with low stress. Those experiencing high stress had less perceived
cognitive impairments and better quality of life than those with both moderate and low stress.
Results from this study indicate that higher stress levels have a negative effect on memory as
measured and compared using the PSS and the EMQ. Results from this study demonstrate that
higher stress levels do not necessitate a negative effect on perceived cognitive impairments when
using the FACT-Cog. Women with breast cancer have varied levels of stress as well as different
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types of stress as they relate to various factors related to cancer diagnosis, treatment, and
normative life factors. Stress has been found to be positively correlated with cognitive decline in
patients receiving treatment for cancer (Andreotti et al., 2014; Hoskins et al., 2008; Joels, 2006;
McEwen, 2014; Papanastasiou et al., 2019).
Implications
The results from this study demonstrate that there is still a lot that is unknown
surrounding cancer- and treatment-related cognitive impairments. What was once thought of as
only a side effect of chemotherapy is now being seen in those who have received other treatment
modalities such as radiation, surgery, and hormonal therapy, as this study shows. Cognitive
impairments and problems with memory can be a concern for cancer patients prior to receiving
treatment (Janelsins et al., 2014) and as demonstrated by the results of this study, can be
associated with stress and life factors ,including lack of awareness and knowledge of the
phenomenon by healthcare providers, depression, anxiety, and the diagnosis of cancer and worry
of reoccurrence, among others. Results of this study have shed light on the need for future
research to enhance knowledge about causative mechanisms, symptoms, detriments to the
quality of life of those living with cognitive impairments during their cancer journeys, and to
help develop therapeutic treatments to offset or mitigate symptoms associated with the effect of
cancer and related treatments on both memory and other cognitive domains. As with previous
research, this study brings to light the need for more comprehensive and standard approaches to
the way healthcare providers screen patients for cognitive impairments at diagnosis, during
treatment, and into survivorship. It is imperative for researchers to study and develop assessment
tools that can become the gold standard for determining the presence and severity of cancer- and
treatment-related cognitive impairments.
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Recommendations
While, in this study, age was the only participant characteristic demonstrating a
relationship with impaired memory and cognition, future studies may benefit from having a more
diverse sample on other demographics such as race/ethnicity, marital status, and educational
attainment. In designing future studies, it may be useful to utilize either a larger sample size from
one organization or a multi-center approach to the sample to provide for more comparable
groups, including participant characteristics, treatment modalities, and medications received. A
longitudinal study exploring the effect of factors on participants’ memory/cognition may be
appropriate for future studies. This approach should include a baseline cognitive assessment as
well as cognitive assessments set at particular time-points to compare data over time.
Not many medications showed significance in this study; however, there is much
literature that has been conducted demonstrating relationships between the presence of cognitive
impairments or memory problems and particular medications. Literature suggests that 5fluorouracil and Cytoxan, two medications included in this study, are toxic for the central
nervous system and attribute to cognitive issues (Argyriou et al., 2011). Platinum-based anticancer drugs and anthracycline agents (both used in breast cancer patients) as well as estrogen
receptor modulators (SERMs) and aromatase inhibitors (AIs), which are commonly used as
adjuvant treatments, for breast cancer have been shown to inhibit cognitive processed through
different mechanisms influencing declines in multiple domains (Lv et al., 2020). It is
recommended that this study design be replicated with a sample size more reflective of receiving
the particular medications found to influence impairments in both memory and other cognitive
domains, such as Adriamycin, Cytoxan, Taxol, 5-FU, Methotrexate, and Tamoxifen. It is
possible that in this study, due to the sample size reflected in each of these medications,
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statistical significance could not be determined. For example, in this study, those receiving
Methotrexate (n = 2) were compared to those who did not receive Methotrexate (n = 168).
Appendix H provides a table representing descriptives on chemotherapy, immunotherapy, and
hormonal therapy agents for those who received and did not receive these agents in the study’s
sample. This demonstrates support for future large-scale studies reflective of a more diverse
sample that includes groups with more comparable representation based on medications
received.
It is recommended that future studies further explore the relationship between those
receiving radiation or not and EMQ scores with more equal groups (received radiation, n= 104;
did not receive radiation, n= 47). Additionally, future studies may need to focus solely on
radiation without any other potentially confounding treatments utilizing measures used in this
study. Another suggestion is to utilize other measures along with those used in this study. Much
of the literature to date has been focused on chemotherapy and its effect on memory and other
cognitive domains. However, more recent attention has been assessing for the presence of
memory problems and cognitive impairments in patients who have received other treatment
modalities, including radiation and hormonal therapies.
More research needs to be conducted to further explore the relationship between
Tamoxifen and Perceived Cognitive Impairments with a recommendation of having more
equivalent samples in each group (receiving Tamoxifen, n= 56; not receiving Tamoxifen, n=
115). Tamoxifen in particular is known to cross the blood-brain-barrier, increasing the likelihood
of increased neurotoxicity influencing problems in cognition (Novick et al., 2020). Researchers
are urging for a push in studies to better demonstrate potential relationships between endocrine
therapy (particularly Tamoxifen) and cognition in breast cancer patients, mainly due to the newer
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recommendations lengthening the time with which these patients should be taking these
medications. However, Zwart et al. (2015) explained that much of the current literature have
reported limitations of small sample sizes and design flaws as complicating and possibly
skewing results. It is suggested that along with having larger sample sizes and stronger designs,
that researchers utilize baseline pre-treatment neuropsychological assessments to better identify
impairments along course of treatment with endocrine therapy (Zwart et al., 2015).
While there was no statistically significant relationship between the time since last
treatment and memory or cognition as measured by the scales in this study, future studies
exploring potential relationships should be conducted. One study by Janelsins et al. (2018) has
supported that the effects on cognitive domains as they relate to chemotherapy have been shown
to decrease over time from pre-chemotherapy to six months post-chemotherapy. Janelsins et al.
(2017) conducted a longitudinal study comparing breast cancer patients and age-matched
noncancer controls. This study consisted of a nationwide, multi-center sample (n = 945), with
results demonstrating that breast cancer patients showed statistically significant self-reported
cognitive declines compared to the control group from prechemotherapy to 6 months after
chemotherapy completion utilizing the FACT-Cog total scale and subscales.
The focus of both Research Questions 3 and 4 sought to examine various participantidentified life factors that respondents perceived to have an effect on stress (question 3) and
memory (question 4). Narrative, qualitative responses were examined and grouped into
reoccurring categories identified by the researcher. Four groups arose in reviewing the narrative
responses of factors that affected the participants’ memories (Group 1: Cancer and Cancer
Treatment Related Stress/Anxiety/Depression, Group 2: General Stress/Anxiety/Depression,
Group 3: Cancer Treatments and Medications, Group 4: Miscellaneous).
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While there was no statistical significance using the PSS as a whole, the researcher
examined for potential significance using the individual items of this scale. A statistically
significance occurred between participant reports of stress/no stress and item 3 on the PSS. Item
3 states “In the last month, how often have you felt nervous and stress?” This result indicates
that this general question about nerves and stress scored high among participants. The mean
score for those indicating “yes” on stress was significantly different than those indicating “no”
on stress. This result demonstrates that those who indicated having stress scored higher on the
PSS, indicating that there is a relationship between participants’ perception of stress and their
levels of stress as measured on the PSS. As this study is the first step to develop a memory
support strategy using a web-based nursing intervention that considers the impact of stress, it is
recommended that a new assessment tool be developed and piloted among a sample of women
with breast cancer currently receiving treatments, including particular items from scales that may
be clinically relevant.
While there was no statistical significance using the EMQ as a whole, the researcher
examined for potential significance between participant reports of stress/no stress and the
individual items on the EMQ with item 9 showing significance. Item 9 states, “When reading a
newspaper or magazine, being unable to follow the thread of the story; losing track of what it is
about.” This result actually correlated with some of the narrative responses from participants
answering the question, “If you feel your memory was impacted, what additional factors do you
feel have negatively affected your memory during your breast cancer journey? Please be as
specific as possible” and could indicate the need for future studies to include this type of
question in assessments. Participant 86 responded stating, “Just feel muddled and not like
myself. Struggle to read articles I normally would, to help kids with homework, to get around to
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doing things.” Participant 111 responded to this question stating, “As a once avid reader and
crossword puzzle player, I believe the lack of ability to focus on these activities has affected my
memory.”
Although there was no statistical significance using the FACT-Cog and its subscales as a
whole, the researcher examined for potential significance between participant reports of stress/no
stress and individual items on the FACT-Cog subscales with items PCI5 and CogPM1 showing
clinical relevance. Item PCI15 states, “I have had trouble remembering where I put things, like
my keys or my wallet.” Item CogPM1 states, “I have been able to remember things, like where I
left my keys or wallet.” While both of these items are not statistically significant, a clinical
relevance may be indicated, especially when compared to narrative responses in this study as
well as documented reports from participants from other studies. Part of this item elicited a
relation between stress and the effect on memory should be explored in future research studies.
Participant 59 stated, “I used to cry because of loss of cognitive function, forgetting from the
refrigerator to 3 steps away. at the counter/stove/sink. I just laugh now and think of myself as a
bobble head. (I majored in math in college) I’m now 65.” Participant 19 responded, “It’s just
annoying. It’s been simple things like forgetting to be my load in my basket and not in the dryer
and somehow piling up clean dry clothes on top of my damp clothes. Forgetting items on my
grocery list. Forgetting conversations...” Participant 32 stated, “I forget how to drive to a
location I've been to before. If I have several places to go, I struggle with organizing my route.”
Participant 193 stated, “Because I have to write down a “to do” list every single day or post
reminders of particularly important dates or events and keep a calendar now, my brain just isn’t
as active as it once was.”
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Individual items from the FACT-Cog subscales did demonstrate either significance or
clinical relevance. Items demonstrating a statistical significance include PCI13 (CogF24) that
states, “I have forgotten names of people soon after being introduced…” and item CogPF1 that
states, “I am able to pay attention and keep track of what I am doing without extra effort…”.
Item PCI6 from the Perceived Cognitive Impairments subscale showed a nearing statistical
significance, which can demonstrate a clinical relevance as seen in the narrative responses in this
study. Item PCI6 states, “I have had trouble remembering new information, like phone numbers
or simple instructions…” These are consistent with previous studies as well as narratives
examined in this study. Participant 32 also stated, “I'm an attorney who speaks often in court, I
have found that words I routinely use will completely escape me. Also, spelling words has
become increasingly difficult. Even if I attempt to sound out a word, I do not identify oblivious
sounds and will misspell the word.” Participant 47 stated, “Struggle to recall words - bit of a
problem being a teacher ;) Struggle concentrating - again a problem when data crunching. Tried
to order resources but couldn't think of the word 'cellophane' - asked for acetate???” Participant
12 stated, “It takes longer to recall something when asked...sometimes not until the next day.
Sometimes I vaguely recall a story or tv show I’ve already heard or seen and needed to be
reminded of it.”
Many of the narrative responses in this study mentioned hormonal therapy or aromatase
inhibitors in particular affecting memory in respondents. Hormone and endocrine therapy are
commonly utilized for breast cancer patients to help stop receptors or proteins from attaching
estrogen and progesterone, which is thought to increase tumor or cancer growth (American
Cancer Society, 2021). The recommended length of time of medication use is 5 to 10 years after
completing active treatment for breast cancer. Some practitioners have recommended that
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patients stay on them for life if tolerated. Future studies should look at the use of hormone and
endocrine therapy and the relationship between memory and cognitive impairments.
One category developed after analyzing respondent narratives was “lack of knowledge.”
This supports other literature reporting many health care providers still do not acknowledge
cancer- and treatment-related cognitive impairments as a side effect, or they are not
knowledgeable about it enough to educate their patients. A common theme among respondents
of one study focused on the need for healthcare workers to at least acknowledge the possibility of
cognitive impairments related to cancer treatments, especially chemotherapy (Becker et al.,
2015). Some women said that their doctors never discussed the possible deficits in cognitive
function, while one participant said the doctor dismissed her concerns as being more related to
her stress than associated with her treatment (Becker et al., 2015). Also, there is a lack of
supported assessments, both objective psychometric testing and appropriate subjective testing, to
assess for cancer- and treatment-related cognitive impairments. In a study by Klaver et al. (2020)
it was recommendation that “professionals’ knowledge about cancer survivorship issues, and
cancer-related cognitive problems in particular needs to be expanded” (p. 177). Cancer survivors
participating in this study indicated that they require more acknowledgement from healthcare
professionals and society. They reported that lack of acknowledgement only increases the
psychological distress already being experienced.
Future research on the lived experiences of cancer patients and survivors experiencing or
living with memory and cognitive impairments would help support acknowledgement of these
debilitating side effects that are often denoted through self-reports. A qualitative,
phenomenological approach would aid in determining what cancer patients report experiencing
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in terms of their memory problems and declines in other cognitive domains. The current study
demonstrates that perceptions of memory and cognition problems are extremely stressful, which
could also play a role in worsening the symptoms being experienced. More research should be
conducted with a qualitative approach to determine specific problems occurring, which may help
in developing a more appropriate subjective assessment tool as it may be more reflective of what
cancer patients are actually experiencing as opposed to what researchers objectively believe are
symptoms and thus attempt to measure through psychometric cognitive assessments. Subjective
data is information provided by participants. Developing a new tool to assess cognitive
impairments and memory problems using a more subjective approach may be more apt at
capturing these problems and thus better diagnosing the phenomenon.
Limitations
A limitation of this study was that while there was sufficient power in the sample size, it
was relatively small (n = 171), which leads to the suggestion that in future research, a sample
taken from a large organization or a multi-center design should be utilized. Another limitation in
this study was the lack of diversity in the sample with a majority of the sample being 89.5%
White/Caucasian (n = 153), 49.7% college educated (n = 85), and 76% married or partnered (n =
130). While the design of this study included many components in terms of particular
medications, it may be better for research purposes to design studies focusing on each treatment
modality individuals, especially those containing many medications. While there were few
significant findings in medications, which sometimes is inconsistent with the literature, breaking
up the modalities or clarifying these modalities into separate questions on the survey may have
been useful. Another limitation of this study was that the survey should have separated the
hormonal or endocrine therapy agents, immunotherapy agents, and chemotherapy agents into
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their own questions. This would have clarified potential confusion in participants as well as
simplified data analysis. Another suggestion is to utilize other measurements to assess for
cognitive impairments among participants to see if the various factors assessed in this study
would demonstrate more significance on other measures.
A strength of this study was that some of the narrative responses corresponded with
particular items on scales that demonstrated significance or showed a clinical relevance.
Narrative responses were consistent with previous literature. Another strength of this study was
that it was an online survey, which increased feasibility and ease of use for respondents,
especially during an ongoing pandemic. While the COVID-19 mandate did not demonstrate
significant differences in memory or cognitive impairments, this aspect of the current study
could be considered a strength as it was the first step in determining how changes in treatment
plans could affect one’s stress level or memory/cognition. Another strength was the time frame
in which respondents had completed treatment for breast cancer. Some were still receiving
treatments when completing this survey, while others were upwards of 5-years post completion.
The addition of hormone and endocrine therapy as inclusion criteria also helped strengthen
findings from previous literature as well as self-reports from cancer patients and survivors
indicating that these types of treatments could hinder their memory and cognition.
Conclusion
With the richness of both the qualitative and quantitative data, the results from this study
demonstrated that treatment modalities (chemotherapy, radiation, and hormonal therapy) have an
effect on memory/cognition utilizing measures of FACT-Cog, EMQ and PSS. Other areas
demonstrating significance include medications (Adriamycin, Cytoxan, and Tamoxifen). Age
was also seen to affect memory and cognition on various measures.
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Although this study demonstrated small areas of significance, it is important to note that
many other studies have utilized psychometric and objective testing with mixed results, whereas
this study focused on utilizing measures for self-reports or participant perceptions. In educating
healthcare professionals on the presence and severity of cognitive decline as it relates to cancer
and cancer treatments, an important first step is enhancing the ability to assess for these
problems. In educating providers, research can help increase patient/survivor awareness, possibly
increasing self-reporting. When those experiencing symptoms report them in higher levels, it
may be easier to develop appropriate assessments for these symptoms as well as benefit research
studies in analyzing for the presence, severity, causes, and possible treatments.
The phenomenon of cancer- and treatment-related cognitive impairments, especially
focused on the cognitive domain of memory, remains of high importance for improving
symptom burden and overall quality of life for patients and survivors. Literature has
demonstrated the devastating consequences of cancer diagnoses and treatments on patient during
treatment and survivors for years after treatment completion. More research needs to be
conducted to determine more definitive causative mechanisms, appropriate assessments, and
proper interventions and treatments.
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Consider participating in my study to describe factors that have had
an effect on your memory during your cancer journey. If you are
interested in taking my questionnaire, please use the following link:
https://www.surveymonkey.com/r/cancerandmemory
If you have any problems please contact the researcher, Heather
Reens, Registered Nurse, at 516-242-1046 or email me at
hreens@molloy.edu
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Appendix C
Functional Assessment of Cancer Therapy – Cog (FACT-Cog, Ver 3)
FACT-Cognitive Function (Version 3)
Below is a list of statements that other people with your condition have said are important. Please circle
or mark one number per line to indicate your response as it applies to the past 7 days.
Never

PERCEIVED COGNITIVE IMPAIRMENTS

About
once a
week

Two to
three
times a
week

Nearly
every
day

Several
times
a day

CogA1

I have had trouble forming thoughts .....................................
0 0

1

2

3

4

CogA3

My thinking has been slow ....................................................
0 0

1

2

3

4

CogC7

I have had trouble concentrating ...........................................
0 0

1

2

3

4

CogM9

I have had trouble finding my way to a familiar
place .......................................................................................
0 0

1

2

3

4

I have had trouble remembering where I put things,
like my keys or my wallet .....................................................
0 0

1

2

3

4

I have had trouble remembering new information,
0 0
like phone numbers or simple instructions ...........................

1

2

3

4

I have had trouble recalling the name of an object
0
while talking to someone ......................................................

1

2

3

4

I have had trouble finding the right word(s) to
0 0
express myself .......................................................................

1

2

3

4

I have used the wrong word when I referred to an
object .....................................................................................
0 0

1

2

3

4

I have had trouble saying what I mean in
conversations with others ......................................................
0 0

1

2

3

4

I have walked into a room and forgotten what I
meant to get or do there .........................................................
0 0

1

2

3

4

I have had to work really hard to pay attention or I
would make a mistake ...........................................................
0 0

1

2

3

4

I have forgotten names of people soon after being
introduced ..............................................................................
0 0

1

2

3

4

CogM10

CogM12

CogV13

CogV15

CogV16

CogV17b

CogF19

CogF23

CogF24

FACT-Cog V3
Copyright 2006, 2016
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Last Revised 10 February 2008
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FACT-Cog (Version 3)

Please circle or mark one number per line to indicate your response as it applies to
the past 7 days.
Never

About
once a
week

Two to
three
times a
week

Nearly
every
day

Several
times a
day

My reactions in everyday situations have been
slow........................................................................................
0 0

1

2

3

4

I have had to work harder than usual to keep track
0 0
of what I was doing ...............................................................

1

2

3

4

CogC32

My thinking has been slower than usual ...............................
0 0

1

2

3

4

CogC33a

I have had to work harder than usual to express
0 0
myself clearly ........................................................................

1

2

3

4

I have had to use written lists more often than
usual so I would not forget things .........................................
0 0

1

2

3

4

I have trouble keeping track of what I am doing if I
am interrupted ........................................................................
0 0

1

2

3

4

I have trouble shifting back and forth between
different activities that require thinking ................................
0 0

1

2

3

4

CogF25

CogC31

CogC33c

CogMT1

CogMT2

Please circle or mark one number per line to indicate your response as it applies to
the past 7 days.
Never

About
once a
week

Two to
three
times a
week

Nearly
every
day

Several
times a
day

Other people have told me I seemed to have trouble
remembering information .....................................................
0 0

1

2

3

4

Other people have told me I seemed to have trouble
0 0
speaking clearly ....................................................................

1

2

3

4

Other people have told me I seemed to have trouble
0 0
thinking clearly .....................................................................

1

2

3

4

Other people have told me I seemed confused .............. 0

1

2

3

4

COMMENTS FROM OTHERS
CogO1

CogO2

CogO3

CogO4

FACT-Cog v3
Copyright 2006, 2016
Page 2 of 3
Last Revised 10 February 2008

212

FACT-Cog (Version 3)
Please circle or mark one number per line to indicate your response as it applies to
the past 7 days.
PERCEIVED COGNITIVE ABILITIES

Not
at all

A little
bit

Somewhat

Quite
a bit

Very
much

Cog
PC1

I have been able to concentrate .....................................................
0

1

2

3

4

Cog
PV1

I have been able to bring to mind words that I wanted to
use while talking to someone ........................................................
0

1

2

3

4

Cog
PM1

I have been able to remember things, like where I left
my keys or wallet ..........................................................................
0

1

2

3

4

Cog
PM2

I have been able to remember to do things, like take
medicine or buy something I needed.............................................
0

1

2

3

4

Cog
PF1

I am able to pay attention and keep track of what I am
doing without extra effort ..............................................................
0

1

2

3

4

Cog
PCH
1

My mind is as sharp as it has always been ....................................
0

1

2

3

4

Cog
PCH
2

My memory is as good as it has always been ...............................
0

1

2

3

4

Cog
PMT
1

I am able to shift back and forth between two activities
that require thinking ......................................................................
0

1

2

3

4

Cog
PMT
2

I am able to keep track of what I am doing, even if I am
interrupted .....................................................................................
0

1

2

3

4

Please circle or mark one number per line to indicate your response as it applies to
the past 7 days.
Not
at all

IMPACT ON QUALITY OF LIFE

A little
bit

Somewhat

Quite
a bit

Very
much

CogQ35

I have been upset about these problems ................................
0 0

1

2

3

4

CogQ37

These problems have interfered with my ability to
0 0
work ......................................................................................

1

2

3

4

These problems have interfered with my ability to
0 0
do things I enjoy....................................................................

1

2

3

4

These problems have interfered with the quality of
0 0
my life ...................................................................................

1

2

3

4

CogQ38

CogQ41

FACT-Cog v3
Copyright 2006, 2016
Page 3 of 3
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Appendix D
Everyday Memory Questionnaire
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Appendix 1
Everyday Memory Questionnaire – Revised
Instructions
Below are listed some examples of things that happen to people in everyday life. Some of them may happen
frequently and some may happen very rarely. We should like to know how often on average you think each one
has happened to you over the past month. Write the appropriate letter in the box beside the item.
A.
B.
C.
D.
E.

Once or less in the last month.
More than once a month but less than once a week.
About once a week.
More that once a week or less than once a day.
Once or more in a day.

1. Having to check whether you have done something that you should have done.
2. Forgetting when it was that something happened; for example, whether it was
yesterday or last week.
3. Forgetting that you were told something yesterday or a few days ago, and maybe
having to be reminded about it.
4. Starting to read something (a book or an article in a newspaper, or a magazine)
without realizing you have already read it before.
5. Finding that a word is ‘on the tip of your tongue’. You know what it is but cannot
quite find it.
6. Completely forgetting to do things you said you would do, and things you planned
to do.
7. Forgetting important details of what you did or what happened to you the day
before.
8. When talking to someone, forgetting what you have just said. Maybe saying
‘what was I talking about?’
9. When reading a newspaper or magazine, being unable to follow the thread of a story;
losing track of what it is about.
10. Forgetting to tell somebody something important, perhaps forgetting to pass on a
message or remind someone of something.
11. Getting the details of what someone was told you mixed up and confused.
12. Forgetting where things are normally kept or looking for them in the wrong
place.
13. Repeating to someone what you have just told them or asking someone the same
question twice.
Please check that you have put a letter in EVERY box. THANK YOU.

View publication stats
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Appendix E
Perceived Stress Scale (PSS)
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Appendix F
Letter of Permission for Perceived Stress Scale – PSS

Our Ref: JB/IDRE/P19/0204
29 January 2019
Dear Professor Heather Reens,
Material requested: Appendix 1 from ‘The Everyday Memory Questionnaire – revised:
Development of a 13-item scale by Jane Royle & Nadina B. Lincoln Disability and
Rehabilitation Vol 30:2 pp. 114-121 (2008).
Thank you for your correspondence requesting permission to reproduce the above mentioned material
f om o Jo nal in o p in ed he i en i led UTILIZING A STANDARDIZED MEMORY NOTEBOOK FOR
WOMEN WITH BREAST CANCER WITH SELF-REPORTED COGNITIVE IMPAIRMENTS AFTER
CHEMOTHERAPY: A WEB-BASED RANDOMIZED CONTROL TRIAL and to be posted in o
ni e i
repository - Molloy College.
We will be pleased to grant entirely free permission on the condition that you acknowledge the original
o ce of p blica ion and in e a efe ence o he Jo nal
eb i e: http://www.tandfonline.com
Please note that this licence does not allow you to post our content on any third party websites or
repositories.
Thank you for your interest in our Journal.
Yours sincerely,
Jo Bateman Permissions & Licensing Executive, Journals
Taylor & Francis Group
3 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK.
Tel: +44 (0)20 7017 7617
Fax: +44 (0)20 7017 6336
Web: www.tandfonline.com
e-mail: joanne.bateman@tandf.co.uk

Taylor & Francis is a trading name of Informa UK Limited,
registered in England under no. 1072954

2&4 Park Square, Milton Park, Abingdon, Oxfordshire OX14 4RN
Tel: +44 (0) 20 7017 6000; Fax: +44 (0) 20 7017 6336
www.tandf.co.uk
Registered in England and Wales. Registered Number: 1072954
Registered Office: 5 Howick Place, London, SW10 1WG
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IRB Approval

1000 Hempstead Ave., PO Box 5002, Rockville Center, NY 11571-5002
www.molloy.edu

Kathleen Maurer Smith, Ph.D.
Dean, Graduate Academic Affairs
T: 516.323.3801
F: 516.323.3398
E: ksmith@molloy.edu
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Appendix H
Chemotherapy, Immunotherapy, and Hormonal Therapy Agents Descriptive Statistics
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